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Abstract 
Rationale +/- 3,4-Methylenedioxymethamphetamine (MDMA) produces effects on 
a number of neurochemical systems. Many studies have shown that repeated MDMA 
administration produces deficits in central serotonergic neurotransmission, which have 
been suggested to underlie some of the behavioural changes associated with use. 
Objectives The present studies sought to evaluate the functional statuses of the 
serotonin transporter (SERT) and the serotonin2c (5-HT2c) and serotonin2a (5-HT2a) 
receptors following treatment with MDMA to determine whether behavioural deficits 
could be attributed to alterations in these proteins.  
Methods Rats received a pretreatment regimen of MDMA (4 x 10mg/kg MDMA 
injections administered at 2h intervals) or the saline vehicle and, 2 weeks later, [3H] 
paroxetine binding was undertaken to assess densities of SERT. In other groups, dose-
effect curves for MDMA-produced hyperactivity were determined. Additional groups were 
tested following a 12-week withdrawal period from MDMA in order to assess whether 
there was recovery of function. The functional status of the SERT was further examined by 
determining the effect of MDMA pretreatment on the reduction in MDMA-produced 
hyperactivity (0.0 – 10.0mg/kg) produced by the selective serotonin reuptake inhibitor, 
clomipramine (0.0 – 5.0mg/kg). The ability for the 5-HT2c receptor agonist, m-CPP (0.0 – 
2.5mg/kg) to produce hypolocomotion or increased emergence latency or for the 5-HT2a 
receptor agonist, DOI (0.0 – 2.0mg/kg) to produce wetdog shakes (WDS) were examined 
in MDMA pretreated rats. The ability for the 5-HT2c receptors to modulate MDMA-
produced hyperactivity was assessed by examining the effect of MDMA pretreatment on 
the potentiation of MDMA-produced hyperactivity produced by the selective antagonist, 
RS102221 (0.0 – 1.0mg/kg). Conversely, the modulatory abilities of the 5-HT2a receptors 
were assessed by examining the effect of MDMA pretreatment on the attenuation of 
MDMA-produced hyperactivity produced by the antagonist, ritanserin (0.0 – 10.0mg/kg). 
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Results MDMA pretreatment produced widespread reductions in SERT binding 
densities 2 weeks following administration. Prior exposure to MDMA rendered rats 
tolerant to MDMA-produced hyperactivity when tested 2, but not 12, weeks following 
MDMA administration. Two weeks following MDMA pretreatment rats were also less 
responsive to the clomipramine-produced attenuation of MDMA-produced hyperactivity. 
MDMA pretreatment failed to alter M-CPP -produced hypolocomotion or increased 
emergence latency, but decreased the ability for DOI to induce WDS. Further, MDMA 
pretreated rats exhibited tolerance to RS102221 as shown by a rightward shift in the dose 
effect curve and complete tolerance to ritanserin. 
Conclusions Following MDMA pretreatment, the decreased SERT binding 
densities and inability of clomipramine to attenuate MDMA-produced effects might 
explain tolerance to the locomotor activating effects produced by MDMA. Functional 
recovery also occurred with extended abstinence from the drug, suggesting that MDMA 
produced transient serotonergic alterations. The results support the idea that the 5-HT2a 
and 5-HT2c receptors that modulate MDMA-produced hyperactivity are functionally 
distinct from the receptors that mediate m-CPP- and DOI-induced behavioural responses, 
as m-CPP-produced behaviours were resilient, yet RS102221-induced effects were 
reduced, by MDMA pretreatment. RS102221 is highly selective in comparison to 
ritanserin, yet there was only one dose that produced significant potentiation of MDMA-
produced hyperactivity, whereas there were several effective ritanserin doses. This 
suggests that the 5-HT2a receptors had a greater role in modulating MDMA-produced 
hyperactivity. Additionally, 5-HT2a receptors might be more susceptible to MDMA-
induced desensitisation than 5-HT2c receptors, as MDMA pretreated rats exhibited some 
tolerance to the potentiating effects of RS102221 but were unresponsive to any ritanserin 
dose. In conclusion, MDMA-induced locomotor tolerance was attributable to decreased 
SERT densities and function as well as desensitisation of 5-HT2a receptors that facilitate 
hyperactivity. 
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Introduction 
Introduction to MDMA 
Origins 
3,4-Methylenedioxymethamphetamine (MDMA or ‘ecstasy’) is a ring-substituted 
derivative of phenylisopropylamine and is structurally similar to both methamphetamine 
and mescaline (McKenna and Peroutka, 1990; White et al., 1996). MDMA is a drug that 
has been purported to have unique subjective effects, with hallucinogenic- and 
psychostimulant-like properties. As a result, a novel drug class termed ‘entactogens’ 
(literal meaning ‘producing a touching within’) was proposed to include MDMA with 
structurally related compounds that also produce hallucinogenic and stimulant effects 
(Nichols, 1986). 
MDMA was first synthesised by Merck pharmaceuticals and patented in 1914. In 
1977, the United Kingdom Home Office scheduled MDMA as a class A drug on the 
premise that it had no known medicinal uses. Despite these legalities, MDMA was still 
used as an adjunct to psychotherapy in the late 1970’s and early 1980’s. It was also legally 
available in some regions of the United States such as Texas until 1985, when the United 
States Food and Drug Administration followed suit and added MDMA to schedule 1 of the 
Controlled Substances Act (Cole and Sumnall, 2003).  
Use Patterns & Purity 
MDMA became a popular recreational drug in the United Kingdom in the 1980’s 
(Cole and Sumnall, 2003) where it became the most commonly used illicit drug at all night 
dance parties or ‘raves’ (Brown et al., 1995; Lenton et al., 1997; Weir, 2000; Wilkins, 
2003; Engels and ter Bogt, 2004; Parks and Kennedy, 2004) and the increasing popularity 
of the ‘rave subculture’ during the 1990’s led to more widespread use. 
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There are numerous reports suggesting that MDMA use has been steadily 
increasing. The World Drug Report compiled by the United Nations Office on Drugs and 
Crime (UNODC, 2004) presented long-term worldwide trends in production, trafficking 
and abuse of drugs and was based on a compilation of data obtained from the Annual 
Reports Questionnaire sent by governments to UNODC in 2003. The reports revealed that 
the consumption of certain illicit drugs such as heroin and cocaine were decreasing. 
However, cannabis was still the most commonly used illicit drug and use was accelerating. 
During the last decade, amphetamine-type stimulants (mainly MDMA) were the second 
most commonly used illicit drug. The main producers of amphetamine and MDMA were in 
Europe, including the Netherlands (the largest producer), Belgium, Poland, the Baltic 
States, the UK and Germany. The production of amphetamine-type stimulants increased 
globally during the last decade and was dominated by methamphetamine, followed by 
MDMA and amphetamine. The number of clandestine MDMA laboratories primarily in 
Europe rose almost 3-fold between 1992 and 2002. Global MDMA consumption has 
increased consistently over the last decade and continued to rise in 2002, although at a 
slower pace than in 2001. There appears to be a trend towards increasing use in developing 
countries, whilst some of the largest MDMA markets of Europe and North America 
stabilised, possibly due to the massive increases in popularity and use during the 1990’s. 
Reports and surveys suggest that MDMA use is prevalent and on the increase in 
New Zealand and Australia. National Drug Surveys in New Zealand indicated that MDMA 
use had increased by those aged between 15-45 years from 1.5% in 1998 to 3.4% in 2001 
(Wilkins, 2003). MDMA-produced seizures have also increased within this time frame. 
The 2005 National Drug Strategy Household Surveys in Australia revealed that 22% of the 
populace aged between 20-29 years reported having used MDMA. Statistics showing 
recent drug use of the total population 14 years revealed that the frequency of MDMA use 
had increased from 2.9% in 2001 to 3.4% in 2004. In comparison, cocaine, cannabis and 
hallucinogen use had decreased during this period.  
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 Regular MDMA use is usually associated with polydrug use. In a World Wide 
Web study, drug usage patterns were reported by novice, moderate, heavy and non-
MDMA users (Scholey et al., 2004). It was found that MDMA users who did not take any 
other illicit substances were very rare and MDMA users reported significantly greater 
psychoactive drug usage than non-MDMA users. Experienced MDMA users took 
significantly more tablets on each occasion, and reported higher maximum weekly intake 
than moderate MDMA users.  
Many regular MDMA users also described tolerance to the effects of MDMA, 
complaining that their acute drug reaction was weakened with repeated usage. Structured 
interviews were completed by 430 regular MDMA users recruited from London (68%) and 
Manchester (32%) in the UK (Verheyden et al., 2003). When asked how often participants 
combined other drugs with MDMA, 59% reported always mixing MDMA with another 
drug. Thus, MDMA appears to be increasing in use, availability and popularity. Regular 
users tend to be rave attendees (Brown et al., 1995; Lenton et al., 1997; Weir, 2000; 
Wilkins, 2003; Engels and ter Bogt, 2004; Parks and Kennedy, 2004) and also typically 
ingest a range of other drugs in addition to MDMA (Verheyden et al., 2003; Wilkins, 2003; 
Scholey et al., 2004). Reports suggest that prolonged use of MDMA leads to tolerance to 
the effects; the implications of this being that users take the drug more frequently and/or at 
higher doses to obtain the effects that were initially experienced; indeed, these predictions 
have been confirmed (Verheyden et al., 2003; Scholey et al., 2004; Parrott, 2005). 
MDMA is usually administered orally and sold in tablet form; however, these 
tablets seldom contain ‘pure’ MDMA. The amount of MDMA within a tablet varies 
widely, and many contain other drugs such as amphetamine, 3,4-
methylenedioxyethamphetamine (MDEA), 3, 4-methylenedioxyamphetamine (MDA), N-
methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), 4-bromo-2,5-
dimethoxyphenethylamine (2C-B, ‘Nexus’), ketamine, caffeine or ephedrine. The actual 
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MDMA content of ecstasy tablets has been reported to range from 34% to 75% (Sherlock 
et al., 1999; Bell et al., 2000; Cole et al., 2002; Cole and Sumnall, 2003).  
Mechanisms and Pharmacology 
MDMA induces massive increases in extracellular levels of serotonin (5-HT), 
dopamine (DA) and norepinephrine (NE) (Gough et al., 1991; White et al., 1996; Lyles 
and Cadet, 2003; Colado et al., 2004; Green et al., 2004). The greatly increased synaptic 
levels of these monoamines leads to the activation of numerous receptors (White et al., 
1996). Therefore, the unique subjective effects experienced following ingestion of MDMA 
are likely a consequence of multiple 5-HT, NE and DA receptor activation. In addition, 
MDMA induces release of other neurotransmitters such as acetylcholine (Fischer et al., 
2000), and has also been reported to inhibit gamma amino butyric acid (GABA) activity 
(Yamamoto et al., 1995). MDMA directly interacts with numerous brain recognition sites 
with highest affinity for the serotonin transporter (SERT) (Battaglia et al., 1988). MDMA 
also binds the NE transporter (NET), DA transporter (DAT), 5-HT1 and 5-HT2 receptors, 
D1- and D2-like receptors, α1- α2- and β2-adrenergic receptors, muscarinic and histamine 
receptors. 
MDMA induces substantial extracellular 5-HT and DA release via exocytosis 
(Yamamoto and Spanos, 1988; Gough et al., 1991; Rudnick and Wall, 1992; Yamamoto et 
al., 1995; Shankaran and Gudelsky, 1999) and elevations in synaptic levels of these 
neurotransmitters have been associated with many behavioural and neurochemical effects 
observed following MDMA administration. Numerous reports also suggest that MDMA 
induces increased monoamine levels by interacting with carrier proteins on the plasma 
membrane. MDMA-produced increases in extracellular 5-HT might occur via the SERT 
(Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 1992; Gudelsky 
and Nash, 1996; Iravani et al., 2000), since selective 5-HT reuptake inhibitors (SSRIs) 
such as imipramine or fluoxetine administered in conjunction with MDMA antagonised the 
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MDMA-induced synaptic 5-HT increase (Hekmatpanah and Peroutka, 1990; Berger et al., 
1992; Rudnick and Wall, 1992; Gudelsky and Nash, 1996). Further supportive evidence 
showed that tetrodotoxin (TTX) did not entirely block MDMA-induced increases in 
synaptic 5-HT (Gudelsky and Nash, 1996), suggesting that release can occur in the absence 
of cell firing and 5-HT increases still occurred after Ca2+ depletion, which is normally an 
essential agent required for vesicular release (Schmidt et al., 1987b).  
It is clear that MDMA blocks reuptake, however, there is still speculation as to 
whether MDMA also induces 5-HT release via SERT-mediated reverse transport 
(Hekmatpanah and Peroutka, 1990). MDMA was purported to produce elevations in 
intracellular 5-HT via interaction with vacuolar amine transporters located on storage 
vesicle membranes (Rudnick and Wall, 1992). MDMA disrupted the sequestration process, 
preventing the repackaging of cytosolic 5-HT into vesicles (Rudnick and Wall, 1992). In 
addition to increasing synaptic 5-HT, MDMA also inhibited tryptophan hydroxylase (TPH) 
(Stone et al., 1987; Schmidt and Taylor, 1987a; Stone et al., 1989a; Stone et al., 1989b; 
Garcia-Osta et al., 2004) and monoamine oxidase activity (Gu and Azmitia, 1993; 
Leonardi and Azmitia, 1994). MDMA-induced increases in synaptic levels of NE have 
been partly attributed to effects at the NET, as these were reduced by co-administration 
with the NE-uptake blocker, desmethylimipramine (Fitzgerald and Reid, 1990).  
DAT blockade also contributed to MDMA-produced DA elevations, as reuptake 
inhibitors such as mazindol or GBR12909 co-administered with MDMA reduced DA 
outflow (Nash and Brodkin, 1991; Shankaran et al., 1999). Increases in DA levels might 
involve more complex mechanisms than those involved with 5-HT and NE. It was found 
that TTX and ritanserin (5-HT2 receptor antagonist) attenuated MDMA-induced DA 
release in the striatum and substantia nigra (Yamamoto et al., 1995). Conversely, it has 
also been discovered that direct infusion of 5-HT2 receptor agonists into the nucleus 
accumbens or striatum increased DA levels in these areas (Benloucif and Galloway, 1991; 
Parsons and Justice, 1993). It was concluded that 5-HT2 receptor activation modulates DA 
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release in addition to effects of MDMA at the DAT. The fact that TTX attenuated DA 
release was also indicative of a partly impulse-mediated mechanism (Yamamoto et al., 
1995).  
Time-course measurements of DA levels provide additional information regarding 
the mechanisms involved in MDMA-produced effects. Following administration of 
MDMA (10mg/kg), in vivo microdialysis showed an immediate increase in caudate DA, 
which was followed 70 minutes later by an increase in the nucleus accumbens (Yamamoto 
and Spanos, 1988). In another study direct infusion of MDMA via a dialysis probe into the 
nucleus accumbens caused an increase in DA that was delayed in relation to the 5-HT 
increase (White et al., 1994). It was suggested that MDMA may produce an initial but 
relatively small increase in DA, possibly via DAT-mediated mechanisms, whereas the later 
increase might be 5-HT2 receptor-mediated (White et al., 1994). Local 5-HT application to 
the nucleus accumbens induced DA release (Jacocks and Cox, 1992), which supports the 
idea that MDMA-induced increases in extracellular 5-HT might be a trigger for DA 
release.  
The stereoisomers of racemic (-/+) MDMA have different potencies, 
pharmacokinetics and effects on neurotransmitter release. Measurements of the half-life or 
clearance of each isomer type revealed that the (+) isomer has faster clearance; therefore 
drug-induced effects are shorter in duration (Fitzgerald et al., 1990). All derivatives have 
been reported to release comparable levels of 5-HT; however, the (+) MDMA isomer 
increases synaptic DA to a greater extent than (-) MDMA or the racemic compound 
(Johnson et al., 1986; Hiramatsu and Cho, 1990). These subtle differences in 
neurochemistry induced by these derivatives are reflected behaviourally in that (+) MDMA 
has more stimulant-like and (-) MDMA more hallucinogenic-like effects (Paulus and 
Geyer, 1992; Baker et al., 1995; Fantegrossi et al., 2003). 
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Effects of MDMA on Humans 
Physiological Effects 
MDMA plasma concentrations are highest 2 hours following oral ingestion. The 
half-life of MDMA in humans is approximately 8 hours and most is excreted in the urine. 
Pharmacokinetic studies revealed that increasing the MDMA dose by a factor of 3 
increased peak plasma concentrations by a factor of 6, thus there is a non-linear 
pharmacokinetic relationship between drug and plasma levels so that small increases in 
dose lead to relatively large changes in plasma levels (Mas et al., 1999; de la Torre et al., 
2000a; de la Torre et al., 2000b).  
The first physiological effects induced by MDMA begin to manifest approximately 
15 minutes following ingestion. The stimulant-like characteristics of MDMA are 
represented by increases in heart rate, blood pressure and cardiac output (Vollenweider et 
al., 1998; Mas et al., 1999; Lester et al., 2000; de la Torre et al., 2000a; de la Torre et al., 
2000b). Increases in muscle tension, as well as bruxism (grinding of teeth) are also 
commonly reported side effects (Greer and Tolbert, 1986; Siegel, 1986; Peroutka et al., 
1988; Liester et al., 1992; Solowij et al., 1992; Cohen, 1995), as well as occasional nausea 
and vomiting (Downing, 1986). 
 MDMA administration produced dose-dependent increases in body temperature in 
laboratory animals (Gordon et al., 1991; Clemens et al., 2004). Controlled laboratory 
experiments involving human participants have not, however, found significant changes in 
body temperature as a result of acute MDMA administration (Vollenweider et al., 1998). 
This discrepancy may be due to the fact that hyperthermia was only found at higher 
ambient temperatures, whilst conversely, hypothermia occurred when the environment was 
colder (Dafters, 1994), suggesting that MDMA leads to a loss of thermoregulation. If so, 
this might explain the disparity between the Vollenweider (1998) results where no 
significant change in body temperatures occurred after MDMA, whereas MDMA-induced 
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hyperthermia has been reported to occur at dance parties (Coore, 1996; Smith et al., 2002; 
Parrott, 2004). As MDMA is usually consumed at crowded, hot venues where dance 
parties are held and people are actively dancing for many hours, ambient temperatures are 
high and dehydration is likely to occur. In some cases, MDMA-induced hyperthermia has 
been fatal, and cardiac arrythmias, acute renal failure, rhabdomyolysis, hepatic toxicity and 
disseminated intravascular coagulation have been reported (Chadwick et al., 1991; Fahal et 
al., 1992; Screaton et al., 1992; Oranje et al., 1994; Dykhuizen et al., 1995; Khakoo et al., 
1995; Malpass et al., 1999). However, fatalities as a result of MDMA ingestion are 
relatively rare, and as a result, it is perceived as a ‘safe’ drug (Greer and Tolbert, 1986; 
Grinspoon and Bakalar, 1986; Siegel, 1986). Many other MDMA-related adverse effects 
that do not entail fatality may go unrecorded (Whitaker-Azmitia and Aronson, 1989). 
Subjective Effects 
MDMA has been reported to have hallucinogenic-like effects or perceptual altering 
properties. Users have reported increased ‘feelings of closeness’ to others, enhanced 
insight, increased sensory awareness, euphoria, increased extraversion and elevated self-
confidence; hence the street name ‘ecstasy’ (Downing, 1986; Greer and Tolbert, 1986; 
Solowij et al., 1992; Cohen, 1995, 1996; Cohen and Cocores, 1997; Liechti and 
Vollenweider, 2001a; Lyles and Cadet, 2003; Verheyden et al., 2003). When participants 
were pretreated with an SSRI, the positive MDMA-produced subjective effects were 
attenuated (Liechti et al., 2000b; Liechti et al., 2001; Liechti and Vollenweider, 2001). 
These findings suggest that binding to the SERT might produce many of these subjective 
effects following MDMA administration. In addition to this, the 5-HT2a/2c receptor 
antagonist, ketanserin, prevented MDMA-produced perceptual changes (Liechti et al., 
2000a; Liechti et al., 2001; Liechti and Vollenweider, 2001). These observations concur 
with other studies reporting that 5-HT2a receptor activation produced hallucinogenic 
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effects (Jakab and Goldman-Rakic, 1998; Aghajanian and Marek, 1999; Nelson et al., 
1999). 
Negative side effects after MDMA ingestion such as paranoia, restlessness, 
depersonalisation, suppressed appetite, lack of energy, concentration difficulties, delirium 
and anxiety have been extensively documented (Peroutka et al., 1988; Liester et al., 1992; 
Vollenweider et al., 1998; Verheyden et al., 2003), and may explain why many discontinue 
use of this drug, or use it less frequently. Cognitive abilities are detrimentally affected 
during MDMA intoxication (Parrott and Lasky, 1998). Pre-drug baselines were compared 
to measures taken whilst the participants were intoxicated with MDMA at a Saturday night 
dance and the acute dose markedly reduced memory scores and impaired visual search 
tasks. There are numerous studies that have assessed cognitive abilities and psychiatric 
statuses in MDMA users, but an extensive review of this literature is beyond the scope of 
the present thesis. There was general consensus, however, that the long-term consequences 
of MDMA use were associated with memory and mood impairments (Peroutka et al., 
1988; Liester et al., 1992; Vollenweider et al., 1998; Verheyden et al., 2003).  
Behavioural Effects of MDMA on Laboratory Animals 
Overview 
MDMA administration produces ubiquitous neurochemical effects, and amongst these, 
substantial elevations in synaptic 5-HT and DA levels. As a consequence of this massive 
release of neurotransmitters, postsynaptic receptors are activated and several behaviours 
are induced. The MDMA-produced behaviours that have been characterised in the 
literature will be reviewed, and the contribution of 5-HT and DA, where relevant, will be 
outlined.  
Stereotypy 
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Role of Dopamine 
Stereotypy in the rat includes sniffing, repetitive head and limb movements, 
gnawing, biting and licking, which are typically drug-induced behaviours (Costall et al., 
1975). Stereotypy has been reported following the administration of indirect or direct DA 
agonists, such as amphetamine or apomorphine. Dose response relationships showed that 
there was a significant relationship between amphetamine-induced increases in stereotypy 
and magnitude of dialysate DA release (Kuczenski and Segal, 1989; Kuczenski and Segal, 
1990). In addition, the DA receptor antagonist, haloperidol, prevented amphetamine-
produced stereotypy from occurring and reduced existing stereotypy when administered 
after amphetamine (Conti et al., 1997). 
The majority of evidence indicates that D1- and D2-like DA receptor activation 
produces stereotypy. The D1- and D2-like DA receptor agonist, apomorphine, induces 
stereotypy when administered systemically (Gordon and Beck, 1984; Sandoval and 
Palermo-Neto, 1995). When two agonists selective for these receptor subtypes were 
administered directly into striata of rats, stereotypy was markedly enhanced by both and 
blocked by concomitant infusion of the selective D1-like receptor antagonist, SCH 23390, 
or the D2-like receptor antagonist, sulpiride (Bordi and Meller, 1989). Additionally, mice 
that were bred with differential expression of D1- and D2-like receptors showed 
differential stereotypy responses to apomorphine (Seale et al., 1984). 
Differential activation of the D1- and D2-like receptor subtypes might produce 
different components of stereotypy behaviours. Amphetamine-produced stereotypy was 
differentiated into two components: sniffing and repetitive head and limb movements (low 
intensity component) and gnawing, biting and licking (high intensity component) (Costall 
et al., 1975). Low intensity components occurred at low doses of apomorphine and high 
intensity components at larger doses. Although tempting, it would be too simplistic to 
attribute low or high intensity behaviour with either receptor subtype, as the two 
behaviours never occurred independently. These observations suggest interactive 
relationships between the D1- and the D2-like receptors.  
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The striatum, namely the caudate putamen, is the site where these behaviours 
originate. Increased striatal DA dialysate levels were positively correlated with increasing 
stereotypy (Sharp et al., 1987). The intensity of stereotyped head and forepaw movements 
was closely correlated with the amount of DA released in striatum but not in the nucleus 
accumbens. In contrast, increased locomotor activity was correlated with the time course 
and amount of dialysate DA in the nucleus accumbens.  
In addition to dopaminergic manipulations, central GABA systems have also been 
implicated in apomorphine-produced stereotypy. GABA manipulations facilitated 
apomorphine-produced stereotypy, and it was postulated that this was a consequence of 
disinhibition of dopaminergic circuits (Sandoval and Palermo-Neto, 1995). Indeed, 
stereotypy was induced by local impairment of GABA circuits in the caudate nuclei, which 
was attenuated by haloperidol. These findings suggest that GABA circuits exert inhibitory 
control over dopaminergic systems in the caudate region, and that disinhibition leads to 
DA-produced stereotypy behaviours (Kryzhanovsky and Aliev, 1981). 
Role of Serotonin 
Amphetamine also elevates striatal dialysate 5-HT at higher doses (Kuczenski and 
Segal, 1989), therefore some studies have examined a possible role for 5-HT in the 
expression of stereotypy. The majority of evidence suggests a minor, but inhibitory role for 
5-HT in this drug-induced behaviour. For example, stereotypy induced by apomorphine or 
methamphetamine was enhanced when the synthesis of 5-HT was inhibited (Dickinson and 
Curzon, 1983) or 5-HT antagonists administered (Balsara et al., 1979). Similarly, 
amphetamine produced stereotypy when 5-HT was depleted (Segal, 1976; Dickinson and 
Curzon, 1983) and methamphetamine-induced stereotypy decreased following L-
tryptophan administration (Balsara et al., 1979).  
A study examined the contribution of both DA and 5-HT elevations to slow head 
shaking (SHS) and stereotyped gnawing (SG) induced by methamphetamine in rats 
  
  
13 
(Honma and Fukushima, 1979). SHS was mediated predominantly by serotonergic 
mechanisms, as 5-HT antagonists attenuated SHS, whilst the administration of the 5-HT 
precursor L-5-hydroxytryptophan and peripheral decarboxylase inhibitor enhanced these 
behaviours. Conversely, SG behaviours were predominantly mediated by DA, as tyrosine 
hydroxylase inhibitors blocked, whilst dopamine-beta-hydroxylase inhibitors and 
combined administration of L-3, 4-dihydroxyphenylalanine and Ro-4-4602 enhanced SG 
but did not affect SHS behaviours. SG was comparable to DA-mediated stereotyping 
behaviour, whereas SHS might be a component of the 5-HT syndrome (see next 
paragraph). These findings do highlight the importance of specifying which behaviours are 
defined as ‘stereotypy’, as some are clearly mediated by differential neurochemical 
mechanisms.  
MDMA-Produced Stereotypy 
As MDMA affects both 5-HT and DA systems, stereotypy has been observed 
following acute administration (O'Loinsigh et al., 2001). Consistent with its ability to 
increase DA to a greater extent than the -MDMA isomer, +MDMA was more effective at 
inducing stereotyped behaviour such as sniffing, head-weaving and turning (Hiramatsu et 
al., 1989). Another study reported that MDMA did not produce stereotypy behaviours 
following administration of 10 and 30mg/kg, whilst 5-HT syndrome behaviours and 
elevated locomotor activity were present and attributed to the predominant effects of 
MDMA on serotonergic systems (Matthews et al., 1989). These differential findings are 
consistent with the idea that elevated synaptic 5-HT levels inhibit the expression of 
stereotypy behaviours. Since MDMA elicits a relatively large efflux of 5-HT in the brain 
compared to other psychostimulants (Crespi et al., 1997), DA-mediated stereotypy would 
be an unexpected behavioural outcome. It is possible that difficulty in differentiating 
between stereotypy- and 5-HT syndrome-like behaviours might have led to these mixed 
findings. 
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Serotonin Syndrome 
Role of Serotonin 
Serotonin syndrome (SS) behaviours resemble some components of DA-mediated 
stereotypy, but have been differentiated in that they can be induced by 5-HT agonists such 
as 5-methoxy-N, N-dimethyltryptamine (5-MeDMT) or d-lysergic acid diethylamide 
(LSD) (Lucki and Frazer, 1982). SS behaviours include flattened body posture, salivation, 
resting tremor, hunch back, Straub tail, hypothermia, lower lip retraction, piloerection and 
body tremors (Goodwin et al., 1987; Mokler et al., 1992; Kleven et al., 1997; Van Oekelen 
et al., 2003b; Morley et al., 2005). These behaviours were attenuated by 5-HT depletion 
(Goodwin et al., 1987), serotonergic lesions produced by 5,7-DHT (Goodwin et al., 1987) 
or 5-HT receptor antagonists (Kleven et al., 1997). The 5-HT1a receptors have a major role 
in the expression of SS behaviours, as 5-HT1a receptor agonists such as buspirone or 8-
hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT) produced dose-related increases in 
one or more elements of the SS (Blanchard et al., 1993; Kleven et al., 1997). The selective 
5-HT1A antagonist, N- [2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl]-N- (2-pyridinyl) 
cyclone xanecarboxamide (WAY 100635), attenuated SS produced by both agonists 
(Goodwin et al., 1987; Kleven et al., 1997). 
MDMA-Produced Serotonin Syndrome 
Acute MDMA produced dose-dependent increases in duration and intensity of SS 
behaviour, including low body posture, forepaw treading, head weaving, salivation and 
piloerection (Spanos and Yamamoto, 1989; Morley et al., 2005; Piper et al., 2005). The 
most consistently observed SS behaviour was head weaving in the rat, which was defined 
by Spanos and Yamamoto (1989) as a lateral side-to-side movement of the head with no 
net locomotion. These MDMA-produced behaviours were attenuated by pretreatment with 
the selective 5-HT1a receptor antagonist, WAY 100635 (Morley et al., 2005). Head 
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weaving and forepaw treading have also been described as DA-mediated stereotypy 
behaviour (Honma and Fukushima, 1979), but because blockade of 5-HT receptors 
attenuated these behaviours, they were likely mediated by serotonergic mechanisms.  
Anxiety 
Overview 
Behavioural paradigms such as the elevated plus maze (EPM), the emergence and 
open field tests have been used to measure anxiety as an avoidance response to open 
spaces or novel environments. Ultrasonic vocalisations in response to stressful stimuli have 
also been used as an index of anxiety and provides a measure of distress unrelated to the 
movement of the animal and thus avoids a confound that might distort other measures 
(Siemiatkowski et al., 2001). Additionally, the social interaction test suggests anxiety when 
there is a decreased interaction time.  
Role of Dopamine  
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There was indication that elevation of synaptic DA levels produced anxiogenesis, 
as amphetamine or DA reuptake inhibitors at doses subthreshold for locomotor activation 
produced anxiogenesis (File and Hyde, 1979; Simon et al., 1993; Silva et al., 2002). 
Studies regarding the role of specific D1- or D2-like DA receptors have yielded a 
multitude of conflicting findings. Some studies showed that D1-like receptor agonists 
produced little change in anxiety tests (Rodgers et al., 1994; Bartoszyk, 1998). D2-like 
receptor agonists and antagonists have both produced anxiolysis in many instances. 
Quinpirole, a D2-like receptor agonist, reduced ultrasonic vocalisations (Bartoszyk, 1998) 
and apomorphine, a D1/D2-like receptor agonist, decreased avoidance behaviours 
(Talalaenko et al., 1994) suggesting anxiolytic effects. A substantial number of the D2-like 
receptors are autoreceptors, thereby limiting DA release upon activation (Cragg and 
Greenfield, 1997; Usiello et al., 2000). These anxiolytic effects were postulated to be due 
to autoreceptor activation, thereby limiting DA synthesis and release. However, the fact 
that D2-like receptor antagonists have also produced anxiolysis (Costall et al., 1987; 
Bruhwyler et al., 1990; Rodgers et al., 1994; Talalaenko et al., 1994; Siemiatkowski et al., 
2001) indicates that DA and associated receptors have an indeterminate role in anxiety as 
measured by these paradigms. 
Role of Serotonin  
A number of studies have suggested a role of 5-HT in anxiety. Depletion of central 
5-HT induced by the selective 5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT) or a 
tryptophan hydroxylase inhibitor, parachlorophenylalanine (pCPA) were found to increase 
time spent in the light chamber and in social interaction (File and Hyde, 1977; Clarke and 
File, 1982; Koprowska et al., 1999). Buspirone, a 5-HT1a receptor agonist, produced 
anxiolysis in the open-field and elevated T maze tests (Moser, 1989; Angrini et al., 1998; 
Graeff et al., 1998; Belzung et al., 2001; Merali et al., 2003). In addition, another 5-HT1a 
agonist, ipsapirone, decreased ultrasonic vocalisations and induced time and dose-
dependent decreases in firing rates of serotonergic dorsal raphe neurons (Sommermeyer et 
al., 1993). The vast majority of 5-HT1a receptors are autoreceptors; therefore receptor 
activation limits 5-HT release, reducing synaptic 5-HT levels (Routledge et al., 1993; 
Sommermeyer et al., 1993; Gartside et al., 1999; Hjorth et al., 2000).  
These findings suggest that anxiety is inversely related to 5-HT level. Indeed, 
increasing synaptic 5-HT levels by administration of SSRIs such as fluoxetine and 
sertraline induced anxiogenesis in the EPM and social interaction tests (Martin et al., 1998; 
To et al., 1999; To and Bagdy, 1999; Kurt et al., 2000; Silva and Brandao, 2000; Bagdy et 
al., 2001) and SERT knockout mice exhibited significantly greater anxiety than their 
wildtype counterparts in an emergence test (Holmes et al., 2003). The absence of this 
transporter protein allows for prolongation of 5-HT in the synaptic cleft, thereby 
replicating the situation produced by SSRIs. In addition, the non-selective 5-HT agonist, 
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m-CPP, also induced anxiety in the emergence, EPM and social interaction tests (Kennett 
et al., 1989; Gibson et al., 1994; Kennett et al., 1994a; Meert et al., 1997; Bilkei-Gorzo et 
al., 1998; Graeff et al., 1998; Bagdy et al., 2001).  
In contrast to the acute effects, chronic administration of SSRIs were anxiolytic 
(Burghardt et al., 2004), and this might reflect alterations in receptor responsiveness as a 
consequence of chronic activation (Kennett et al., 1994b; Kantor et al., 2001; Burghardt et 
al., 2004). Chronic fluvoxamine, paroxetine, clomipramine and fluoxetine reduced 
behavioural responses to m-CPP (Kennett et al., 1994b; Yamauchi et al., 2004). Numerous 
studies have also reported altered functional properties of 5-HT1a receptors after chronic 
SSRI or 5-HT1a agonist treatments (Schechter et al., 1990; Lund et al., 1992; Sim-Selley et 
al., 2000; Subhash et al., 2000; Cremers et al., 2004) and as this receptor has an established 
role in anxiety (Moser, 1989; Sommermeyer et al., 1993; Angrini et al., 1998; Beneytez et 
al., 1998; Graeff et al., 1998; Olivier et al., 1998; Belzung et al., 2001; Merali et al., 2003), 
it is likely that these alterations also underlie anxiolysis. 
MDMA-Produced Anxiety 
MDMA increased anxiety in the EPM (Lin et al., 1999; Morley and McGregor, 
2000; Navarro and Maldonado, 2002; Ho et al., 2004; Sumnall et al., 2004; Morley et al., 
2005) and emergence tests (Maldonado and Navarro, 2000; Morley and McGregor, 2000; 
Morley et al., 2005) but increased social interaction in rats (Morley and McGregor, 2000; 
Morley et al., 2005). Recent findings suggest that these discrepancies between paradigms 
were attributable to different neurochemical mechanisms. MDMA-produced anxiogenesis 
in the emergence test was unaffected by pretreatment with the selective 5-HT1a antagonist, 
WAY 100635, whereas increased social interaction was attenuated by this antagonist 
(Morley et al., 2005). These mixed findings suggest that MDMA-produced ‘anxiey’ 
comprises several behavioural components, which might be mediated by differential 
mechanisms. 
  
  
18 
Decreased anxiety in the EPM after low dose and increased anxiety after high dose 
MDMA have been found (Lin et al., 1999; Ho et al., 2004). These differential effects might 
reflect activation of 5-HT receptors with varying affinities for 5-HT. The 5-HT1 receptors 
have a higher affinity for 5-HT than the 5-HT2 receptors (Zifa and Fillion, 1992), therefore 
following administration of low doses of MDMA, receptors such as presynpatic 5-HT1a 
receptors might be activated and produce anxiolysis (Moser, 1989; Sommermeyer et al., 
1993; Angrini et al., 1998; Beneytez et al., 1998; Graeff et al., 1998; Olivier et al., 1998; 
Belzung et al., 2001; Merali et al., 2003) whilst following administration of higher doses, 
receptors such as the 5-HT2c receptor might become preferentially activated and produce 
anxiogenesis (Kennett et al., 1994a; Kennett et al., 1995; Mora et al., 1997; Bagdy et al., 
2001; Campbell and Merchant, 2003). These findings highlight the complexity of 
serotonergic systems involved in anxiety.  
Locomotion 
Overview 
MDMA exerts predominant effects on 5-HT systems, and it is these effects as well 
as significant elevations in extracellular DA levels that produce hyperactivity in laboratory 
animals. It has been demonstrated that the ability of MDMA to bind the SERT as well as 
the activation of numerous 5-HT and DA receptor subtypes all contribute to MDMA-
produced hyperactivity.  
Role of Dopamine 
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A role for DA in both basal and drug-induced locomotion has been demonstrated in 
numerous studies. In general, enhanced dopaminergic transmission increases locomotor 
activity. Administration of the D2-like receptor antagonist, haloperidol, dose-dependently 
reduced baseline levels of locomotor activity in rats (Emerich et al., 1991). Conversely, 
administration of DA agonists, such as apomorphine (Irifune et al., 1995), DA reuptake 
inhibitors such as GBR 12909 (Heikkila and Manzino, 1984; Ichihara et al., 1993; 
Schindler and Carmona, 2002; McGeehan et al., 2004) and the D1-like receptor agonist, 
SKF 82958 (Schindler and Carmona, 2002) significantly increased locomotor activity 
levels. These increases were clearly related to DA receptor activation, as the D1-like 
receptor antagonist SCH23390 (Ichihara et al., 1993) and haloperidol (Heikkila and 
Manzino, 1984) blocked GBR 12909-induced hyperactivity. 
Stimulant-produced hyperactivity has also been largely attributed to increased 
synaptic DA levels. Stimulant drugs that produce hyperactivity activate the dopaminergic 
system. For example, amphetamine and cocaine bind to the DAT with high affinity 
(Calligaro and Eldefrawi, 1987; Amara and Sonders, 1998), and thus significantly increase 
synaptic levels of DA (Morgan et al., 1997; Lamensdorf et al., 1999; Chefer et al., 2003). 
Hypermotility coincided with increased DA outflow in the nucleus accumbens and caudate 
as revealed by microdialysis following psychostimulant administration (Di Chiara and 
Imperato, 1988). Indeed, hyperactivity produced by cocaine, amphetamine and other 
psychostimulants was attenuated by co-administration of a range of DA antagonists (Le et 
al., 1997; O'Neill and Shaw, 1999; Schindler and Carmona, 2002; Bubar et al., 2004; 
Daniela et al., 2004) or following neurotoxic 6-hydroxydopamine lesions (Roberts et al., 
1975; Koob et al., 1981; Itoh et al., 1984; Louis and Clarke, 1998). 
Role of Serotonin 
Depletion of brain 5-HT in rats increased spontaneous daytime activity (Kostowski, 
1968; Fibiger HC, 1971; Borbely, 1973; Jacobs, 1975; Marsden and Curzon, 1976; 
Steigrad et al., 1978; Dringenberg, 1995). Electrolytic lesions to mid-brain raphe nuclei 
reduced forebrain 5-HT levels and consequently increased spontaneous locomotor activity 
(Kostowski, 1968). Synthesis inhibition via pCPA also increased daytime activity, which 
was reversed when the precursor, L-tryptophan, was administered (Marsden and Curzon, 
1976). The findings suggest that the increased daytime activity levels were related to 5-HT 
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levels reductions. One surprising anomaly was that despite the continuously falling 5-HT 
levels, 72 hours after pCPA when the depletions were the most severe, activity returned to 
control levels. This disparity between the neurochemical and behavioural data was 
explained in terms of compensatory alteration in 5-HT receptor responsivities. It was 
postulated that 5-HT receptors had upregulated, which has been reported following 5-HT 
depletion (Lucki et al., 1989; Berendsen et al., 1991; Aguirre et al., 1995; Aguirre, 1998; 
Compan, 1998) 
An inhibitory role of 5-HT in basal locomotion is supported by studies that have 
examined the effects of increased 5-HT neurotransmission. For example, pretreatment with 
agonists such as fluvoxamine (McMahon and Cunningham, 2001a), RO 60-0175 (Martin 
et al., 1998) and m-CPP (Sills et al., 1985; Aulakh et al., 1989; Lucki et al., 1989; Gleason 
and Shannon, 1998; Gleason et al., 2001; Takahashi et al., 2001) decreased locomotor 
activity. M-CPP-produced hypolocomotion was linked to activation of the 5-HT2c receptor 
as it was attenuated by pretreatment with selective 5-HT2c receptor antagonists (Kennett 
and Curzon, 1988; Klodzinska et al., 1989; Kennett et al., 1994, 1994a; Kennett et al., 
1997; Takahashi et al., 2001). Agonists such as RO 60-0175 that were relatively selective 
for 5-HT2c receptors also produced hypolocomotion (Martin et al., 1998), further 
supporting a role for this receptor in mediating the hypolocomotor effects produced by 
agents that increase serotonergic transmission. 
Increased activity as a result of pCPA pretreatment has been reported to occur 
when animals were in familiar environments (Kostowski, 1968; Fibiger HC, 1971; 
Borbely, 1973; Jacobs, 1975; Marsden and Curzon, 1976; Dringenberg, 1995). Conversely, 
decreased locomotor activity was observed when animals that had been administered 
pCPA were placed in novel environments (Dringenberg, 1995). The decrease in activity in 
response to novel environments was thought to reflect anxiogenesis as opposed to 
locomotor effects. This suggests that in certain circumstances, anxiety might override 
locomotor effects. As described above, serotonergic neurotransmission has been implicated 
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in some forms of anxiety (Martin et al., 1998; Kurt et al., 2000; Silva and Brandao, 2000; 
Bagdy et al., 2001); therefore it has been problematic in some instances to clearly 
differentiate between anxiety-related behaviours and effects on locomotor activity. Some 
frequently used behavioural assays such as the EPM, emergence or social interaction tests 
used to measure anxiety might be affected by drug-produced hypolocomotion, which could 
then be incorrectly interpreted as an elevation in anxiety. Anxiety-related effects can, 
however, be dissociated from effects on locomotor activity by examining dose-effect 
relationships (Kennett et al., 1989; de Angelis, 1996). For example, m-CPP increased 
anxiety at doses that were below the threshold for hypolocomotion (Kennett et al., 1989).  
Stimulant & MDMA-Produced Locomotion 
Amphetamine-produced hyperactivity was potentiated by sertraline, fluoxetine or 
fenfluramine (Sills et al., 1999a, 1999b; Bankson, 2002). It was noted that there was an 
initial reduction in activity levels following drug administration, followed by potentiation. 
This potentiation was attributed to pharmacokinetics, as fluoxetine inhibits cytochrome 
P450 enzymes in the liver involved in amphetamine degradation. This was confirmed in 
that SSRI pretreated rats had significantly higher brain levels of amphetamine at a single 
point in time and the potentiation was thus not the result of elevated 5-HT levels or 
competitive binding.  
Cocaine-produced hyperactivity was also potentiated by fluoxetine and 
fluvoxamine pretreatment (Herges and Taylor, 1998). Microdialysis was conducted 
whereby DA levels in the nucleus accumbens were measured following cocaine, SSRI and 
then the treatment with both drugs (Bubar, 2003). Cocaine significantly elevated accumbal 
DA levels, whereas either SSRI alone had no effect. When cocaine was combined with 
each SSRI, the DA levels were higher than when cocaine was administered alone; leading 
to the conclusion that elevated DA had yielded potentiation of cocaine-produced 
hyperactivity. 5-HT increases have been purported to elevate DA outflow via 5-HT2 
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receptors (Benloucif and Galloway, 1991; Parsons and Justice, 1993). Alternatively, 
competitive binding might account for these findings, as cocaine binds with higher affinity 
to the SERT than the DAT. If SERT sites were occupied following SSRI pretreatment, a 
greater number of cocaine molecules would be available to bind DAT sites, thereby 
elevating DA levels and potentiating hyperactivity. The evidence suggests that despite the 
involvement of SERT binding and 5-HT increases in hyperactivity produced after 
amphetamine or cocaine, these drugs might produce SSRI-potentiated hyperactivity via 
different mechanisms. 
Specific 5-HT receptor mechanisms have been implicated in psychostimulant-
produced hyperactivity. Evidence suggests that the 5-HT1b receptor plays a facilitatory 
role, as blockade attenuated, whilst agonists potentiated both amphetamine-(Papla et al., 
2002) and cocaine-(Przegalinski et al., 2002) produced hyperactivity. 5-HT2a receptor 
blockade produced similar effects, as the 5-HT2 receptor antagonist, ritanserin, attenuated 
both cocaine and amphetamine-produced hyperactivity (O'Neill et al., 1999). These effects 
were further explored in cocaine-studies, where attenuation of hyperactivity by ritanserin 
was attributed to the 5-HT2a receptor, because a selective 5-HT2a receptor antagonist was 
equipotent at reducing cocaine-produced hyperactivity (O'Neill et al., 1999; McMahon and 
Cunningham, 2001b; Fletcher PJ, 2002a; Filip et al., 2004) and an agonist potentiated these 
effects (Filla et al., 2004). The 5-HT2c receptor had an inhibitory influence on these 
behavioural effects, as blockade potentiated (McCreary and Cunningham, 1999; Fletcher 
PJ, 2002a; Filip et al., 2004), whilst 5-HT2c receptor agonists attenuated (Grottick et al., 
2000) hyperlocomotive effects produced by cocaine. A role for the 5-HT2b receptors was 
discounted, as 5-HT2b antagonists/agonists were without effect (Fletcher PJ, 2002a; Filla 
et al., 2004). These findings indicate that the activation of numerous 5-HT receptor 
subtypes modulates the locomotive effects produced by both cocaine and amphetamine 
administration in a similar manner. 
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MDMA produces dose-dependent hyperactivity (Spanos and Yamamoto, 1989; 
Callaway et al., 1990; Kehne et al., 1996a) and this behavioural effect has been attributed 
to increases in both synaptic DA and 5-HT. MDMA-produced hyperactivity was mirrored 
by increased DA outflow (Yamamoto and Spanos, 1988; Bubar, 2003) and was attenuated 
by DA receptor antagonists (Kehne et al., 1996a; Bubar et al., 2004; Daniela et al., 2004) 
or 6-hydroxydopamine lesions (Gold et al., 1989b). Increased DA outflow might be related 
to direct effects on the DAT, or increased cell firing. A study monitored single striatal 
dopaminergic neurons of freely moving rats to determine levels of excitation in this area 
following MDMA administration and also to observe whether this was correlated with the 
pattern of activity (Ball et al., 2003). The results showed that 5mg/kg MDMA produced 
significant neuronal excitation in the striatum that was positively correlated with increased 
locomotor activity. When the D1-like receptor antagonist, SCH 23390, was administered in 
conjunction with MDMA, a late onset of hyperactivity was observed and this was 
associated with a delay in neuronal excitation. Administration of the D2-like receptor 
antagonist, eticlopride with MDMA, completely abolished hyperactivity, and subsequently 
no neuronal excitation was detected. The behavioural data reflected the 
electrophysiological recordings in that increased DA outflow, excited striatal neurons and 
MDMA-induced hyperactivity were all interrelated (Ball et al., 2003).  
The different behavioural effects of the MDMA stereoisomers also demonstrate the 
important role that DA plays in MDMA-produced hyperactivity. The (+) MDMA isomer 
increased DA in striatal areas to a greater extent than its (-) congener (Johnson et al., 1986; 
Hiramatsu and Cho, 1990) and induced greater levels of hyperactivity than comparable 
doses of (+/-) MDMA or the (-) isomer (Paulus and Geyer, 1992; Fantegrossi et al., 2003).  
Evidence has shown that MDMA-produced 5-HT outflow and binding to the SERT 
are also necessary for full expression of MDMA-produced hyperactivity. Rats that had 
sustained 5-HT depletion following 5,7-DHT lesions or pCPA administration showed 
attenuation of MDMA-produced hyperactivity (Callaway et al., 1990; Kehne et al., 1996a). 
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The administration of SSRIs such as fluoxetine, sertraline and zimelidine completely or 
partially attenuated MDMA-produced hyperactivity (Callaway et al., 1990; Callaway and 
Geyer, 1992b) and SERT knockout mice did not exhibit  hyperactivity following MDMA 
administration (Bengel et al., 1998), suggesting that MDMA binding to the SERT is 
critical for the full expression of MDMA-produced hyperactivity. It is possible that this 
attenuation was due to reduced synaptic 5-HT levels, as SERT selective compounds dose-
dependently prevented MDMA-produced increases in synaptic levels of 5-HT 
(Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 1992; Gudelsky 
and Nash, 1996). Following MDMA administration, SERT-produced 5-HT elevations 
might be necessary to activate facilitatory 5-HT receptors involved in hyperactivity, as 
antagonism of the 5-HT1b or the 5-HT2a receptors attenuated MDMA-produced 
hyperactivity (Kehne et al., 1996a; McCreary et al., 1999; Bankson, 2002; Herin et al., 
2005). 
The majority of reports indicate that both DA and 5-HT play a role in MDMA-
produced hyperactivity. MDMA is a drug that produces substantial increases in synaptic 
levels of these neurotransmitters and therefore provides an ideal tool for studying possible 
interactive effects. Given the inhibitory role for 5-HT upon basal locomotor activity, it 
might seem counter-intuitive that MDMA produces dose-dependent hyperactivity (Spanos 
and Yamamoto, 1989; Callaway et al., 1990; Kehne et al., 1996a; Fletcher PJ, 2002b; 
Herin et al., 2005) when it has higher affinity for the SERT than the DAT (Battaglia et al., 
1988) and increases synaptic 5-HT levels substantially (Gough et al., 1991; White et al., 
1996; Lyles and Cadet, 2003; Colado et al., 2004; Green et al., 2004). It is likely that 
interactions between DA and 5-HT systems can explain these seemingly inconsistent 
results. The combination of 5-HT and DA release might be synergistic when considering 
MDMA-produced hyperactivity. This was demonstrated in an eloquent study that 
examined the effects of selective SERT and DAT reuptake inhibitors on locomotor activity 
(McMahon and Cunningham, 2001a). When low dose of a DA reuptake inhibitor that did 
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not alter locomotor activity was administered with varying fluvoxamine doses, dose-
dependent hyperactivity was produced by the combination. A 5-HT2a receptor antagonist 
attenuated this hyperactivity (Gold, 1988b; Kehne et al., 1996a; Herin, 2001; Bankson, 
2002; Fletcher PJ, 2002b; Herin et al., 2005), suggesting that hyperactivity produced by the 
reuptake inhibitor combination might have similar mechanisms to that produced by 
MDMA. Increased 5-HT and DA input might be synergistic because the 5-HT1b and 5-
HT2a receptors contribute to MDMA-produced hyperactivity (Kehne et al., 1996a; 
McCreary et al., 1999; Fletcher PJ, 2002a; Herin et al., 2005) by facilitating DA outflow 
(Benloucif and Galloway, 1991; Galloway et al., 1993; Schmidt et al., 1994; Iyer, 1996; 
Yan, 2000; Kuroki et al., 2003). 
A Behavioural Analysis of Serotonergic Integrity After MDMA Pre-Exposure: The Present 
Study 
Tolerance to MDMA Following Pre-Exposure 
MDMA Users 
There are mixed reports concerning the consequences of long-term MDMA use. 
Anxiety (Cohen, 1996; Schifano et al., 1998; Parrott, 2002a; Parrott et al., 2002b), memory 
impairments (Bolla et al., 1998; Verkes et al., 2001; Curran and Verheyden, 2003; Hanson 
and Luciana, 2004), cognitive difficulties (McCann et al., 1999), mood disturbances 
(Cohen, 1996; Parrott and Lasky, 1998; Schifano et al., 1998; MacInnes et al., 2001; 
Parrott, 2002a; Verheyden et al., 2003; de Win et al., 2004) and suicidal tendencies 
(Cohen, 1996; Shannon, 2000; Kalant, 2001) have all been reported. Contrary to these 
findings, some studies have reported minimal impact of prior MDMA exposure 
(Verheyden et al., 2003). A consistently reported consequence is tolerance to the subjective 
effects of the drug following regular use (Verheyden et al., 2003; Scholey et al., 2004; 
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Parrott, 2005). Because tolerance to MDMA has been so frequently reported, 
neurochemical changes associated with use have been investigated.  
Since most of the subjective effects produced by MDMA have been attributed to 5-
HT mechanisms (Liechti et al., 2000b; Liechti et al., 2001; Liechti and Vollenweider, 
2001), alterations in serotonergic neurotransmission have been a focal point. Cerebrospinal 
fluid (CSF) 5-HIAA levels provide a means of assessing brain 5-HT turnover in humans, 
as lowered 5-HIAA concentration coincided with decreased tissue 5-HT levels in non-
human primates after MDMA (Ricaurte et al., 1988b; Insel et al., 1989; Taffe et al., 2001; 
Taffe et al., 2003). MDMA users exhibited reduced 5-HIAA levels, suggesting central 5-
HT depletions (McCann et al., 1994; Bolla et al., 1998; McCann et al., 1999). The ability 
of MDMA to elevate synaptic 5-HT levels could be compromised when there are central 5-
HT depletions, producing tolerance.  
It is also possible that MDMA exposure alters 5-HT metabolism. For example, 
following a tryptophan augmented drink, MDMA users had significantly higher plasma 
tryptophan increases than controls, possibly as a consequence of disrupted serotonergic 
metabolism (Curran and Verheyden, 2003). It is possible that these results were due to 
TPH inhibition, as this was a consequence of MDMA exposure in animals (Stone et al., 
1987; Schmidt and Taylor, 1987a; Stone et al., 1989a; Stone et al., 1989b; Garcia-Osta et 
al., 2004). Thus, elevated plasma tryptophan levels in MDMA users might have reflected 
an impaired ability to metabolise tryptophan. 
There are other physiological measures of the 5-HT systems that have been used to 
assess serotonergic function in MDMA users. Single Photon Emission Computed 
Tomography (SPECT) or Photon Emission Tomography (PET) scans following 
radioligand injection revealed evidence of altered serotonergic neurotransmission. SERT 
(McCann et al., 1998; Semple et al., 1999; Buchert et al., 2003; Thomasius et al., 2003) 
and 5-HT2a receptor binding densities (Reneman et al., 2002) were significantly decreased 
in participants who were currently using MDMA. Following abstinence, there was a 
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significant increase in 5-HT2a receptor binding densities in the occipital cortices of this 
group (Reneman et al., 2002). Because receptors are sensitive to changes in synaptic levels 
of 5-HT and up- or down-regulate in response to these levels (Teeple, 1990; Lohse, 1993; 
Cooper, 2002), these results might reflect altered 5-HT turnover and/or levels. Length of 
abstinence from MDMA use was also positively correlated with recovery of SERT binding 
(Semple et al., 1999; Buchert et al., 2003; Thomasius et al., 2003). 
5-HT receptor desensitisation might contribute to the diminished effects of 
MDMA, as users were tolerant to the subjective and physiological effects of a range of 5-
HT agents. For example, the ability of the 5-HT agonists, m-CPP or fenfluramine, to 
increase plasma levels of prolactin and cortisol was decreased (McCann et al., 1999; 
Verkes et al., 2001; Hatzidimitriou et al., 2002) and additionally, users did not experience 
m-CPP-produced anxiety or negative effect (McCann et al., 1999). These reduced m-CPP-
related subjective effects and blunted neuroendocrine responses are consistent with 
reduced 5-HT2 receptor densities resulting from MDMA exposure (Reneman et al., 2002).  
Similar mechanisms might underlie tolerance to the subjective effects of MDMA, 
as both a 5-HT2a/2c receptor antagonist (Liechti et al., 2000a; Liechti et al., 2001; Liechti 
and Vollenweider, 2001) and a SERT blocker attenuated MDMA-produced subjective 
effects (Liechti et al., 2000b; Liechti et al., 2001; Liechti and Vollenweider, 2001), 
therefore decreased 5-HT2a receptor and SERT binding densities in MDMA users might 
contribute to tolerance to MDMA. 5-HT2a receptor activation has been associated with 
hallucinogenic drug effects (Jakab and Goldman-Rakic, 1998; Aghajanian and Marek, 
1999; Nelson et al., 1999), therefore, it is possible that decreased receptor densities might 
contribute to tolerance to some of the perception-altering properties of MDMA. 
MDMA Pre-Treatment in Animal Studies 
There were also mixed findings with regards to the effects of MDMA pre-exposure 
on baseline behaviour in laboratory animals. Anxiogenesis (Morley et al., 2001; Gurtman 
  
  
28 
et al., 2002; Bull, 2003; McGregor et al., 2003; Bull, 2004; Clemens et al., 2004; 
Thompson et al., 2004; Morley et al., 2005), anxiolysis (Mechan et al., 2002b; Piper and 
Meyer, 2004) or no change in anxiety (Bull, 2003; Bull, 2004; Ho et al., 2004; Sumnall et 
al., 2004) or locomotor (Callaway and Geyer, 1992a; McNamara et al., 1995; Piper and 
Meyer, 2004) measures were reported following MDMA pre-treatment.  
Decreased 5-HT tissue levels have been reported following MDMA exposure 
(Battaglia et al., 1987; Commins et al., 1987; Ricaurte et al., 1988b; Ricaurte et al., 1988c; 
Insel et al., 1989; Molliver, 1990; Scanzello et al., 1993; Aguirre et al., 1995; Colado and 
Green, 1995; Fischer et al., 1995; McNamara et al., 1995; Sabol et al., 1996; Sexton et al., 
1999; Mayerhofer et al., 2001; Boot, 2002; McGregor et al., 2003; Clemens et al., 2004; 
Sumnall et al., 2004; Wang et al., 2004; Nair and Gudelsky, 2006) and both decreases or 
no changes to basal 5-HT dialysate levels were measured in MDMA pretreated rats 
(Matuszewich et al., 2002). Despite inconsistencies in basal dialysate results, 5-HT release 
was consistently impaired in response to pharmacological, physiological or stressful 
stimuli in MDMA pretreated animals (Gartside et al., 1996; Shankaran and Gudelsky, 
1999; Matuszewich et al., 2002). These findings might explain why laboratory animals 
tolerant to the behavioural effects produced by an acute MDMA challenge showed little 
change in baseline behaviour (Callaway and Geyer, 1992a; Shankaran and Gudelsky, 
1999) and suggest that pharmacological challenge might be required for functional 
impairments to be evident. 
Animal studies provide evidence to support the idea that tolerance to MDMA is due 
to serotonergic deficits produced following chronic exposure. MDMA exerts predominant 
effects on the 5-HT system, as it has highest affinity for the SERT (Battaglia et al., 1988; 
Rudnick and Wall, 1992), inhibits vesicular 5-HT uptake (Brodkin, 1993), inhibits TPH 
(Stone et al., 1987; Schmidt and Taylor, 1987a; Stone et al., 1989a; Stone et al., 1989b; 
Garcia-Osta et al., 2004) and induces widespread 5-HT release (Gough et al., 1991; White 
et al., 1996; Lyles and Cadet, 2003; Colado et al., 2004; Green et al., 2004). These 
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serotonergic changes likely instigate many of the other neurological changes reported after 
MDMA treatment, such as altered 5-HT receptor status (Scheffel et al., 1992; Aguirre et 
al., 1995; Aguirre, 1998; Reneman et al., 2002; McGregor et al., 2003) and SERT binding 
densities (Battaglia et al., 1987; Scanzello et al., 1993; Yau et al., 1994; Aguirre et al., 
1995; Colado and Green, 1995; Lew et al., 1996; O'Shea et al., 1998; Scheffel et al., 1998; 
Colado et al., 1999; Sexton et al., 1999; Brown, 2000; Boot, 2002; McGregor et al., 2003; 
Sumnall et al., 2004). The most robust long-term effect of MDMA administration is 5-HT 
depletion (Battaglia et al., 1987; Commins et al., 1987; Ricaurte et al., 1988b; Ricaurte et 
al., 1988c; Insel et al., 1989; Molliver, 1990; Scanzello et al., 1993; Aguirre et al., 1995; 
Colado and Green, 1995; Fischer et al., 1995; McNamara et al., 1995; Sabol et al., 1996; 
Sexton et al., 1999; Mayerhofer et al., 2001; Boot, 2002; McGregor et al., 2003; Clemens 
et al., 2004; Sumnall et al., 2004; Wang et al., 2004; Nair and Gudelsky, 2006) and this 
might lead to relevant downstream changes.  
Consistent with these findings, a relationship between altered serotonergic 
neurotransmission and tolerance was demonstrated. MDMA pretreatment (10mg/kg X4, 
total = 40mg/kg) and subsequent microdialysis revealed an impaired ability of acute 
MDMA to increase striatal 5-HT (Shankaran and Gudelsky, 1999). MDMA-produced 
behaviours were also suppressed, as 5-HT syndrome and hyperthermic responses were 
attenuated in pretreated rats. MDMA-produced hyperactivity (Kehne et al., 1996a; 
Bankson, 2002; Fletcher PJ, 2002b; Herin et al., 2005), 5-HT syndrome and hyperthermia 
have been associated with 5-HT receptor activation (Goodwin et al., 1986a; Goodwin et 
al., 1987b; Murthy and Pranzatelli, 1992; Aguirre et al., 1995; Kleven et al., 1997; Aguirre, 
1998), therefore impaired ability to elevate synaptic 5-HT levels and reduced postsynaptic 
receptor activation might lead to behavioural tolerance. Indeed, MDMA-produced 
hyperactivity is largely dependent upon activation of receptor subtypes such as the 5-HT1b 
and 2a receptors (Kehne et al., 1996a; McCreary et al., 1999; Fletcher PJ, 2002a; Herin et 
al., 2005). Decreased binding densities of these receptor subtypes were reported post 
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MDMA exposure (Scheffel et al., 1992; Reneman et al., 2002; McGregor et al., 2003), 
therefore tolerance might reflect reduced availability of 5-HT to activate receptors that 
facilitate MDMA-produced hyperactivity.  
There was evidence to suggest that tolerance to MDMA following preexposure was 
due to 5-HT depletions. MDMA pretreated rats were tolerant to MDMA, but exhibited an 
augmented response to amphetamine challenge (Gately et al., 1986). These observations 
were purported to relate to MDMA-induced 5-HT depletions, as 5-HT depletion has 
potentiated locomotor response to amphetamines (Segal, 1976). Further, the response to 
amphetamine confirms that tolerance to MDMA-produced hyperactivity was not likely 
generalised impairment of motor function or insurmountable fatigue (Callaway and Geyer, 
1992a).  
MDMA pretreated rats were tolerant not only to the activating effects of MDMA 
36 hours post initial exposure, but also to hyperactivity produced by the 5-HT1 receptor 
agonist, RU24969 (Callaway and Geyer, 1992a; Rempel et al., 1993). MDMA 
pretreatment also produced tolerance to the effects of other serotonergic compounds, 
suggesting that tolerance is indeed reflective of changes to 5-HT systems targeted by these 
drugs. For example, MDMA pretreated rats were tolerant to the effects of the 5-HT2 
receptor agonist, DOI, following an 8-week withdrawal period (Bull, 2004) and to the 
ability of 8-OHDPAT to produce SS-like behaviours (Piper et al., 2006). These findings 
suggest that 5-HT1 and 5-HT2 receptor desensitisation might account for reduced 
behavioural response to the 5-HT agonists. 
MDMA-produced serotonergic deficits have recovered over time. Following a 
withdrawal period, TPH levels increased as did TPH mRNA expression in cortical regions 
(Garcia-Osta et al., 2004).  5-HT levels and SERT binding returned to control values 16-32 
weeks post MDMA exposure (Scanzello et al., 1993; Fischer et al., 1995; Lew et al., 1996; 
Sabol et al., 1996). SERT recovery showed regional distribution, with densities in some 
areas such as the hippocampus (Scanzello et al., 1993; Fischer et al., 1995; Sabol et al., 
  
  
31 
1996; Sumnall et al., 2004) and occipital cortex (Lew et al., 1996) slower to recover than 
others. Downregulated 5-HT2 receptor binding densities (Scheffel et al., 1992; Reneman et 
al., 2002) also recovered over time, probably in response to increases in synaptic 5-HT 
levels. These neurochemical findings are consistent with the notion that MDMA produces 
neuroadaptations that recover over time (Wang et al., 2004; Wang et al., 2005).  
MDMA pretreated rats (10mg/kg twice daily for 4 days) that were tolerant to the 
activating effects of MDMA 3 days afterwards exhibited recovery following a 3 weeks 
withdrawal (Callaway and Geyer, 1992a). Substantial 5-HT depletions were evident in 
hippocampus and striatum immediately after MDMA pretreatment and these depletions 
persisted beyond 3 weeks. Tolerance to MDMA might be due to functional desensitisation 
of the postsynaptic receptors that mediate the behavioural effects of MDMA rather than 
depleted 5-HT levels (Callaway and Geyer, 1992a) since 5-HT1b and 5-HT2a/2c receptors 
underwent region and MDMA-dose specific alteration (McGregor et al., 2003). 
Since MDMA alters serotonergic systems, DA neurotransmission might be affected 
because the systems are interrelated. No changes, however, to DA levels or metabolism 
were found after monkeys had received MDMA when analyses of brain tissue and CSF 
were conducted (Ricaurte et al., 1988a; Ricaurte et al., 1988b; Ricaurte et al., 1988c). In 
rats, no changes to DAT binding densities were reported following MDMA exposure 
(Battaglia et al., 1987; Lew et al., 1996; McGregor et al., 2003). No change (Callaway and 
Geyer, 1992a), elevated (McNamara et al., 1995; Mayerhofer et al., 2001) or lowered 
(Commins et al., 1987) DA levels in the striatum, nucleus accumbens and hippocampus 
have been reported following administration of high dose MDMA. When DA 
neurotransmission was affected by MDMA, it was possible that this was a secondary 
occurrence to changes in the serotonergic system. Numerous 5-HT receptors have the 
ability to modulate the dopaminergic system; suggesting that changes in function/number 
of these receptors might impact DA neurotransmission in affected areas (Daniela et al., 
2004). In addition to this, GABA has been found to influence MDMA-produced DA 
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release in the nucleus accumbens (Bankson and Yamamoto, 2004) and decreased GABA-1 
transporters has been reported following MDMA exposure (Peng and Simantov, 2003). 
The present study is investigating tolerance to the behavioural response to MDMA 
following preexposure, but MDMA pretreatment has also produced sensitisation to the 
activating effects of MDMA (Spanos and Yamamoto, 1989; Dafters, 1995; Kalivas et al., 
1998; McCreary et al., 1999; Ramos et al., 2004, 2005). Sensitisation was consistently 
produced by repeated and intermittent MDMA dosing regimens (Spanos and Yamamoto, 
1989; Kalivas et al., 1998; Ramos et al., 2004, 2005). When tolerance (Callaway and 
Geyer, 1992a) or no changes (McNamara et al., 1995) in MDMA-produced hyperactivity 
were reported, MDMA was administered at higher doses over shorter periods and 
behavioural testing was conducted shortly thereafter. A withdrawal period was important 
for the development of sensitisation to psychostimulants (Kolta et al., 1985; Kalivas and 
Duffy, 1993; Heidbreder et al., 1996; Kalivas et al., 1998). This was specifically 
demonstrated for MDMA, as immediately following an 8-day MDMA pretreatment period, 
rats that were administered lower MDMA doses showed a sensitised response to MDMA; 
but those that had received the higher dose pretreatment did not display sensitisation 
(Kalivas et al., 1998). Interestingly, after an 11-day withdrawal period, both low and high 
MDMA groups exhibited sensitisation. 
 The MDMA dosing regimen might also determine which neurotransmitter systems 
are affected. Whilst tolerance to MDMA was associated predominantly with serotonergic 
changes, altered dopaminergic neurotransmission was reported in animals that were 
sensitised to MDMA. For example, following a chronic and intermittent MDMA 
pretreatment regimen, microdialysis measuring DA levels produced after acute MDMA 
administration showed potentiated DA increases in these animals (Kalivas et al., 1998). 
These differential neurochemical changes likely explain the different behavioural profiles 
following an MDMA challenge. 
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Present Study 
Outline 
The present study utilised behavioural measures to determine whether functional 
changes to two different 5-HT receptor subtypes or the SERT might account for the 
suppressed behavioural response to MDMA following pre-exposure in rats. Since there 
have been no consistent reports regarding changes to baseline behaviour following MDMA 
exposure, most of the experiments assessed behaviour following acute MDMA 
administration. It has been widely reported that even low doses of MDMA produce 
serotonergic deficits, but these deficits only become evident following pharmacological 
challenge. There have been attempts to assess 5-HT receptor status following MDMA 
preexposure, but the range of varying methodologies has made it difficult to draw 
unambiguous conclusions. The present study provides several behavioural assays to assess 
the SERT and 5-HT2a/2c receptors in rats that received the same MDMA pretreatment 
regimen.  
MDMA produces several behavioural effects, but MDMA-produced hyperactivity 
was the primary behavioural assay used in this thesis. This behaviour was selected over 
other MDMA-produced behaviours for several reasons. Firstly, stereotypy predominantly 
involves dopaminergic mechanisms (Gordon and Beck, 1984; Sandoval and Palermo-Neto, 
1995) and has not been consistently reported as an MDMA-produced behavioural effect 
(Matthews et al., 1989). Secondly, although MDMA-produced 5-HT syndrome (Kleven et 
al., 1997), anxiety (Martin et al., 1998; To et al., 1999; To and Bagdy, 1999; Kurt et al., 
2000; Silva and Brandao, 2000; Bagdy et al., 2001) and hyperactivity (Callaway et al., 
1990; Kehne et al., 1996a) have been attributed to serotonergic systems , the advantage 
that the locomotor activity paradigm has over these more qualitative assessments is that 
clear dose-dependent effects are visible. It is therefore possible to gauge the sensitivities of 
target binding sites, as time course data and dose effect curves allow specific versus non-
  
  
34 
specific effects of pharmacological manipulation to be determined. Finally, both the 5-
HT2a (Kehne et al., 1996a; Bankson, 2002; Herin et al., 2005) and 5-HT2c (Gold, 1988b; 
Hutson et al., 2000; Herin, 2001; Bankson, 2002; Fletcher PJ, 2002b; Fletcher et al., 2006) 
receptor subtypes and the SERT (Callaway et al., 1990; Callaway and Geyer, 1992b) have 
identifiable roles in MDMA-produced hyperactivity, thus use of this single paradigm 
enabled a comparative assessment.   
Although MDMA-produced hyperactivity was the primary assay, 5-HT2 receptor 
agonists were also administered to MDMA pretreated rats in order to determine whether 
any other functional changes had occurred that were not visible in locomotor activity. 5-
HT2c agonists produce hypolocomotion (Klodzinska et al., 1989; Kennett et al., 1994a; 
Martin et al., 1998; McCreary et al., 1999; Gleason et al., 2001), whereas 5-HT2a agonists 
tend to increase locomotor activity (Darmani et al., 1996; Hillegaart et al., 1996; Kaur and 
Ahlenius, 1997; Bull, 2004; Ross et al., 2005). In addition to these locomotor effects, 5-
HT2c receptor activation increases emergence latency (Bilkei-Gorzo et al., 1998) and 5-
HT2a receptor activation produces wetdogshakes (Kleven et al., 1997; Willins and 
Meltzer, 1997; Bartoszyk et al., 2003). These 5-HT2 agonist-induced behaviours were 
measured in MDMA and saline pretreated rats in order to determine whether the receptor 
subtypes were differentially affected by MDMA exposure.  
MDMA Pretreatment and Hyperactivity  
An MDMA pretreatment regimen (10mg/kg X4, total 40mg/kg MDMA) and 2-
week withdrawal time were selected for the present study, as serotonergic deficits 
(Scanzello et al., 1993; Fischer et al., 1995; Sumnall et al., 2004; Nair and Gudelsky, 2006) 
and behavioural tolerance (Shankaran and Gudelsky, 1999) following this protocol are well 
documented. The 2-week recovery period was also selected because evidence suggests that 
MDMA-produced serotonergic deficits are most pronounced after a short withdrawal 
period. For example, 5-HT levels were depleted by approximately 20-30% 6 hours 
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following MDMA exposure, whilst 30 days later, 5-HT levels had further reduced by 80% 
(Reneman et al., 2002). Similarly with SERT binding, decreases in SERT sites were visible 
24 hours after the last dose of MDMA, but regions such as dorsal striatum exhibited 
greatest reductions 2 weeks later (Battaglia et al., 1991). Since suppressed behavioural 
responsiveness to MDMA is probably related to these deficits, it was expected that at the 
2-week time point, rats might exhibit maximal tolerance to MDMA. In order to verify that 
the regimen used in the present study produced comparable serotonergic deficits to 
previous reports, SERT binding was measured across multiple brain regions 2 weeks 
following preexposure. 
Many of the deficits produced by MDMA have been reported to recover over a 
longer period of time (Scanzello et al., 1993; Fischer et al., 1995), which concurs with 
recent reports suggesting that MDMA does not induce irreversible neurological changes 
(Wang et al., 2004; Wang et al., 2005). TPH activity (Garcia-Osta et al., 2004), 5-HT 
levels (Scanzello et al., 1993; Fischer et al., 1995), SERT binding (Scanzello et al., 1993; 
Fischer et al., 1995) and 5-HT2 receptor densities (Scheffel et al., 1992; Reneman et al., 
2002) returned to control levels following an adequate post MDMA withdrawal period. 
Behavioural measures of the integrity of the 5-HT system would also be expected to show 
similar time-dependent recovery. As the neurological recovery following the selected 
pretreatment regimen has been well documented, the present study sought to determine 
whether there was a functional correlate. MDMA-produced hyperactivity was also 
assessed after 12-week withdrawal period, as previous studies showed that serotonergic 
deficits were apparent at the earlier test period but had largely dissipated approximately 12 
weeks following exposure (Scanzello et al., 1993; Fischer et al., 1995). 
The Serotonin Transporter  
Overview 
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The SERT controls the synaptic actions of 5-HT by rapidly clearing released 
neurotransmitter. The transporters are sites of action for SSRIs and high affinity targets for 
drugs such as cocaine, amphetamine and MDMA. Displacement of MDMA binding to 
SERT ablates 5-HT release (Hekmatpanah and Peroutka, 1990; Berger et al., 1992; 
Rudnick and Wall, 1992; Gudelsky and Nash, 1996) and also diminishes behavioural 
effects. For example, when SSRIs were administered in combination with MDMA, 
hyperactivity was attenuated (Callaway et al., 1990). One of the most consistently reported 
consequences of MDMA exposure was reduced SERT binding densities (Battaglia et al., 
1987; Scanzello et al., 1993; Yau et al., 1994; Aguirre et al., 1995; Colado and Green, 
1995; Lew et al., 1996; O'Shea et al., 1998; Scheffel et al., 1998; Colado et al., 1999; 
Sexton et al., 1999; Brown, 2000; Boot, 2002; McGregor et al., 2003; Sumnall et al., 
2004), thus it was hypothesised that loss of SERT sites might contribute to behavioural 
suppression. 
Distribution 
In situ hybridisation studies have revealed that SERT is primarily expressed by 
serotonergic neurons (Blakely et al., 1994). The highest SERT binding densities were 
observed in the midbrain and thalamus, with the lowest in the cerebellum and occipital 
cortex (Brust et al., 2003). Specifically, SERT-rich brain areas were the globus pallidus, 
thalamus, hypothalamus, substantia nigra, interpeduncular nucleus, amygdala, and raphe 
nucleus, where the dorsal raphe nucleus had the highest 5-HT uptake (Lin et al., 2004).  
Neurochemical Roles 
Neural activity, hormones, aging, environmental factors and pharmacological 
agents have the ability to regulate SERT-mediated 5-HT uptake, radioligand binding and 
mRNA expression (Jayanthi and Ramamoorthy, 2005). Much of the detail regarding SERT 
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regulatory mechanisms are beyond the scope of this thesis, but second messenger 
mechanisms are affected by amphetamines, and have therefore been considered.  
Second messengers regulate SERT via phosphorylation of the transporter protein, 
which alters turnover rate, plasma membrane insertion or sequestration from the plasma 
membrane (Jayanthi and Ramamoorthy, 2005). Phosphorylation state and transporter 
regulation is a balance between the actions and localisation of protein kinases and 
phosphatases, as application of protein kinase C (PKC) activators reduced the transport 
capacity for 5-HT. Also, agents that maintained a phosphorylation state, such as 
phosphatase inhibitors, rapidly reduced transport capacity (Ramamoorthy et al., 1998). 
SERT-selective substrates can influence transporter trafficking and plasma 
membrane residency (Ramamoorthy and Blakely, 1999). Since transporters are regulated 
by kinase-dependent mechanisms, it is possible that substrates influence transporter surface 
expression by regulating kinase-mediated transporter phophorylation. For example, SERT 
substrates such as 5-HT, amphetamines, SSRIs and cocaine control PKC-mediated SERT 
phosphorylation and surface redistribution (Ramamoorthy and Blakely, 1999). 
Chronic administration of SSRIs, paroxetine or sertraline, decreased SERT binding 
densities in the hippocampus, but had no effect on 5-HT levels or SERT mRNA expression 
(Benmansour et al., 1999). Since multiple kinase pathways regulate SERT, whole brain 
kinase mRNA expression was studied following chronic fluoxetine or citalopram treatment 
(Rausch et al., 2002). Chronic treatment with either SSRI produced downregulation in 
PKC-delta, PKC-gamma, stress-activated protein kinase, cAMP-dependent protein kinase 
beta isoform, Janus phosphokinase and phosphofructokinase M, whereas acute treatment 
produced no changes. These findings suggest that decreased SERT binding following 
chronic SSRI exposure might involve changes in SERT-regulatory mechanisms rather than 
SERT mRNA expression. 
Behaviours Produced by Selective Reuptake Inhibitors 
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SSRIs primarily target the SERT and are clinically effective as antidepressants. The 
forced swim test (FST) is the most widely used model for assessing pharmacological 
antidepressant activity (Cryan et al., 2005). The test is based on the observation that 
rodents eventually develop immobility when they are placed in a cylinder of water after 
they stop active escape behaviours, such as climbing or swimming. Generally, it has been 
observed that drugs that increase serotonergic neurotransmission increase swimming, 
whilst those that affect catecholaminergic mechanisms affect climbing behaviours (Cryan 
et al., 2005). The FST is used as a screen in antidepressant discovery research due to its 
sensitivity to a broad range of antidepressant drugs, including not only SSRIs, but also 
tricyclics, monoamine oxidase inhibitors and atypical antidepressants. The exceptions are 
psychomotor stimulants, which also reduce immobility in the FST but are not clinically 
effective as antidepressants. In order to distinguish between stimulants and SERT-selective 
compounds, locomotor activity tests are typically conducted alongside FST tests.  
Most clinically established SSRIs, such as fluvoxamine and fluoxetine, decrease 
locomotor activity (Rodriguez Echandia et al., 1983; To et al., 1999; McMahon and 
Cunningham, 2001a). Also consistent with elevated synaptic serotonergic levels, SSRI 
administration decreased exploration of open arms in the EPM (Matto et al., 1996; Silva et 
al., 1999; Kurt et al., 2000; Pollier et al., 2000) and social interaction (To et al., 1999; To 
and Bagdy, 1999). However, the role for SSRIs in anxiety tests are not clear, as acute 
administration has also induced anxiolysis (Molewijk et al., 1995; Bagdy et al., 2001). 
These findings likely reflect the range of pharmacological properties, in addition to 5-HT 
reuptake inhibition, exhibited by different SSRI compounds. For example, anticholinergic 
activity as well as some affinity for the D2-like, H1 histamine and adrenergic receptors 
have been reported (McTavish and Benfield, 1990; Fujishiro et al., 2002).  
Anxiolysis as measured in the EPM (Griebel et al., 1999; Silva et al., 1999) and 
social interaction tests (To et al., 1999; To and Bagdy, 1999) were reported following 
chronic SSRI treatment. In the FST paradigm, SSRIs are effective following both acute 
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and chronic administrations. Low doses of fluoxetine (2-5mg/kg) that were inactive 
following acute administration, became active after chronic administration in the FST 
(Detke et al., 1997). It has also recently been observed that an acute fluoxetine dose 
(5mg/kg) that did not produce any observable behavioural effects, significantly reduced 
immobility in the FST following a 14-day treatment regimen (Vazquez-Palacios et al., 
2004). These findings probably reflect adaptive changes in postsynaptic receptors that 
mediate these effects as a consequence of enhanced synaptic 5-HT levels.  
Effects of MDMA on the Serotonin Transporter 
Acute Effects of MDMA Administration 
MDMA binding to the SERT was necessary for full expression of MDMA-
produced hyperactivity, as coadministration of SSRIs such as fluoxetine, sertraline and 
zimelidine completely or partially attenuated MDMA-produced hyperactivity (Callaway et 
al., 1990; Callaway and Geyer, 1992b) and SERT knockout mice did not exhibit  MDMA-
produced hyperactivity (Bengel et al., 1998). SSRIs produce hypomotility (Rodriguez 
Echandia et al., 1983; To et al., 1999; McMahon and Cunningham, 2001a), but attenuation 
of hyperactivity was not likely due to non-selective behavioural suppression, as MDMA-
induced reductions in rears or holepokes were not attenuated (Callaway et al., 1990; 
Callaway and Geyer, 1992b). Also, amphetamine-produced hyperactivity was augmented 
by SSRI pretreatment, indicating a selective effect on MDMA-produced hyperactivity 
(Sills et al., 1999a, 1999b). These differential effects might be explained in that 
amphetamine has highest affinity for the DAT (Rothman and Baumann, 2003), thus 
hyperactivity is probably driven mostly by dopaminergic mechanisms in comparison to 
MDMA.  
Neurochemical Effects of MDMA Exposure 
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One of the most frequently reported consequences of MDMA exposure was 
reduced SERT binding densities and 5-HT depletions. These observations were initially 
thought to reflect 5-HT neurotoxicity but measuring SERT densities appears to have 
limited use as an index of MDMA-produced neurotoxicity. The SERT is not a structural 
element of the nerve terminals and is therefore susceptible to pharmacological regulation, 
maturation, aging and food restriction (Zhou et al., 1996; Sumnall et al., 2004). Deficits in 
serotonergic systems could alternatively reflect persistent adaptive changes in gene 
expression or protein levels rather than neurotoxicity (Baumann et al., 2006). In studies 
that have assessed MDMA as a potential neurotoxin, silver staining (Switzer, 2000) and 
FluroJade Blue have been utilised. Fluoro Jade Blue is an anionic fluorescein derivative 
that selectively stains degenerating terminals, axons and cell bodies (Schmued and 
Hopkins, 2000). Since neuronal damage is accompanied by hypertrophy of astrocytes or 
‘reactive gliosis’, an increase in the expression of glial fibrillary acidic protein (GFAP) has 
also been used as an indicator of neurotoxicity (O'Callaghan and Sriram, 2005).  
Rats have been pretreated with excessively high doses of MDMA (80-600mg/kg) 
and silver-markers for neurotoxicity examined (Commins et al., 1987; Jensen et al., 1993). 
Extensive damage and degenerating nerve terminals were observed in striatum and parietal 
cortex, indicating that these doses of MDMA could cause neuronal damage. However, it 
was suggested that these doses induced non-specific neuronal damage due to excessive 
sympathetic activation and hyperthermia (Baumann et al., 2006). Indeed, silver staining 
was not confined to 5-HT neurons and the staining pattern did not correspond to 5-HT 
innervation or pattern of 5-HT depletions. When Fluoro Jade Blue was used to assess the 
effects of 10-40mg/kg MDMA, doses of 20mg/kg or greater produced neurotoxicity, but 
again, staining did not overlap with the pattern of 5-HT deficits and toxicity occurred in the 
rats with the highest body temperatures (Schmued, 2003).  
GFAP expression studies indicated that moderate doses MDMA were not 
neurotoxic, yet extremely high doses produced non-selective damage. MDMA 
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pretreatment (10-30mg/kg daily for 7 days) markedly reduced 5-HT levels in the cortex, 
hippocampus and striatum, but GFAP expression was unaffected (O'Callaghan and Miller, 
1993). However, when a separate group was treated at higher doses (75-150mg/kg twice 
daily for 2 days), GFAP expression was elevated in several brain regions but expression 
changes did not correlate to the degree of 5-HT depletions.  
The 5-HT and DA neurotoxins 5,7-DHT and methamphetamine respectively, 
increased GFAP expression. MDMA was administered at doses that produced comparable 
decreases in SERT binding and 5-HT levels to these treatments, but MDMA had no effect 
on GFAP expression (O'Callaghan and Miller, 1993; Pubill et al., 2003). Indeed, two other 
substituted amphetamines, fenfluramine and p-chloroamphetamine (PCA) decreased 5-HT 
levels by approximately 50-60%, but neither affected SERT or GFAP expression 
(Rothman et al., 2003; Wang et al., 2004; Wang et al., 2005). These findings suggest that 
drug-induced decreases in 5-HT levels and reduced SERT binding densities can occur in 
the absence of neurotoxicity.  
Since decreased SERT binding was not due to degenerating 5-HT nerve terminals, 
it was hypothesised that central 5-HT depletions might have altered SERT binding 
properties. MDMA, 5,7-DHT or a tryptophan hydroxylase inhibitor, pCPA all depleted 5-
HT levels, yet only 5,7-DHT (Gobbi et al., 1994; Neumaier et al., 1996) and MDMA 
(Battaglia et al., 1987; Scanzello et al., 1993; Yau et al., 1994; Aguirre et al., 1995; Colado 
and Green, 1995; Lew et al., 1996; O'Shea et al., 1998; Scheffel et al., 1998; Colado et al., 
1999; Sexton et al., 1999; Brown, 2000; Boot, 2002; McGregor et al., 2003; Sumnall et al., 
2004) reduced SERT binding. Effects on SERT binding might, therefore, be dependent on 
the properties of the compound administered and not on the ability to reduce 5-HT levels. 
5,7-DHT reduced SERT binding, 5-HT levels, altered SERT mRNA expression, increased 
GFAP expression and reduced plasma membrane SERT levels (Wang et al., 2004; Wang et 
al., 2005). MDMA did not, however, affect SERT mRNA, GFAP expression or SERT 
protein levels in plasma membrane, suggesting that the SERT might undergo 
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conformational/functional change after MDMA exposure and that decreased 5-HT levels 
were not a necessary prerequisite. 
MDMA pretreatment might affect SERT regulatory mechanisms, as MDMA and 
other substituted amphetamines induced PKC translocation from the cytosol to the plasma 
membrane (Kramer et al., 1998). MDMA pretreatment (20mg/kg X2) increased 
membrane-bound PKC by 48% (Kramer et al., 1995). PKC translocation was triggered by 
5-HT2a receptor and SERT activation, as selective blockade of either site attenuated 
MDMA-induced PKC translocation (Kramer et al., 1997). The administration of fluoxetine 
or 5-HT2a antagonists prior to MDMA pretreatment were protective against MDMA-
produced serotonergic deficits (Malberg et al., 1996; Sprague et al., 1998), thus it is 
possible that 5-HT2a receptor or SERT activation leads to MDMA-produced PKC 
translocation. Since PKC regulates the SERT (Jayanthi and Ramamoorthy, 2005), MDMA-
induced PKC alteration could affect transport capacity and possibly the ability of selective 
ligands to bind this site.  
MDMA-induced reductions in SERT binding recovered over time following drug 
abstinence, suggesting that changes to SERT regulatory mechanisms/conformation were 
transient (Scanzello et al., 1993; Fischer et al., 1995; Lew et al., 1996; Sabol et al., 1996). 
Recovering SERT binding densities did not correlate well with the restoration of 5-HT 
levels, so 5-HT levels might not instigate initial binding decreases or have a role in the 
recovery process. However, if decreased SERT binding were related to the effects of 
MDMA on PKC, it is possible that changes in 5-HT2a receptor densities might initiate 
recovery. Since MDMA exposure induces a downregulation/desensitsation of 5-HT2a 
receptors (Reneman et al., 2002; McGregor et al., 2003; Bull, 2004) and decreased SERT 
binding, reduced 5-HT2a and SERT-mediated input might reverse the effects of MDMA 
on PKC. Future studies might more closely examine the role of PKC in MDMA-induced 
reductions in SERT binding and whether it also plays a role in the recovery process.  
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Behavioural Effects of MDMA Exposure 
MDMA pretreatment produced substantial SERT binding reductions in most brain 
regions examined (Battaglia et al., 1987; Scanzello et al., 1993; Yau et al., 1994; Aguirre et 
al., 1995; Colado and Green, 1995; Lew et al., 1996; O'Shea et al., 1998; Scheffel et al., 
1998; Colado et al., 1999; Sexton et al., 1999; Brown, 2000; Boot, 2002; McGregor et al., 
2003; Sumnall et al., 2004), but the direct effects on behaviour have yet to be elucidated. 
Studies that have examined the consequences of MDMA exposure on baseline and drug-
induced behaviours have reported SERT binding status as verification that MDMA had 
affected serotonergic transmission. There have been no attempts to directly associate 
altered SERT status with behaviour. Since the SERT regulates synaptic 5-HT levels and 
thus neurotransmission, any behaviour that is related to 5-HT neurotransmission might be 
disrupted by changes to the transporters. Therefore, studies that assessed the behavioural 
consequences of MDMA exposure and SERT binding densities will be reviewed to 
determine whether any behavioural changes appear to correlate with SERT binding status. 
Low (1 X 5mg/kg over 4h) or high (4 X 5mg/kg over 4hrs) dose MDMA was 
administered with a withdrawal period of 10 weeks (McGregor et al., 2003). Only the high 
dose MDMA group exhibited significant 5-HT level decreases but both groups showed 
SERT binding reductions. Low dose MDMA produced significantly lower densities in the 
medial hypothalamus, whereas high dose lowered densities in almost every brain region 
examined, thus the higher dose produced more widespread serotonergic disruptions than 
the low dose group. The high dose group also exhibited significantly greater behavioural 
deficits, as evidenced by decreased social interaction and increased emergence latency. 
Since no measures of dopaminergic transmission had changed, it was concluded that 
altered 5-HT neurotransmission had affected baseline behaviours in this case.  
A follow-on study attempted to reverse the deficits produced by the high dose 
MDMA regimen by administering oral doses of fluoxetine in drinking water (Thompson et 
al., 2004). Fluoxetine alone reduced 5-HIAA levels in all regions examined, reflecting 
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decreased turnover of 5-HT. Neurochemical analyses were not conducted on the 
MDMA/fluoxetine pretreated group due to the long half life of fluoxetine metabolites, but 
behavioural tests showed that most deficits were ameliorated by chronic fluoxetine 
treatment, however, decreased social interaction remained unaffected. Although these 
findings do not point to specific mechanisms, the effects of chronic fluoxetine treatment 
support previous hypotheses that altered serotonergic neurotransmission produced most of 
the behavioural deficits. It would have been interesting to assess SERT binding sites in the 
MDMA/fluoxetine group, as this could have provided a clue as to whether the behavioural 
recovery was associated with SERT binding status.  
Young Listar Hooded rats were pretreated with low or high dose MDMA (7.5 or 
15.0mg/kg twice daily for 3 days) that produced modest 5-HT decreases with no changes 
in cortical paroxetine binding (Fone et al., 2002; Bull, 2003). Rats exhibited decreased 
social interaction without any effect on locomotor activity, suggesting in this instance that 
reduced SERT binding densities might not be a necessary prerequisite for decreased social 
interaction. It was interesting that these regimens did not reduce SERT binding when lower 
doses in numerous other studies have consistently produced this result. It cannot be 
assumed from these data that there were no changes to SERT densities when only a single 
region was assessed, as alternatively, MDMA might not have produced serotonergic 
deficits in these rats. The rats were only around 165g in weight at the time of MDMA 
pretreatment, whereas most other studies have utilised animals that were in the 250-350g-
weight range (McGregor et al., 2003; Sumnall et al., 2004). It was suggested by the authors 
that young rats might be less susceptible to the 5-HT altering properties of MDMA. For 
example, the MDMA-induced increases in free radical formation, which have been 
attributed to the production of serotonergic deficits, did not appear to occur in the neonatal 
rat brain (Colado et al., 1997). It was also suggested that in earlier developmental periods, 
MDMA might be metabolised differently. 
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MDMA pretreated rats administered a pharmacological challenge prior to 
behavioural testing have produced some inconsistent findings (Callaway and Geyer, 
1992a; Bull, 2003; Bull, 2004; Sumnall et al., 2004). The response to an acute dose of 
MDMA that produced anxiogenesis in the EPM was assessed in MDMA (10mg/kg X 4 
over 6 hrs) pretreated rats following a 2-week withdrawal (Sumnall et al., 2004). In both 
MDMA pretreated and control rats, 10mg/kg MDMA produced an anxiogenic profile in 
the maze, suggesting that there were no pretreatment differences. Despite these 
behavioural similarities, MDMA pretreated rats exhibited significant decreases in 
paroxetine binding and lowered hippocampal 5-HT and 5-HIAA levels compared to 
controls. The results were somewhat surprising, as MDMA pretreatment would be 
expected to produce tolerance to MDMA, as has been reported for MDMA-produced 
locomotor activity (Callaway and Geyer, 1992a), milk drinking (Zacny et al., 1990), 5-HT 
syndrome and hyperthermia (Shankaran et al., 1999). Recent data collected in our 
laboratory from rats that received an identical pretreatment regimen have indicated that a 
dose of 3.3mg/kg MDMA increased emergence latency, and that MDMA pretreated rats 
were tolerant to these effects (unpublished data). Sumnall’s (2004) findings might be 
explained in that the single dose of MDMA was too high and produced non-selective 
effects, as there were decreased closed and open arm entries, suggesting that this dose was 
affecting locomotor activity. Sumnall suggested that the EPM might not be a behavioural 
measure sensitive enough to gauge MDMA-induced functional deficits.  
MDMA pretreated rats (total of 40 or 80mg/kg MDMA) were tested following 
either a 3-day (Callaway and Geyer, 1992a) or 8-week (Bull, 2004) withdrawal period. 
Both regimens produced 5-HT depletions, but cortical SERT binding was unaffected in the 
low dose group. SERT binding was not assessed after the high dose regimen, but 
considering studies that used comparable methodologies have shown decreased binding, it 
was likely that decreases were present. Also, since only one brain area was assessed 
following low dose MDMA, it is possible that decreased SERT binding had occurred in 
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other regions. Following the high dose regimen, rats were tolerant to the activating effects 
of 3.0mg/kg MDMA (Callaway and Geyer, 1992a) and similarly, the low dose produced 
tolerance to a 5-HT2 agonist (Bull, 2004). These findings indicate that MDMA 
pretreatment had affected serotonergic systems and that behavioural tolerance was evident, 
but the extent that SERT binding was affected could not be determined. 
The inability to determine SERT binding status in past studies highlights the 
importance of conducting multiregional SERT binding assays. Additionally, it has been 
reported that SERT binding is differentially affected by MDMA pretreatment regimen and 
the age and strain of the rats (Colado et al., 1997; McGregor et al., 2003). As a 
consequence, comparisons between studies are equivocal. In order to make valid 
comparisons and avoid the aforementioned confounds, use of the same pretreatment 
methodologies are vital. For example, Bull and colleagues utilised different withdrawal 
times and pretreatment regimens in two studies comparing the effects of MDMA 
preexposure on the behavioural responsiveness to an m-CPP (2003) or DOI (2004) 
challenge. It was concluded that MDMA preexposure did not alter response to m-CPP, yet 
the response to DOI was ablated. However, because the experimental procedures were 
different, differences might be attributable to procedure.  
Experiment Details 
To assess the role of the SERT in MDMA-produced hyperactivity, a SERT-
selective compound, clomipramine, was administered in combination with MDMA. 
Clomipramine was selected for these experiments because it is highly selective for the 
SERT, in fact, more selective than the commonly used fluoxetine (Wu et al., 2005). 
According to ligand binding analysis, the potency of clomipramine for the SERT was at 
least 100-fold higher than for the NET or DAT.  
It has been reported that SSRIs prevented MDMA-produced hyperactivity 
(Callaway et al., 1990; Callaway and Geyer, 1992b), so it was expected that clomipramine 
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would similarly attenuate hyperactivity. SSRIs also produced hypomotility by enhancing 
synaptic 5-HT levels (Rodriguez Echandia et al., 1983; To et al., 1999; McMahon and 
Cunningham, 2001a), so the ability of clomipramine to affect baseline locomotor activity 
was investigated for use as a second behavioural assay. SSRI-induced hypolocomotion was 
consistently reported and most likely to yield dose-dependent effects, whereas there were 
mixed findings in anxiety and FST measures. In addition, as MDMA pretreated rats exhibit 
tolerance to MDMA, examining the inhibitory abilities of clomipramine might be 
confounded, as low activity levels might not be further reduced. For these reasons, it was 
deemed necessary to provide a SERT-mediated assay wherein MDMA was excluded. 
The effects of clomipramine on MDMA-produced hyperactivity were assessed in 
MDMA pretreated and control rats. The MDMA pretreatment regimen produced 
significant SERT binding reductions in multiple brain regions, therefore, it was expected 
that pharmacological SERT manipulation would yield little behavioural response in 
MDMA pretreated rats. These findings would be consistent with the idea that reduced 
SERT binding densities might be a candidate for tolerance to MDMA-induced 
hyperactivity.  
The 5-HT2 Receptors 
Overview 
The 5-HT2 receptor family presently includes three subtypes; the 5-HT2a, 5-HT2b 
and 5-HT2c receptors. The subtypes are similar in terms of their molecular structure, 
pharmacology and signal transduction pathways (Barnes and Sharp, 1999). The 5-HT2 
receptors are coupled positively to phospholipase C and lead to increased accumulation of 
inositol phosphates and intracellular calcium. The availability of selective antagonists has 
allowed receptor distributions to be mapped and the pharmacological and behavioural roles 
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to be studied. There are currently no selective agonists available, which limits further 
progress to some degree. 
Selective antagonists for the 5-HT2a and 5-HT2c, but not the 5-HT2b, receptor 
subtypes modulate MDMA-produced hyperactivity by affecting dopaminergic 
neurotransmission. Changes to these receptor subtypes might contribute to locomotor 
tolerance to MDMA, as dopaminergic mechanisms affect locomotor activity and it was 
reported that 5-HT2 receptors were desensitised or downregulated following MDMA 
exposure. The 5-HT2 receptors were selected over other 5-HT receptor subtypes that also 
modulate MDMA-produced locomotor activity because there were more consistent effects 
of MDMA exposure on these receptors and the selective ligands were available. Also, in 
addition to MDMA-produced locomotor activity, the 5-HT2c and 5-HT2a receptors have 
been implicated in a number of other behavioural functions and are widely distributed 
throughout the central nervous system. Since tolerance to MDMA has been observed in 
other behaviours in addition to locomotor activity, it is possible that 5-HT2 receptor 
desensitisation might also explain general behavioural suppression. 
The 5-HT2c Receptor Subtype 
Distribution 
Extensive work has been conducted to map the distribution of the 5-HT2c receptor 
within the mammalian central nervous system (CNS). 5-HT2c receptor m-RNA labelling 
was the most abundant and widespread of the 5-HT receptor subtypes investigated (Wright 
et al., 1995) and greater 5-HT2c receptor distribution was found to that of the 5-HT2a 
receptor (Pompeiano et al., 1994; Wright et al., 1995). The distribution of this receptor 
subtype is consistent across rat, human and monkey (Abramowski et al., 1995). Dense 5-
HT2c receptor distributions were found in the hippocampus, amygdala, thalamus, 
hypothalamus, cerebral cortex, nucleus accumbens, caudate putamen, olfactory system, 
midbrain and brain stem (Molineaux et al., 1989; Abramowski et al., 1995; Eberle-Wang et 
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al., 1997; Clemett et al., 2000; Lopez-Gimenez et al., 2001). 5-HT2c mRNA was co-
expressed with glutamic acid carboxylase but not tyrosine hydroxylase mRNA in 
substantia nigra, suggesting expression in GABA but not dopaminergic or NE neurons 
(Eberle-Wang et al., 1997). Patterns of mRNA receptor expression indicated that this 
receptor subtype was located mainly in postsynaptic regions (Lopez-Gimenez et al., 2001) 
but some expression was also found in dorsal raphe nuclei neurons, suggesting a 
presynaptic function in this region (Clemett et al., 2000). Higher mRNA densities were 
found in the dorsal raphe nucleus as opposed to the median raphe nucleus and since the 
two regions have projections to different brain regions, there could be functional 
implications of this distribution disparity. 
Neurochemical Mechanisms 
Many investigations have shown that 5-HT2c receptors modulate DA outflow, thus 
providing a means whereby the serotonergic system can alter DA neurotransmission. 
Microdialysis studies have shown that 5-HT2c receptor blockade increased, whilst 5-HT2c 
agonist decreased DA levels in striatum, nucleus accumbens and frontal cortex (Millan et 
al., 1998; De Deurwaerdere, 1999; Di Giovanni, 1999; Gobert et al., 2000). When 
haloperidol was administered at doses that blocked the D2-like autoreceptor, thereby 
significantly elevating striatal DA, DA outflow was potentiated by the 5-HT2b/2c 
antagonist SB 206553 (Lucas et al., 2000). Potentiated cocaine-produced DA increases in 
the striatum and nucleus accumbens were also found after 5-HT2c antagonist pretreatment 
(Navailles et al., 2004). Additional support for an inhibitory role on DA outflow for the 5-
HT2c receptors was demonstrated in that 5-HT2c receptor knockout mice had higher DA 
levels in the nucleus accumbens than wildtypes following cocaine administration (Rocha et 
al., 2002). These findings suggest that 5-HT2c receptor activation has an inhibitory 
influence on DA mechanisms. 
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This inhibitory influence of the 5-HT2c receptor on dopaminergic 
neurotransmission was demonstrated further in electrophysiological studies. The basal 
firing rate of DA neurons in the ventral tegmental area and substantia nigra increased 
following 5-HT2c antagonist administration (Di Giovanni, 1999; Gobert et al., 2000). 
Conversely, the 5-HT2c agonist, Ro 60-0175 caused a dose-dependent reduction in the 
firing of the ventral tegmental area dopaminergic neurons and a decrease in DA levels in 
the nucleus accumbens (Di Matteo, 2000; Gobert et al., 2000).  
The inhibitory role of the 5-HT2c receptor on DA outflow might relate to GABA, 
as 5-HT2c receptors have been localised on GABA neurons (Stanford and Lacey, 1996; 
Eberle-Wang et al., 1997; Liu et al., 2000). An investigation used microdialysis to 
simultaneously monitor GABA and DA levels in the ventral tegmental area and nucleus 
accumbens respectively, following MDMA administration (Bankson and Yamamoto, 
2004). GABA levels were significantly increased after MDMA, as were DA levels. When 
SB 206553 was perfused into the ventral tegmental area, GABA efflux was markedly 
reduced and accumbal DA levels potentiated. It was postulated that elevated 5-HT levels 
following MDMA had activated 5-HT2c receptors on GABA neurons in the ventral 
tegmental area, with a resulting GABA efflux. This efflux inhibited accumbal DA outflow 
and SB 206553 disinhibited DA.  
A splice variant of the 5-HT2c receptor has been isolated and localised in brain 
tissue of the rat, mouse and human (Canton et al., 1996). Recently it has been reported that 
5-HT2c receptor mRNA undergoes post-transcriptional editing to yield multiple 5-HT2c 
receptor isoforms with different distributions in the brain. The 5-HT2c receptor undergoes 
editing of the second intracellular loop (IL2) at 5 sites. The non-edited receptor contains 
isoleucine, asparagine and isoleucine (INI) at positions 156, 158, 160, whilst the two 
principal edited isoforms have valine, serine, valine (VSV) or valine, glycine and valine 
(VGV) at these positions. It is known that the IL2 plays a role in G-protein coupling and it 
is therefore not surprising that following editing, reduced G-protein coupling efficiency, 
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agonist affinity and basal activity levels of isoforms have been observed (Herrick-Davis et 
al., 1999; Niswender et al., 1999; Wang et al., 2000; Berg et al., 2001; Visiers et al., 2001).  
Indeed, reports support propositions that mRNA editing can produce 5-HT2c 
receptor subpopulations with reduced functional capacities. The 5-HT2c receptor 
stimulates PLC resulting in production of inositol phosphate (IP) and diacylglycerol and 
these compounds can be measured as an index of receptor activity (Niswender et al., 
1999). A relatively large proportion of 5-HT2c-ini receptors exist in a G-protein coupled 
state compared to the 5-HT2c-vsv and 5-HT2c-vgv receptors (Niswender et al., 1999). 
This was cited as the first evidence to show that different isoforms have different G-protein 
coupling efficiencies. In addition, some receptors have the ability to induce effective G-
protein coupling in the absence of an agonist, and this is termed constitutive activity. The 
non-edited 5-HT2c-ini receptor has the capacity to spontaneously change conformation to 
produce an active state whereby it can interact with G-proteins, thus exhibiting constitutive 
activity as measured by IP production. In contrast, the 5-HT2c-vgv isoform yielded only a 
modest amount of IP formation. The edited isoform also had lower affinity for 5-HT. Brain 
regions that contain the non-edited receptor might be more sensitive to 5-HT and it was 
postulated that editing might occur to modulate receptor responses to endogenous 5-HT at 
serotonergic synapses. 
Agonists do not have the same effect on the edited 5-HT2c receptor isoforms, in 
that they do not exhibit agonist-directed trafficking in the same manner as the non-edited 
receptor does (Berg et al., 2001). Agonist directed trafficking theory states that agonists 
promote the formation of ligand-specific receptor conformations which have different 
capacities to couple to/activate signalling molecules (G-proteins). The relative efficacy of 
agonists at the 5-HT2c-ini receptor isoform differed depending on whether arachidonic 
acid (AA) or IP were measured (Berg et al., 1998). Relative to 5-HT, DOI/bufotenin/LSD 
preferentially activated the AA pathway, whereas quipazine/TFMPP favoured IP 
accumulation, demonstrating agonist directed trafficking. The edited isoforms did not show 
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these different second messenger responses to these agonists, suggesting that only the non-
edited receptor appears to have the ability to ‘direct traffic’. It is possible that DA-
modulatory abilities are related to the activation of specific pathways. 5-HT2c receptor 
editing might therefore reduce the ability of agonists to activate the pathways that enable 
the receptor to affect DA outflow.  
Paradoxically, a facilitatory role for the 5-HT2c receptor on DA outflow has also 
been documented. When a non-selective 5-HT2 agonist, DOI, was perfused into either the 
nucleus accumbens (Yan, 2000) or the striatum (Lucas and Spampinato, 2000), dose-
dependent increases in extracellular DA levels occurred.  SB 206553 and TTX attenuated 
increased DA levels in these areas (Lucas and Spampinato, 2000; Yan, 2000). A role for 
the 5-HT2b receptor was discounted, as no changes to DA outflow occurred when a 5-
HT2b agonist or antagonist was administered (Di Matteo, 2000; Gobert et al., 2000). It was 
concluded that DOI had increased DA via 5-HT2c receptors, as a receptor-mediated 
process is also TTX-sensitive. As a result, it was postulated that different subpopulations 
of 5-HT2c receptors might exist with differential functions. 
Finally, some evidence suggests the existence of presynaptic 5-HT2c receptors and 
consequent ability to limit 5-HT release to some degree. 5-HT2c receptor manipulations do 
not affect basal 5-HT levels, as numerous studies report no effect on dialysate 5-HT levels 
in any brain region studied following 5-HT2c antagonist or agonist administration (Millan 
et al., 1998; Gobert et al., 2000; Cremers et al., 2004). However, a recent study examined 
the effects of 5-HT2c antagonists on elevated 5-HT levels produced after the 
administration of SSRIs (Cremers et al., 2004). Significantly elevated 5-HT levels were 
recorded in rats following SSRI administration, then SB 242084 and RS102221 
significantly potentiated 5-HT levels, whilst 5-HT2a antagonists had no effect.  
Behavioural Roles 
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The 5-HT2c receptors limit basal locomotor activity, as activation produced dose-
dependent hypolocomotion following the 5-HT2 agonist, m-CPP (Sills et al., 1985; Aulakh 
et al., 1987; Kennett and Curzon, 1988; Aulakh et al., 1989; Bagdy et al., 1989; Klodzinska 
et al., 1989; Lucki et al., 1989; Freo et al., 1990; Kennett et al., 1994a; Bonhaus, 1997; 
Kennett et al., 1997a; Gleason and Shannon, 1998; Gleason et al., 2001) or other more 
selective 5-HT2c agonist administration (Martin et al., 1998). Hypolocomotion following 
5-HT2c receptor activation was attenuated by 5-HT2c antagonists (Klodzinska et al., 1989; 
Kennett et al., 1994a; Martin et al., 1998; McCreary et al., 1999; Gleason et al., 2001) but 
not 5-HT2a or 5-HT2b antagonists (Gleason et al., 2001). In addition, there were no 
changes to basal locomotion in 5-HT2c receptor knockout mice after m-CPP 
administration (Heisler and Tecott, 2000; Dalton et al., 2004). It is unknown whether the 
mechanisms for m-CPP-induced 5-HT2c receptor activation and subsequent 
hypolocomotion were attributable to downstream effects on dopaminergic or other 
neurotransmitter systems.  
Activation of the 5-HT2c receptors with m-CPP also increased the time spent in 
peripheral areas in the open field test (Meert et al., 1997), decreased time spent in open 
arms of the EPM and increased emergence latency (Bilkei-Gorzo et al., 1998), which are 
all properties that are consistent with an anxiogenic compound. These m-CPP-produced 
behavioural effects were attenuated by selective 5-HT2c antagonists (Kennett et al., 1994a; 
Kennett et al., 1995; Mora et al., 1997; Bagdy et al., 2001; Campbell and Merchant, 2003) 
and some of the 5-HT2c antagonists produced opposite effects to those produced by m-
CPP when administered alone (Kennett et al., 1994a; Kennett et al., 1994c; Griebel et al., 
1997; Kennett et al., 1997a; Martin et al., 2002).  
Bilateral infusions of m-CPP into the basolateral amygdala (BLA) altered open 
field behaviours, ultrasonic vocalisation and latency to approach a novel object. Rats 
pretreated with SB242084 or SB 200646A showed significant attenuation of these m-CPP-
produced behaviours (Kennett et al., 1994a; Campbell and Merchant, 2003). 5-HT2c 
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receptor agonists were also applied to dorsal or ventral hippocampi and ensuing behaviour 
in the EPM assessed (Alves et al., 2004). Ventral hippocampal administration reduced 
open arm entries, whereas these agonists were without effect in the dorsal hippocampus. 
These studies indicate that 5-HT2c receptors in the BLA and ventral hippocampus might 
play an important role in 5-HT2c receptor-mediated behavioural effects. 
Few studies have examined the role of the 5-HT2c receptors in MDMA-produced 
behaviours. As MDMA and m-CPP produce widespread 5-HT2 receptor activation, 5-
HT2c receptor activation probably contributes to the acute behavioural effects produced by 
both compounds. Recently, a role for the 5-HT2c receptor in MDMA-induced increased 
emergence latency was discounted due to the inability of the 5-HT2c/2b antagonist, SB 
206553 (2mg/kg), to antagonise these effects (Morley et al., 2005). However, the long 
antagonist pretreatment time and use of only one dose of SB 206553 might not have 
allowed for the optimal effects of this antagonist to be behaviourally apparent. The non-
selectivity of SB 206553 for the 5-HT2c receptor might also confound these results, as the 
5-HT2b (Kennett et al., 1996; Duxon et al., 1997; Kennett et al., 1998; Nic Dhonnchadha 
et al., 2003) and 5-HT2c receptors (Kennett et al., 1994a; Kennett et al., 1995; Mora et al., 
1997; Bagdy et al., 2001; Campbell and Merchant, 2003) have opposite roles in related 
paradigms. 
Role in Stimulant-Produced Effects 
5-HT2c receptor antagonists potentiated cocaine (McCreary et al., 1999; Fletcher 
PJ, 2002a; Filip et al., 2004), amphetamine, methylphenidate, nicotine, morphine, 
phencyclidine and MDMA-produced hyperactivity (Gold, 1988b; Hutson et al., 2000; 
Herin, 2001; Bankson, 2002; Fletcher PJ, 2002b; Fletcher et al., 2006), whilst 5-HT2c 
agonists attenuated morphine, nicotine and cocaine-produced hyperactivity (Willins and 
Meltzer, 1998; Grottick et al., 2000; Grottick et al., 2001; Di Matteo et al., 2004). These 
behavioural effects have been attributed to the ability of the 5-HT2c receptor to modulate 
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mesolimbic DA (Millan et al., 1998; Gobert et al., 2000; Lucas et al., 2000; Lucas and 
Spampinato, 2000; Yan, 2000). These behavioural studies have been paired with evidence 
for 5-HT2c receptor-mediated altered dopaminergic neurotransmission. 5-HT2c receptor 
knockout mice display enhanced hyperactivity paired with significantly higher accumbal 
DA dialysate levels when compared to wildtypes following cocaine administration (Rocha 
et al., 2002). Secondly, pretreatment with SB242084 potentiated the increase in 
extracellular levels of DA in the nucleus accumbens and striatum elicited by 15mg/kg of 
cocaine (Navailles et al., 2004).  
The ability of 0.5mg/kg SB242084 to potentiate hyperactivity produced by drugs 
that affect mainly DA or 5-HT systems were compared (Fletcher et al., 2006). 
Fenfluramine and citalopram both selectively increased synaptic 5-HT levels at doses that 
did not significantly affect locomotor activity. Interestingly, the SB242084 and 
fenfluramine (5.0mg/kg) combination potentiated locomotor activity, but the lower dose of 
fenfluramine was ineffective and there were no interactions between SB242084 and 
citalopram. It was postulated that activation of facilitatory 5-HT2a and 5-HT1b receptor 
subtypes in addition to 5-HT2c receptor blockade had produced fenfluramine/SB242084-
induced hyperactivity. This suggests that the inability of SSRIs to affect baseline 
locomotor activity might be related to simultaneous activation of facilitatory and inhibitory 
receptors. It was suggested that failure of the citalpram/SB242084 combination to 
potentiate activity might have been due to an inability of citalopram to elevate synaptic 5-
HT levels high enough to activate facilitatory receptors. Alternatively, these observations 
might relate to the fact that fenfluramine is a substituted amphetamine with some DA-
releasing abilities. Fenfluramine, PCA, amphetamine and MDMA released DA via the 
DAT (Crespi et al., 1997), thus was likely to affect these mechanisms to a greater extent 
than citalopram. The fenfluramine dose selected did not significantly affect extracellular 
DA levels, but it is possible that significant 5-HT2c-receptor-induced potentiation occurs 
only when there is some activation of dopaminergic neurotransmission. Indeed, supporting 
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this idea, it was reported that the hyperactivity induced by a 5-HT1b agonist, RU24969, 
was not potentiated by SB242084 (Fletcher et al., 2006). 
SB242084 potentiated both methylphenidate and amphetamine-produced 
hyperactivity at both doses tested, and it was confirmed that these doses had little effect on 
5-HT levels (Fletcher et al., 2006). The antagonist-produced potentiation indicated that 5-
HT2c receptor blockade enhances the stimulant effects of drugs that selectively increase 
dopaminergic neurotransmission. In opposition to these observations, SB206553, a mixed 
5-HT2b/2c receptor antagonist, did not alter the DA-elevating abilities of 2.0mg/kg 
amphetamine. The inability of the antagonist to affect amphetamine-induced DA outflow 
in this instance might be dose-dependent. Indeed, Fletcher et al. (2006) reported that the 
behavioural response to 1mg/kg amphetamine was unaffected by SB242084 pretreatment, 
whereas effects of the 0.25 and 0.5mg/kg doses were significantly potentiated. It was 
suggested that the modulatory effects of 5-HT2c receptor blockade on amphetamine-
produced hyperactivity might be ‘overwhelmed’ by relatively high synaptic DA levels. 
In addition to the differential behavioural effects produced by the combination of 
SB242084 and the DA/5-HT releasing drugs, differential doses and pharmacological 
properties of 5-HT2c antagonists have produced inconsistencies in behavioural and 
neurochemical results. For example, a high dose of SB 206558 potentiated cocaine-
produced hyperlocomotion, whilst lower doses produced attenuation (McCreary et al., 
1999). These findings raise the possibility of the existence of two distinct 5-HT2c receptor 
populations: pre- and postsynaptic receptors. The presynaptic receptors might be located in 
the hippocampus since bilateral m-CPP infusions increased locomotor activity that was 
blocked by co-infusion of SB 242084 (Takahashi et al., 2001). Additionally, 5-HT2c 
receptor antagonists have different DA-modulatory abilities. SB 206553 significantly 
increased DA levels in the striatum and nucleus accumbens, whereas this did not occur 
following SB242084 administration (Gobert et al., 2000; De Deurwaerdere et al., 2004), 
SB 206553 was an agonist for differential second messenger responses (De Deurwaerdere 
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et al., 2004), whereas even though SB 242084 was comparable, it displayed low efficacy 
agonism towards the phospholipase C (PLC) response. It was proposed that disparate DA-
modulatory abilities might reflect activation of differential second messenger pathways.  
5-HT2c receptor-mediated behavioural effects might also produce inconsistent 
results in some instances, as it has been suggested that two distinct 5-HT2c receptor 
subpopulations exist. Prefrontal cortical infusions of 5-HT2c agonists significantly 
attenuated cocaine-produced hyperactivity (Filip and Cunningham, 2003) but a significant 
potentiation of cocaine-produced hyperactivity was produced when the agonists were 
applied to the nucleus accumbens shell (Filip, 2002). 5-HT2c antagonists enhanced 
cocaine-produced locomotor activity when applied to the prefrontal cortex (Filip and 
Cunningham, 2003), but hyperactivity was attenuated when they were infused into the 
nucleus accumbens shell (McMahon et al., 2001b; Filip, 2002). These results suggest that a 
population of 5-HT2c receptors in the prefrontal cortex are inhibitory whereas a population 
in the nucleus accumbens shell is facilitatory. The effects of local agonist/antagonist 
application to the prefrontal cortex are comparable to those produced following systemic 
administration, suggesting a predominant effect in the prefrontal cortex (McCreary et al., 
1999; Grottick et al., 2000; Fletcher PJ, 2002a) 
Effects of MDMA Exposure 
5-HT receptor changes after MDMA exposure might be attributable to altered 
serotonergic neurotransmission. Indeed, altered receptor densities in response to changing 
levels of 5-HT have been reported. For example, 5-HT1b receptors significantly increased 
(Manrique et al., 1994; Compan, 1998), whilst 5-HT1a receptors decreased (Gobbi et al., 
1994) in number following 5,7-DHT or pCPA treatment. 5-HT2a/2c receptor binding was, 
however, consistently reduced following either 5-HT depletion (Skrebuhhova et al., 1999), 
agonist (Koshikawa et al., 1985; Fone, 1998) or antagonist treatments  (Scheffel et al., 
1992), suggesting atypical regulation properties (Van Oekelen et al., 2003a). MDMA 
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exposure produced dose-dependent decreases in 5-HT2a/2c receptor densities in the cortex 
septum and caudate putamen (McGregor et al., 2003), likely a consequence of altered 
serotonergic transmission. Further ligand binding studies have revealed decreases in 5-
HT2a (Reneman et al., 2002) and 5-HT2 (Scheffel et al., 1992) receptor densities in the 
frontal cortex 6 hours post MDMA exposure. Since 5-HT2 receptors in the choroid plexus 
remained unchanged following MDMA (Scheffel et al., 1992), the effects might be 
regionally selective.  
In addition to downregulation, the 5-HT2c receptor also undergoes functional 
change in response to changing levels of synaptic 5-HT. PCPA resulted in 80% reduction 
in 5-HT/5-HIAA and initiated 5-HT2c receptor mRNA editing (Gurevich, 2002). Isoforms 
with higher sensitivity to 5-HT were expressed. Prolonged stimulation of 5-HT2c receptors 
achieved by frequent injections of DOI produced isoforms that were less responsive to 5-
HT. Similar editing of the 5-HT2c receptor might also occur as a neuroadaptive response 
to altered synaptic 5-HT levels after MDMA exposure.  
Functional receptor changes might affect associated behaviour, however, the 
response to a 5-HT2c receptor agonist was not altered by prior MDMA exposure (Bull, 
2003). Bull et al. (2003) pretreated young Listar Hooded rats (15mg/kg twice daily for 3 
days) and examined baseline and m-CPP-produced behavioural responses in locomotor, 
social interaction, open field and EPM tests. Three weeks later, MDMA pretreated rats 
exhibited decreased social interaction in comparison to controls. Two days later, a 
2.5mg/kg dose of m-CPP was administered to both pretreatment groups to examine 
locomotor activity and open field behaviour. This m-CPP dose did not significantly affect 
baseline locomotor activity or open field behaviour in either pretreatment group. Four days 
after these tests, a 1.0mg/kg dose of m-CPP produced equipotent behavioural effects in 
both pretreatment groups, by reducing time spent in the open maze arms. Decreased 5-HT 
levels were observed in the hippocampus and frontal cortex of MDMA pretreated rats, 
whereas the cortex and striatum showed no changes. It was concluded that MDMA 
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pretreatment had not affected 5-HT2c receptor function, despite the fact that some 
serotonergic depletion and decreased social interaction was evident. Since social 
interaction was the only measure affected by MDMA exposure, the type of anxiety 
detected by the EPM likely involves distinct brain mechanisms from that produced by the 
social interaction test (File, 1992).  
It is possible that the protocols used did not reveal underlying 5-HT2c receptor 
changes. The 2.5mg/kg dose did not significantly produce hypolocomotion in the control 
rats, thus was a ‘subthreshold’ dose for the intended effect. Since MDMA pretreated rats 
were suspected to be less sensitive to m-CPP, it was not surprising that no differences were 
observed when administering this dose that did not induce significant hypolocomotion in 
controls. This study would have benefited from examining dose effect curves, as left or 
rightward shifts would have revealed changes in receptor sensitivities. Although no 
changes were observed in the EPM following the 1.0mg/kg m-CPP dose, it has been 
demonstrated that different paradigms involve different mechanisms. Thus, if a dose that 
produced significant hypolocomotion were used in the locomotor tests, it might have been 
possible to see pretreatment differences even if there were none evident in the EPM. 
The regimen used in this study might not have produced 5-HT2c receptor changes. 
A laboratory group have utilised various MDMA dosing regimens (7.5 or 15mg/kg twice 
daily for 3 days, and 5mg/kg hourly for 4 hours on 2 days), rat strains (Listar Hooded or 
Wistar rats) and withdrawal times (3 or 8 weeks), and consistently shown modest 5-HT 
depletions with no  effect 
 on cortical SERT binding (Fone et al., 2002; Bull, 2003; Bull, 2004). Since most 
other studies have reported SERT binding reductions, these findings seem unusual. There 
was, however, a common difference these studies and others; young, small rats were used. 
As previously mentioned, younger rats have been purported to be less susceptible to 
MDMA-induced serotonergic alteration (Colado et al., 1997). Had these experiments been 
conducted using older rats; greater effects on serotonergic markers might have been 
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evident. Since MDMA-induced alterations to serotonergic neurotransmission probably 
initiate changes to postsynaptic receptors, functional changes to 5-HT2c receptors might 
only be evident in older rats. 
5-HT2c Receptor Experiments in the Present Study 
It has been consistently reported that 5-HT2c receptor antagonists potentiated 
MDMA-produced hyperactivity (Gold, 1988b; Herin, 2001; Bankson, 2002; Fletcher PJ, 
2002b; Fletcher et al., 2006). The present study aimed to replicate these findings using a 
selective 5-HT2c receptor antagonist, RS102221. This compound was chosen because it 
was 100-fold more selective for the 5-HT2c receptor compared to the 5-HT2a and 5-HT2b 
receptor subtypes (Bonhaus, 1997). The ability of RS102221 to potentiate MDMA-
produced locomotor activity was then assessed in MDMA and vehicle pretreated rats.  
There have been few investigations into the effects of MDMA on the binding or 
functional properties of the 5-HT2c receptors. It was reported that MDMA pretreatment 
decreased 5-HT2 receptor binding, but the 5-HT2a and 5-HT2c subtypes were not 
differentiated due to the use of non-selective ligands (Scheffel et al., 1992; McGregor et 
al., 2003). It is possible that MDMA pretreatment could have produced 5-HT2a receptor 
downregulation, whilst the 5-HT2c receptor remained unchanged or vice versa. Despite 
these considerations, there is evidence to suggest that mRNA editing of the 5-HT2c 
receptor occurred in response to changing synaptic 5-HT levels (Gurevich, 2002), 
therefore, altered receptor function might occur following MDMA exposure. Generally, 
tolerance to serotonergic compounds has been documented after MDMA exposure, so the 
massive 5-HT efflux produced by the MDMA pretreatment regimen might lead to 5-HT2c 
receptor desensitisation. 
5-HT2c receptor desensitisation might be expected to produce a potentiated 
locomotor response to MDMA. This suggests that MDMA pretreatment might result in 
little or no change to 5-HT2c receptors, since tolerance to MDMA-induced hyperactivity 
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was evident in pretreated animals. Although 5-HT2c receptor 
desensitisation/downregulation might not explain tolerance to MDMA, it might contribute 
to other aspects of behavioural suppression. The existence of distinct 5-HT2c receptor 
populations with differential behavioural roles has been documented. It is possible that 
some populations and associated behavioural functions are affected by MDMA, whilst 
others are not. In order to characterise the status of several 5-HT2c receptor populations 
post MDMA exposure, m-CPP-produced behaviours were also examined. 
Activation of 5-HT2c receptors produced dose-dependent hypolocomotion and 
increases in emergence latency following m-CPP administration (Sills et al., 1985; Aulakh 
et al., 1987; Kennett and Curzon, 1988; Aulakh et al., 1989; Bagdy et al., 1989; Klodzinska 
et al., 1989; Lucki et al., 1989; Freo et al., 1990; Kennett et al., 1994a; Bonhaus, 1997; 
Kennett et al., 1997a; Gleason and Shannon, 1998; Gleason et al., 2001). The social 
interaction, open field and the EPM were not as easily quantifiable and less likely to 
exhibit dose dependent effects compared to hypolocomotion and emergence latency. 
Although emergence latency has been used as an anxiety measure, in the present study, it 
was used only to pharmacologically determine shifts in receptor responsivities.  
This study extended work by Bull and colleagues (2003), where no functional 
change to 5-HT2c receptor-mediated behaviour following MDMA pretreatment was 
reported, although corresponding neurochemcial data revealed that there was minimal 
effect of MDMA on serotonergic parameters. The present study utilised different subjects, 
MDMA pretreatment regimens and testing protocols. The primary objective was to 
investigate behavioural tolerance to MDMA challenge, therefore, all behavioural tests were 
performed upon MDMA pretreated rats that exhibited tolerance to MDMA-produced 
hyperactivity. Several doses of m-CPP that produced significant behavioural effect were 
examined in the hypolocomotion and emergence latency paradigms and compared between 
pretreatment groups. 
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In order to determine what role the 5-HT2c receptors might have in behavioural 
suppression to MDMA, the first novel assay utilised MDMA and a selective 5-HT2c 
receptor ligand. It was hypothesised that the 5-HT2c receptor population being assessed by 
this paradigm had a minor role in locomotor tolerance, so the purpose was mainly to 
dissociate 5-HT2c from 5-HT2a receptor effects. It has been purported that different 5-
HT2c receptor populations have diverse behavioural roles, thus the effect of MDMA 
pretreatment on other 5-HT2c receptor-produced behaviours were also examined, even 
though these might not directly relate to locomotor tolerance.  
The 5-HT2a Receptor Subtype 
Distribution 
High 5-HT2a receptor densities were observed predominantly in forebrain areas 
such as the neocortex, also in caudate nucleus, nucleus accumbens, olfactory tubercle, 
piriform cortex, red nucleus, claustrum, mamillary bodies, pontine nuclei and cranial motor 
nuclei (Pazos et al., 1985b; Lopez-Gimenez et al., 1997; Barnes and Sharp, 1999). 
Immunocytochemical localization of 5-HT2a receptor distributions in the parabrachial and 
paranigral regions of the ventral tegmental area revealed that approximately 40% of the 5-
HT2a-labeled dendrites contained tyrosine hydroxylase, suggesting that they were 
localised on dopaminergic neurons and might exist as heteroreceptors in this region 
(Doherty and Pickel, 2000). 5-HT2a and 5-HT2c receptor mRNA expression was distinct 
but overlapped in several brain regions. There were high levels of 5-HT2a and 5-HT2c 
receptor expression in the anterior olfactory nucleus, piriform cortex, endopiriform 
nucleus, claustrum, pyramidal cell layer of the ventral part of CA3, taenia tecta, substantia 
nigra and several brainstem nuclei. In the caudate-putamen, expression of both receptors 
was present but with different distributions (Pompeiano et al., 1994). 
Neurochemical Mechanisms 
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As shown by receptor distributions, some 5-HT2a receptors have been localised to 
DA neurons and can therefore modulate dopaminergic neurotransmission. In vivo 
microdialysis demonstrated that 5-HT2a receptors facilitate DA release, but there were 
indications that this receptor only has a modulatory role following increased dopaminergic 
neurotransmission. This was demonstrated when microdialysis was used to determine what 
effect amphetamine, the 5-HT2a agonist, DOI, and the 5-HT2a antagonist, M100907 had 
on DA release. When MDL100907 was perfused via reverse microdialysis into the 
prefrontal cortex (PFC) or nucleus accumbens (NAc), no change in basal DA dialysate 
levels occurred (Kuroki et al., 2003). Perfusion of the 5-HT2 agonist, DOI, into the 
striatum or nucleus accumbens did not alter dialysate DA levels at the doses used 
(Ichikawa and Meltzer, 1995). These findings indicate that the 5-HT2a receptor has 
minimal role in basal DA-release modulation, which reaffirms findings from other studies 
(De Deurwaerdere, 1999; Di Giovanni, 1999). 
Systemically administered amphetamine increased dopaminergic 
neurotransmission, as evidenced by a marked increase in extracellular DA levels in the 
mPFC, striatum and NAc (Ichikawa and Meltzer, 1995; Kuroki et al., 2003). When DOI 
was administered in conjunction with amphetamine, DA increases were significantly 
potentiated in both areas compared to amphetamine alone. MDL100907 petreatment had 
no effect on the elevated amphetamine-produced DA levels, however, MDL100907 
reversed the DOI-produced potentiation of DA (Kuroki et al., 2003). It was concluded that 
DA potentiation following DOI administration was a result of 5-HT2a receptor activation.  
The 5-HT2a receptors also have an active role in DA modulation following MDMA 
administration. An electrophysiology study revealed that MDMA-induced 5-HT2a receptor 
activation increased neuronal firing in the striatum (Ball and Rebec, 2005). SR46349B, a 
5-HT2a receptor antagonist, blocked nearly all MDMA (5.0mg/kg)-induced striatal 
excitations. It was not ascertained whether the neurons affected were serotonergic or 
dopaminergic, but microdialysis studies suggest that DA neurons were activated. MDMA 
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significantly elevated striatal extracellular DA levels, which were dose-dependently 
attenuated by MDL100907 (Schmidt et al., 1994). Intrastriatal infusion of tetrodotoxin 
(TTX) reduced both basal and MDMA-stimulated DA efflux and eliminated the effect of 
MDL100907, suggesting that DA elevations were impulse mediated via 5-HT2a receptor 
activation.  
MDL100907 did not attenuate amphetamine-induced DA elevations in the PFC or 
NAc, whereas this antagonist blocked amphetamine-(Auclair et al., 2004) and MDMA-
(Schmidt et al., 1994) induced DA elevations in the striatum. Different brain regions might 
be differentially susceptible to 5-HT2a receptor manipulations, as some areas might have 
higher receptor densities than others. It is also likely that 5-HT2a receptors with 
differential functional capacities exist.  
MDMA-produced striatal DA increases involved a PKC-mediated process (Nair 
and Gudelsky, 2004). Since 5-HT2a receptors use PKC for intracellular signalling (Kramer 
et al., 1997), it is possible that PKC-mediated DA increases occurred following 5-HT2a 
receptor activation. PKC inhibitors were administered via dialysis probes to MDMA 
pretreated rats, which attenuated MDMA-produced striatal dialysate DA increases, 
whereas PKC activators increased DA release. Conversely, it was found that intracortical 
infusion of PKC inhibitors increased MDMA-produced DA levels. These findings suggest 
that PKC-mediated signalling occurred differentially in mesocorticolimbic and nigrostriatal 
regions, which might provide indirect evidence for the existence of 5-HT2a receptor 
populations with different functional roles.  
Role of the 5-HT2a Receptor in Baseline and Stimulant-Induced Behaviour 
Due to the scarcity of selective 5-HT2a agonists, the behavioural effects of 5-HT2a 
receptor activation have been difficult to ascertain. Selective 5-HT2a receptor antagonists 
used in conjunction with 5-HT2 agonists have allowed certain behaviours to be attributed, 
with some degree of confidence, to 5-HT2a receptor activation. Wetdog shakes (WDS) in 
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the rat and head twitches in the mouse are behavioural markers commonly associated with 
5-HT2a receptor activation. These behaviours have been observed following 
administration of the 5-HT2 agonist, DOI (Kennett et al., 1994a; Darmani et al., 1996; 
Kugaya et al., 1996; Willins and Meltzer, 1997; Bartoszyk et al., 2003; Bull, 2004) and 
were attributed to 5-HT2a receptor activation because they were blocked by 5-HT2a 
antagonists (Kleven et al., 1997; Willins and Meltzer, 1997; Bartoszyk et al., 2003), whilst 
5-HT2c antagonists had no effect (Kennett et al., 1994a; Schreiber et al., 1995; Willins and 
Meltzer, 1997). The 5-HT2 antagonists, ketanserin and ritanserin, produced dose-related 
decreases in DOI-induced head twitches (Kleven et al., 1997). Also, in rats trained to 
discriminate DOI from saline in a drug discrimination paradigm, ketanserin and ritanserin 
blocked the discrimitive stimulus effects of the training dose by more than 50%. In 
contrast, 5-HT1 antagonists failed to affect the discrimitive stimulus effects of DOI. It was 
concluded that DOI-induced head twitches and discrimitive stimulus effects were mediated 
via the 5-HT2a receptors. 
DOI administration also produced hyperthermia (Pranzatelli and Pluchino, 1991; 
Mazzola-Pomietto et al., 1995) and further studies have attributed hyperthermia to the 5-
HT2a receptor (Mazzola-Pomietto et al., 1995; Nisijima et al., 2001; Fantegrossi et al., 
2003; Herin et al., 2005). A monoamine oxidase inhibitor and 5-hydroxy-L-tryptophan, a 
precursor of 5-HT, were administered to rats to induce the 5-HT syndrome (Nisijima et al., 
2001). Body temperatures increased to more than 40 degrees C, and all of the animals died 
90 minutes later. Pretreatment with ritanserin and pipamperone, both 5-HT2a receptor 
antagonists, prevented these eventualities. The selective 5-HT2a receptor antagonist, 
MDL100907, attenuated hyperthermia produced by 8 and 12mg/kg MDMA in Sprague 
Dawley rats (Herin et al., 2005). Additionally, pretreatment with ketanserin, MDL100907 
or fluoxetine significantly attenuated MDMA-induced hyperthermia in mice (Fantegrossi 
et al., 2003). There was however, a conflicting finding where MDL100907 failed to affect 
12.5mg/kg MDMA-induced hyperthermia in Dark Agouti rats (Mechan et al., 2002a). 
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These differences might be related to the use of different rat strains, as the ability to 
attenuate MDMA-produced hyperthermia by several MDL100907 doses has been 
demonstrated (Herin et al., 2005). 
Evidence suggests that 5-HT2a receptor activation tends to produce anxiolysis, 
although there were inconsistencies between reports. DOI produced anxiolysis in mice in 
two different measures of anxiety: the four plates test (FPT) and the EPM (Nic 
Dhonnchadha et al., 2003). The 5-HT2c antagonist, RS102221 and 5-HT2c/2b antagonist, 
SB206553 had no effect on the DOI-produced anxiolysis in either paradigm. The 5-HT2a 
receptor was implicated when the specific antagonist, SR46349, significantly inhibited the 
number of open arm entries induced by DOI in the EPM and inhibited the anti-punishment 
action of DOI in the FPT. In concurrence with these findings, decreased ultrasonic 
vocalisations in rats produced by DOI administration was attributed to 5-HT2a receptor 
activation, as these effects were attenuated by MDL100907 (Schreiber et al., 1998).  
A report revealed anxiogenesis in the EPM (Setem et al., 1999) and increased 
ultrasonic vocalisations following 5-HT2a antagonist administration (Olivier et al., 1998), 
however, 5-HT2a receptor antagonists have also been found to have no effect on anxiety 
(Kehne et al., 1996b). One study showed that DOI produced anxiogenesis in the EPM in 
rats (Bull, 2004), making it difficult to conclude what the role of the 5-HT2a receptor is in 
anxiety. As DOI is a mixed 5-HT2 receptor agonist with affinity for the 5-HT2c and 5-
HT2b receptor subtypes, it is possible that drug doses determine what receptors are 
preferentially bound and the resulting behavioural outcome. It is possible that the 5-HT2a 
receptor has no role in anxiety, and that behaviour following DOI administration is 
determined by the ratio of 5-HT2c receptors that are activated compared to the 5-HT2b 
receptors. Both subtypes have opposite roles in anxiety; for example, activation of 5-HT2c 
induced anxiogenesis (Kennett et al., 1994a; Kennett et al., 1995; Mora et al., 1997; Bagdy 
et al., 2001; Campbell and Merchant, 2003), whilst 5-HT2b receptor activation produced 
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anxiolysis (Kennett et al., 1996; Duxon et al., 1997; Kennett et al., 1998; Nic Dhonnchadha 
et al., 2003).  
It does not appear that the 5-HT2a receptor has a major role in locomotor activity 
under basal conditions, as antagonists such as MDL100907 and ketanserin do not affect 
baseline activity levels (Moser et al., 1996; McMahon and Cunningham, 2001b; Herin et 
al., 2005). There are reports documenting a modest increase in forward locomotion 
following administration of the agonist, DOI (Darmani et al., 1996; Hillegaart et al., 1996; 
Kaur and Ahlenius, 1997; Bull, 2004; Ross et al., 2005). These findings suggest, that 
although m-CPP and DOI are both relatively non-selective 5-HT2 receptor agonists, DOI 
preferentially binds the 5-HT2a, whilst m-CPP binds the 5-HT2c receptor, evidenced by its 
ability to induce hypolocomotion. The 5-HT2a receptor also modulates hyperactivity 
induced by psychostimulants. MDL100907, ritanserin and ketanserin blocked hyperactivity 
induced by amphetamine, cocaine and MDMA (Sorensen et al., 1993; Moser et al., 1996; 
Kehne et al., 1996a; O'Neill et al., 1999; McMahon and Cunningham, 2001b; Fletcher PJ, 
2002a; Fletcher PJ, 2002b; Broderick et al., 2004; Herin et al., 2005).  
Co-administration of fluoxetine and cocaine potentiated hyperactivity above that 
produced by cocaine alone (Herges and Taylor, 1998). This potentiation was blocked when 
ketanserin was administered in addition to the other two drug treatments. These data 
suggest that the SSRI-induced potentiation was partly attributable to enhanced synaptic 5-
HT that in turn activated the 5-HT2a receptors. It has been hypothesised that the ability of 
5-HT2a antagonists to attenuate stimulant-produced hyperactivity might be due to 
influences on DA release (Schmidt et al., 1994; Yan, 2000; Kuroki et al., 2003). Indeed, 5-
HT2a-mediated effects on dopaminergic neurotransmission have been linked to increased 
locomotor activity. Electrophysiology revealed that MDMA increased neuronal firing in 
the striatum and that 5-HT2a receptor blockade attenuated both striatal excitations and 
MDMA-produced hyperactivity (Ball and Rebec, 2005). Local perfusion with a 5-HT2a 
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antagonist into the ventral tegmental area blocked both the D-amphetamine-induced 
locomotor activity and DA release in the nucleus accumbens (Auclair et al., 2004). 
The ability of a selective 5-HT2a antagonist, MDL100907, to attenuate MDMA-
produced forward locomotion was demonstrated and compared to the less selective 5-HT2 
antagonist, ritanserin (Kehne et al., 1996a). The antagonists were administered in 
conjunction with 20.0mg/kg MDMA, which was the dose selected for these studies 
because it produced the highest levels of hyperactivity, thus making attenuation clearly 
visible. Both antagonists significantly attenuated MDMA-produced forward locomotion, 
whilst rearing behaviours were unaffected. These results indicate that the attenuating 
ability of ritanserin was a 5-HT2a receptor-mediated effect and also, because 5-HT2a 
receptor manipulations selectively affected forward locomotion, differential mechanisms 
probably underlie these MDMA-produced behaviours.  
A more recent study examined the ability of several MDL100907 doses to attenuate 
MDMA-produced hyperactivity and hyperthermia (Herin et al., 2005). The results revealed 
that the 5-HT2a antagonist attenuated hyperthermia and hyperactivity produced by the 
highest doses of MDMA, whilst lower doses were not affected. These findings concur with 
previous findings indicating that 5-HT2a receptors facilitate MDMA-produced 
hyperactivity only at the highest doses (Bankson, 2002). Hyperactivity produced by low 
dose MDMA was attenuated by 5-HT1b receptor blockade but unaffected by 5-HT2a 
antagonists. These results were explained in that 5-HT has higher affinity for the 5-HT1 
than the 5-HT2 receptors, thus the 5-HT1 receptors have a greater role in hyperactivity 
produced by low dose MDMA. At higher MDMA doses, higher synaptic 5-HT levels 
allow for activation of 5-HT2 receptors. Additionally, it was suggested that the MDMA 
molecule might bind to the 5-HT2a receptors at the higher doses, because MDMA has 
affinity for this site (Battaglia et al., 1988).  
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Evidence suggests that the 5-HT2a receptor might be involved in MDMA-produced 
hyperactivity and hyperthermia, but the time course for the attenuation of these effects 
were not consistent with a common mechanism (Herin et al., 2005).  
Effects of MDMA Exposure 
An elegant study using autoradiography examined the effects of MDMA exposure 
on 5-HT2a receptors in multiple brain regions, and compared MDMA users to rats 
(Reneman et al., 2002). The aim was to determine what the immediate effects of MDMA 
exposure were and then map a time course of receptor binding densities in both humans 
and rats. All subjects were injected with radiolabelled R91150, a selective 5-HT2a receptor 
ligand, whereupon humans underwent SPECT scans, whilst rat brains were removed and 
regions assayed with a gamma counter. In the rat studies, these data were correlated with 
5-HT levels in each brain area.  
There were three groups of human participants: MDMA-naïve controls, recent 
MDMA users and ex-MDMA users. In order to be classified as an MDMA user, it was 
required that a lifetime previous use of 50 tablets had occurred. The recent users had been 
abstinent for 1 week, whilst the ex-users had been abstinent for at least 2 months. Male 
Wistar rats were treated with MDMA (10mg/kg X2 per day for 4 consecutive days, 
80mg/kg total) and separate groups were analysed at the 6h, 3 and 30 days post exposure 
time points. 
 Recent MDMA users exhibited significant decreases in 5-HT2a receptor binding 
densities in frontal, parietal and occipital cortices. These decreases were not apparent in 
ex-MDMA users, and there were significantly increased densities in the occipital cortex of 
this group. The rats showed a similar pattern, as there were significant decreases in 5-HT2a 
receptor densities in all 3 regions 6 hours post MDMA. At the 3-day time point, only the 
occipital cortex still showed significant decreases, whilst the other areas had returned to 
control values. However, at 30 days post MDMA, there was a significant upregulation in 
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the frontal cortex, whilst other areas were comparable to control levels. The 5-HT levels 
were significantly decreased at 6hrs in the frontal and occipital cortices, and over time, 5-
HT levels decreased progressively until all regions exhibited approximately 80% decreases 
at the 30-day time point. Bull (2004) suggested that the magnitude and duration of synaptic 
5-HT depletion might be the primary determinant of any compensatory change in 
expression of the 5-HT2a receptor, but all areas exhibited similar 5-HT depletions. 
It was hypothesised that the receptors were following synaptic 5-HT gradients. The 
massive release of 5-HT initiated by MDMA upon acute exposure was thought to lead to 
the initial downregulation 6 hours following MDMA in rats. Although 5-HT levels have 
been purported to recover over time, this study has shown that levels continue dropping up 
to 30 days after MDMA. This is in agreement with Battaglia and co-workers that showed 
the most extensive depletion in 5-HT uptake sites in some regions 2 weeks after MDMA 
treatment. A more recent study, however, suggests that depleted 5-HT levels are not 
necessary for 5-HT2a receptor changes and that the observed ‘upregulation’ in Reneman’s 
study (2002) might have been misinterpretation of the data (McGregor et al., 2003).  
McGregor and colleagues assessed the effects of a high (5mg/kg every hour for 4 
hours on 2 consecutive days, 40mg/kg total) or low dose MDMA (5mg/kg every day for 2 
consecutive days, 10mg/kg total) regimen on 5-HT2a/2c receptor densities after 10 weeks. 
[125I] DOI was used for the binding assays, and although low dose MDMA reduced DOI 
binding in most regions, only the decrease in the piriform cortex was significant in 
comparison to controls. The high dose group showed significantly decreased binding in 
nearly every region examined. 5-HT levels were depleted in most regions after the high, 
but not after the low dose of MDMA. These results led McGregor to suggest that Reneman 
(2002) might have observed ‘upregulation’ due to the excessively high doses of MDMA 
used for pretreatment. MDMA exposure induced 80% decreases in 5-HT levels, thus 
McGregor suggested that the ‘increased binding to 5-HT2a receptors’ might reflect 
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increased availability to bind due to the lack of competition with depleted endogenous 5-
HT.  
Another study that used the same pretreatment regimen (5mg/kg every hour for 4 
hours on 2 consecutive days, 40.0mg/kg total) and rat strain (Wistars) and a similar 
withdrawal period (8 weeks) to McGregor has revealed evidence of desensitised 5-HT2a 
receptor-mediated behavioural effects (Bull, 2004). The ability of 1mg/kg DOI to induce 
WDS was compared between MDMA and saline pretreated groups. One day later, 
response to the same DOI dose was assessed in the EPM. DOI significantly induced WDS 
in saline pretreated rats, however, significantly MDMA pretreated rats exhibited fewer 
WDS. In these studies, DOI induced an increase in locomotor activity, which was 
equivalent between pretreatment groups. In the EPM, DOI significantly reduced the 
percentage of open to total arm entries and the percentage of time spent in the open arms of 
the EPM in saline- but not MDMA-pretreated rats. It would be interesting to have seen 
whether the low dose MDMA group from McGregor’s study would have also exhibited 
tolerance to DOI, even though there were no significant 5-HT depletions. 
5-HT2a Receptor Experiments in the Present Study 
In order to assess the role of the 5-HT2a receptor in tolerance to MDMA-produced 
hyperactivity, ritanserin, a 5-HT2 antagonist, was administered in combination with 
MDMA. Ritanserin was a readily available ligand, and although relatively non-selective 
for the 5-HT2a receptor, has demonstrated comparable ability to a highly selective 5-HT2a 
antagonist to attenuate MDMA-produced hyperactivity (Kehne et al., 1996a) and DOI-
produced head twitches (Kleven et al., 1997). These effects of ritanserin were not 
attributable to 5-HT2c or 5-HT2b receptor blockade, as 5-HT2c receptor antagonists 
potentiate hyperactivity, whilst 5-HT2b receptors have little role in this behaviour. In the 
present study, the ability of ritanserin (0.0, 2.5 and 5.0mg/kg) to attenuate MDMA-
produced hyperactivity was assessed in MDMA and saline pretreated rats in order to 
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determine the effect of prior MDMA exposure on the ability of 5-HT2a receptors to 
modulate hyperactivity.  
The 5-HT2 receptor agonist, DOI, produces modest increases in locomotor activity 
and WDS in rats that have been attributed to the 5-HT2a receptor. The present study also 
aimed to assess the ability of DOI to produce these effects in MDMA pretreated rats as 
additional receptor assays. A comparable methodology to that used by Bull (2004) and 
colleagues was used in that the ability of a single 1mg/kg dose of DOI to produce 
hypermotility and WDS was assessed. A single dose was used because preliminary studies 
revealed that these behavioural effects were not dose-dependent. This is probably due to 
the fact that DOI is not selective for the 5-HT2a receptor, and additional receptors are 
activated at higher doses, negating specific 5-HT2a receptor-mediated effects. The 
development of more selective 5-HT2a agonists might allow for dose-dependent studies to 
be conducted in the future, but the use of a single dose in this study will be strengthened by 
the use of multiple assays.  
Chronic DOI treatment produced tolerance to the discriminative stimulus properties 
of DOI (Smith et al., 1999). In addition, significant decreases in 5-HT2a binding were 
observed, whereas no changes to 5-HT2c receptors occurred. These findings indicate that 
the 5-HT2a receptors might be more susceptible to up- or downregulation following 
continuous activation. The degree to which MDMA pretreatment might mimic DOI in this 
instance is uncertain, as the drugs were administered using different pretreatment regimens 
and had different pharmacological properties. It is also possible however, that the 5-HT2a 
receptors might be more susceptible to up- or downregulation following MDMA-produced 
alterations in serotonergic neurotransmission. 5-HT2a receptor, with little change to 5-
HT2c receptors, might explain tolerance to the activating effects of MDMA.  
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Summary 
The present study investigated the effects of MDMA exposure on the functional 
statuses of the SERT and 5-HT2c and 5-HT2a receptor subtypes. The existing literature is 
difficult to interpret due to the use of varying methodologies that have produced 
conflicting findings. The present study aimed to resolve these confounds by administering 
the same MDMA pretreatment regimen prior to behavioural tests to allow direct 
comparisons. A well-characterised MDMA pretreatment regimen was used to these ends, 
as previous work has demonstrated that this regimen selectively affected 5-HT systems in 
rats, without inducing non-selective neurotoxicity (Scanzello et al., 1993; Fischer et al., 
1995). 
The MDMA pretreatment regimen produced tolerance to several behavioural 
effects of MDMA, including locomotor activity, which were attributable to serotonergic 
deficits (Shankaran and Gudelsky, 1999). Extensive neurochemical studies have 
documented the time course for recovery of these deficits, therefore, the present study 
sought to determine whether functional recovery was evident 12 weeks later. Since it was 
presumed that functional recovery would reflect serotonergic recovery, the effect on 
behaviour of repeatedly activating 5-HT systems was investigated. Weekly injections with 
a relatively high dose of MDMA were administered to observe the effect on behavioural 
recovery. 
Paroxetine binding was conducted as verification that the pretreatment regimen 
used in the present study produced comparable deficits to those previously reported 
(Scanzello et al., 1993; Fischer et al., 1995). The present study also included the brain stem 
region, which has not previously been assessed. This site has the highest SERT densities of 
any brain region (Lin et al., 2004), thus SERT alteration would be expected to produce 
widespread changes in serotonergic neurotransmission.  
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Although SERT binding has frequently been measured in studies examining the 
effects of MDMA exposure, it has usually been used as an index of ‘neurotoxicity’ or as 
verification for the presence of serotonergic deficits. The present study aimed to extend 
these reports and determine the functional implication of MDMA-induced decreases in 
SERT binding densities. SERT integrity is vital for the full expression of MDMA-
produced hyperactivity (Callaway et al., 1990), as 5-HT released via the SERT activates 5-
HT receptors that have a major contribution towards the expression of MDMA-produced 
hyperactivity (Bankson, 2002). It was, therefore, hypothesised that decreased SERT 
densities might contribute to behavioural tolerance to MDMA following preexposure. The 
SERT selective ligand, clomipramine, blocks MDMA-produced hyperactivity in control 
rats by preventing MDMA-induced 5-HT release (Pifl et al., 2005). The ability of 
clomipramine to attenuate MDMA-produced hyperactivity in MDMA pretreated rats was 
assessed. If decreased SERT binding was responsible for tolerance to MDMA-produced 
hyperactivity, it would be expected that MDMA-produced hyperactivity would be 
unaffected by clomipramine pretreatment. 
Several studies have demonstrated a role for the 5-HT2a and 5-HT2c receptors in 
MDMA-produced hyperactivity (Herin et al., 2005; Fletcher et al., 2006). It has also been 
shown that these receptors are vulnerable to MDMA-induced 
downregulation/desensitisation (Reneman et al., 2002; McGregor et al., 2003; Bull, 2004). 
There have been behavioural studies that suggest that 5-HT2c receptor-mediated m-CPP-
produced behaviours remained unchanged (Bull, 2003), whilst 5-HT2a receptor-mediated 
DOI-produced behaviours were diminished following MDMA exposure (Bull, 2004). The 
present study aimed to replicate these findings using improved methodology and a 
pretreatment regimen that produced tolerance to MDMA.  
5-HT2a receptor desensitisation, as shown by decreased DOI responsiveness, might 
explain locomotor tolerance to MDMA, as 5-HT2a receptor activation facilitates MDMA-
produced hyperactivity (Schmidt et al., 1994; Kehne et al., 1996a; Herin et al., 2005). 
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However, evidence suggests that the receptors that modulate MDMA-produced 
hyperactivity influence DA release (Schmidt et al., 1994; Di Matteo, 2000; Gobert et al., 
2000) and that these functions might be distinct from behaviour produced by agonists such 
as m-CPP and DOI. 
Two novel assays were developed that combined MDMA with 5-HT2c or 5-HT2a 
receptor antagonists in order to assess DA-modulatory function following MDMA 
exposure. These assays were intended to reveal relative contributions of each receptor 
subtype to the tolerance to MDMA-produced hyperactivity. 5-HT2c receptor antagonists 
potentiate, whilst 5-HT2a antagonists attenuate, MDMA-produced hyperactivity. The 
ability for respective antagonists to modulate MDMA-produced hyperactivity was 
examined in MDMA pretreated animals. It was hypothesised that MDMA exposure would 
decrease the ability for the 5-HT2a receptor antagonist to attenuate hyperactivity to a 
greater extent than the ability for the 5-HT2c receptor antagonist to potentiate 
hyperactivity, as this might explain tolerance to MDMA-produced hyperactivity. 
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Methods 
Subjects 
The subjects were male Sprague-Dawley rats, weighing between 250-350g. The 
animals were bred at Victoria University in Wellington, New Zealand and were housed 
singly in a temperature- (21˚C) and humidity- (79%) controlled room. There was a 
controlled 12-hr light/dark cycle with lights on at 0700. Food and water were available ad 
libitum except during testing periods. All experimental protocols were consistent with 
OLAW regulations and approved by the Animal Ethics Committee of Victoria University. 
Apparatus 
Initial experimental work was conducted in measuring apparatus developed in-
house at Victoria University. The chamber used for rat locomotor activity measurement 
was a wooden box lined with Perspex (50 x 50 x 20cm). Activity of an animal was 
recorded as the number of times it crossed infrared light beams. These beams formed an 8 
x 8 lattice 2.2 cm above the bottom and were 5cm apart. Whenever a light beam was 
broken, a computer recorded it with software designed by university technicians.  
Following the failure of this equipment, Med-PC Activity Monitor apparatus was 
acquired and subsequent experiments were carried out using the new equipment. As a 
consequence, the older apparatus was utilized for much of the preliminary work in Part 1, 
whereas Part 2 was conducted mostly using Med PC equipment. The measurements from 
the old (activity counts) versus the new Med-PC (ambulatory counts) equipment yielded 
different numbers, but drug profiles and effective doses, were, in most cases, equivalent 
between apparatus.  
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The Activity Monitor Version 5 program (Med Associates Inc) measured forward 
locomotion and emergence latency. The system consisted of a subject containment 
chamber, infrared red sources and sensors, a system power supply, an environment data 
source controller, connecting cables, PC/environment interface card and data analysis 
software. The subject location was tracked using 16 evenly spaced infrared sources and 
sensors positioned around the periphery of the 4-sided chamber (40 X 40cm). If the 
infrared beam failed to reach the sensor, the system registered this event as a broken beam 
and assumed the presence of the subject. The program specifically recorded forward 
locomotion by dividing the chamber into zones, or ‘boxes ‘. It was possible to set the ‘box 
size’ and for these experiments, the size was set to be the approximate dimensions of a rat. 
When the rat travelled distance and crossed the box perimeters into an adjacent box, this 
was registered as ambulatory counts. 
 Emergence latency was measured using a version of the emergence test developed 
by McGregor’s laboratory group (McGregor et al., 2003, Morley et al., 2005). For these 
tests, wooden hide boxes (16.5 X 25cm) with lift-up lids and slide doors were placed in the 
top left corner of the activity chambers. The hide box lid was lifted, the animal placed 
inside and the lid closed for habituation before the slide door was opened 15 minutes later. 
Full body emergence from the hide box was determined when distance travelled was 
equivalent to the length of a rat, as measured by the Med Associates software. There were 
infrared cameras situated above each locomotor activity chamber to verify emergence and 
also to observe qualitative behaviours, such as wetdog shakes.   
Before and after each animal had been in the test chambers, the interiors and hide 
boxes were wiped with Virkon ‘S’ disinfectant (Southern Veterinary Supplies, Palmerston 
North). All behavioural tests were conducted during the light phase of the light cycle and 
the test room was illuminated with red light. A white noise generator ran throughout 
experiments to reduce auditory disturbance and experimenters remained outside the test 
room during experiments.  
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Procedures 
Part 1 
Overview 
Assays to assess the role of the SERT, 5-HT2c or 5-HT2a receptors in MDMA-
induced hyperactivity, hypolocomotion, emergence latency and wetdog shakes were 
developed. These experiments examined the dose effects of several ligands for the 
aforementioned target sites. The objectives were to develop paradigms where significant 
pharmacologically induced behavioural effects were evident, and to determine which doses 
and drug pretreatment times produced these effects.  
When designing experimental procedures for locomotor activity tests, it was 
necessary to consider drug type. For example, MDMA is a stimulant that induces 
hyperactivity, thus to observe the most pronounced MDMA-induced change in locomotion, 
it was necessary to administer MDMA when baseline activity levels were low. When rats 
were initially placed in activity boxes, there were relatively high levels of activity for the 
first 15 minutes, and following this time, activity slowed. Therefore, prior to MDMA 
administration, the animals were habituated for 30 minutes to the chambers to lower 
baseline activity levels.  
Conversely, serotonergic compounds such as clomipramine and m-CPP tend to 
produce hypomotility. As previously mentioned, rats are most active immediately after 
being placed in the activity chamber. In order to observe suppressive effects on 
locomotion, the drugs were administered to allow peak behavioural effects to coincide with 
the first 15 minutes of highest baseline activity.  
Unless otherwise stated, all experiments were of a between subjects design where 
no repeated testing occurred. In an attempt to minimise subject numbers, several trial 
experiments were conducted where rats were repeatedly tested. It was observed that prior 
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exposure to the test chambers and MDMA altered subsequent behavioural responses. 
Additionally, in some instances, the numbers of rats per group differs in the results 
compared to those outlined in the methods, as data from rats that received misplaced 
injections was discarded. 
MDMA-Produced Hyperactivity 
Dose Effects of MDMA 
Groups of drug-naïve rats (n=8 per group) were placed in the activity chambers and 
allowed a 30-minute habituation period. Thereafter, rats were administered MDMA (old 
boxes, 0.0, 5.0, 10.0, 15.0 or 20.0mg/kg, IP; Med-PC boxes, 0.0, 2.5, 5.0, 10.0 or 
20.0mg/kg, IP) and locomotor activity recorded for a further 60 minutes.  
The Serotonin Transporter 
Dose Effects of Clomipramine on Baseline Locomotor Activity 
Separate groups of drug-naïve rats (n=9 per group) were administered 
clomipramine (0.0, 1.25 or 5.0mg/kg, IP) in the homecage. Thirty minutes later, the rats 
were placed in the Med-PC activity chambers and locomotor activity was recorded for a 
30-minute period thereafter.  
Dose Effects of Clomipramine on MDMA-Produced Hyperactivity 
Groups of drug-naïve rats (n=8 per group) were administered clomipramine (0.0, 
0.3, 1.25, 5.0, 10.0 or 20.0mg/kg, IP) and placed in Med-PC activity chambers. Thirty 
minutes later, MDMA (5.0mg/kg, IP) was administered and locomotor activity recorded 
for the final 60 minutes.  
Using identical methodology, drug-naïve rats (n=10 per group) were administered 
the effective clomipramine doses (0.0, 1.25 or 5.0mg/kg, IP) with a higher MDMA 
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(10mg/kg, IP) dose. The highest clomipramine doses of 10.0 and 20.0mg/kg were excluded 
due to lack of selectivity. 
The 5-HT2c Receptor 
Dose Effects of m-CPP on Baseline Locomotor Activity 
m-CPP (0.0, 0.3, 0.6, 1.25, 2.5 and 5.0mg/kg, IP) was administered to drug-naïve 
rats (n=8 per group), which were then placed in the old activity chambers and activity 
recorded for 60 minutes.  m-CPP has a rapid onset of action, thus the suppressive effects 
were expected within the first 15 minutes. 
Dose Effects of m-CPP on Emergence Latency 
Drug-naïve rats (n=6 per group) were administered m-CPP (0.0, 0.6 or 1.25mg/kg) 
before being placed in hide boxes situated in Med-PC chambers. These doses did not affect 
baseline locomotor activity. Rats were placed in the hide box for 15 minutes following m-
CPP injection and emergence latency into the test arena was measured for 40 minutes after 
the sliding door was opened. 
Dose Effects of MDMA Following RS102221 Pretreatment 
Groups of drug-naïve rats (n=8 per group) were used to test the effect of RS102221 
(0.0 or 0.5 mg/kg) on MDMA- (0.0, 5.0, 10.0 or 20.0mg/kg, IP) produced hyperactivity in 
the old apparatus. Rats were administered RS102221 and placed in the old activity boxes 
for 30 minutes. Thereafter, rats received an injection of MDMA (10.0mg/kg) and 
locomotor activity was measured for a further 60 minutes. MDMA dose was selected as a 
moderate dose that did not produce maximal effects (based on MDMA dose effect data in 
old equipment), thus allowing for potentiation. 
Dose Effects of RS102221 on MDMA-Produced Hyperactivity 
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The potentiating effects of several RS102221 doses (0.0, 0.06, 0.50, 1.25, 1.0 and 
2.0mg/kg, IP) were assessed against 10mg/kg MDMA (see previous study), which was the 
dose where significant RS102221-induced potentiation of hyperactivity was evident. 
Groups of drug-naïve rats (n=6 per group) were administered RS102221 and MDMA and 
placed in the old activity chambers using an identical methodology as specified above. 
The 5-HT2a Receptor 
Dose Effects of DOI on Wetdog Shakes and Baseline Locomotor Activity 
Groups of drug-naïve rats (n=6 per group) were administered DOI (0.0, 1.0 or 
2.0mg/kg, IP) and placed in the Med-PC chambers, using DOI doses and pretreatment 
times based on Bull’s experiments (2004). Locomotor activity and qualitative behaviour on 
video cameras were simultaneously recorded for a 30-minute test period. Analyses of 
videos by an observer blind to experimental condition were conducted 15-minute post DOI 
injection time point for the duration of 10 minutes. The number of wetdog shakes (WDS) 
were counted in 2-minute blocks for the recording period, where a WDS was defined as a 
‘paroxysmic shudder of the head and trunk’ (Darmani and Ahmad, 1999).  
Dose Effects of Ritanserin on MDMA-Produced Hyperactivity 
The effects of several ritanserin doses (0.0, 2.5, 5.0 or 10.0mg/kg, IP) on MDMA 
(10mg/kg, IP)-produced hyperactivity were assessed. Groups of drug-naïve rats (n=10 per 
group) were placed in the Med-PC chambers and administered ritanserin, then 30 minutes 
later, received an MDMA injection and recorded for 60 minutes. A dose of MDMA that 
produced maximal levels of hyperactivity was selected (see MDMA dose effect data for 
Med-PC equipment) in order for ritanserin-induced attenuation to be clearly discernable. 
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Part 2 
Overview 
The objective of Part 2 was to use behavioural assays developed in Part 1 to assess 
the effects of prior MDMA exposure. With the exception of the first experiment that 
examined the effects of repeated MDMA exposure, no repeated testing occurred. 
MDMA Pretreatment 
Pretreatment Procedures 
Rats were placed in individual cages for the day of treatment, whereupon they 
received an injection regimen comprising 4 injections of either MDMA (10mg/kg per 
injection, IP) or the saline vehicle administered at 2 hr intervals (total MDMA exposure = 
40.0 mg/kg) in the home cage. This regimen was selected because it has been demonstrated 
in other studies to produce significant effects on 5-HT neurotransmission 2 weeks 
following treatment (Scanzello et al., 1993, Fischer et al., 1995, Shankaran and Gudelsky, 
1999, Sumnall et al., 2004) and was relatively well tolerated with a 10 percent mortality 
rate. The rats were housed in pairs during a recovery period of either 2 or 12 weeks before 
commencement of behavioural tests. 
Paroxetine Binding 
A group of MDMA-pretreated (n=5) and control (n=5) rats were sacrificed and the 
brains were removed and rapidly frozen in 2-methyl butane at -40°C and stored at -80°C. 
The levels of SERT were measured in membrane homogenates of frontal cortex, striatum, 
hippocampus, and brain stem using [3H] paroxetine as previously described (Backstrom et 
al., 1989) with minor modifications.  Briefly, brain tissues were suspended 1:20 in ice-cold 
buffer (10 mM sodium phosphate, pH 7.4) and homogenized with a Kinematica GmbH 
Polytron (Brinkmann, New Haven, CT) for 15 seconds at setting 4 and left for 30 minutes 
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on ice. The brain tissue homogenate was centrifuged for 10 minutes, 4ºC at 30,000-x g; the 
resulting pellet was resuspended and re-centrifuged. Binding assays were conducted with 5 
mg of membrane tissue in a total volume of 1 ml containing either 0.06 nM or 0.2 nM [3H] 
paroxetine for 2 hours at 25ºC. Non-specific binding was determined in the presence of 1 
µM clomipramine. Radioactivity was measured by liquid scintillation spectrometry and 
counted at 35% efficiency. Data were analysed using PRISM™ (v3.0, GraphPad, San 
Diego, CA) and the density values were corrected for occupancy at two concentrations of 
radioligand.  
MDMA-Produced Hyperactivity 
Repeated Testing Regimen 
Two weeks after pretreatment, groups of MDMA pretreated animals (n=14) and 
controls (n=15) were first habituated to the old activity chambers for 30 minutes, then 
administered an MDMA (0.0 or 10.0mg/kg, IP) injection and activity recorded for 60 
minutes. This behavioural test was conducted weekly for 1 month, where a within subjects 
design was utilised to determine the effects of repeated MDMA exposure. 
Comparison Between 2- and 12-Week Recovery Periods 
Two or 12 weeks following pretreatment, separate groups of MDMA pretreated 
animals (2 weeks: n=27; 12 weeks: n=32) and controls (2 weeks: n=32; 12 weeks: n=36) 
were first habituated to the Med-PC activity chambers for 30 minutes. Following this 
habituation period, they were injected with MDMA (0.0, 2.5, 5.0 or 10.0mg/kg, IP) and 
activity recorded at 5-minute intervals for an additional 60 minutes. 
The Serotonin Transporter 
Clomipramine-Induced Attenuation of MDMA-Produced Hyperactivity 
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MDMA (n=38) and saline (n=37) pretreated rats were used to test the effect of 
several doses of clomipramine that did not significantly affect baseline locomotor activity 
(0.0, 0.3, 1.25 or 5.0mg/kg, IP) on MDMA- (5.0 mg/kg, IP) produced hyperactivity. This 
dose of MDMA was chosen because clomipramine produced dose-dependent attenuation 
of hyperactivity at this dose, whereas the higher MDMA dose was not significantly 
attenuated by clomipramine (see clomipramine dose effect study). Rats were administered 
the clomipramine injection and placed in the activity boxes for 30 minutes. Thereafter, 
they received an injection of MDMA and activity was recorded for a further 60 minutes.  
The 5-HT2c Receptor 
m-CPP-Induced Hypolocomotion 
MDMA (n=29) and saline (n=28) pretreated rats were administered a dose of m-
CPP (0.0, 0.6, 1.25 or 2.5mg/kg, IP) and locomotor activity recorded for 30 minutes 
thereafter.  
m-CPP-Induced Increased Emergence Latency 
MDMA (n=20) and saline (n=34) pretreated rats were administered m-CPP (0.0, 
0.6 or 1.25mg/kg, IP) before being placed in the hide box. Rats were placed in the hide box 
for 15 minutes following an m-CPP injection and emergence latency into the test arena was 
measured for 40 minutes after the sliding door was opened. 
RS102221 Induced Potentiation of MDMA-Produced Hyperactivity 
Groups of MDMA (n=24) and saline (n=33) pretreated rats were used to test the 
effect of RS102221 (0.0, 0.5 and 1.0mg/kg, IP) on MDMA- (5.0 mg/kg, IP) produced 
hyperactivity. Rats were administered RS102221 and placed in the activity boxes for 30 
minutes. Thereafter, they received an injection of MDMA and locomotor activity was 
measured for a further 60 minutes.  
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The 5-HT2a Receptor 
DOI-Induced Wetdog Shakes 
Groups of MDMA (n=12) and saline (n=12) pretreated rats were administered DOI 
(0.0 or 1.0mg/kg, IP), placed in the Med-PC chambers and video taped for 25 minutes. The 
1.0 and 2.0mg/kg DOI doses did not produce significantly different behavioural effects 
(see Part 1), therefore only a single test dose was utilised. Analyses of videos by an 
observer blind to experimental condition were conducted 15 minutes post DOI injection for 
10 minutes. The numbers of wetdog shakes (WDS) were counted in 2-minute blocks for 
the recording period. Locomotion was not recorded, as neither DOI dose tested in Part 1 
altered baseline activity. 
Ritanserin-Induced Attenuation of MDMA-Produced Hyperactivity 
MDMA (n=32) and saline (n=50) pretreated rats were used to assess the ability of 
several ritanserin doses (0.0, 2.5, 5.0 or 10.0mg/kg, IP) to attenuate MDMA (10mg/kg, IP)-
produced hyperactivity. Rats were placed in the Med-PC chambers and administered 
ritanserin, then 30 minutes later, received an MDMA injection and recorded for 60 
minutes. 
Drug Preparation 
8-[5-(2,4-Dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl-5-
oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (RS102221, Tocris) and 
ritanserin (Tocris) were suspended in a solution of 1% polysorbate 80 (Tween® 80). 1-(3-
Chlorophenyl) piperazine hydrochloride (m-CPP, Tocris), 3-chloro-10,11-dihydro-N,N-
dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride (clomipramine, Tocris), +/-  
2,5-dimethoxy-4-iodo-phenylisopropylamine (DOI, Sigma Aldrich) and +/- 3,4-
methylenedioxymethamphetamine hydrochloride (MDMA, ESR) were dissolved in 0.9% 
saline. Injections were intraperitoneal and administered in a volume of 1ml/kg. All drugs 
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were prepared immediately prior to behavioural tests and drug weights refer to the salt. 
Statistical Analyses 
The binding data were analysed by 1-way ANOVAs followed by Tukey’s Post Hoc 
tests (PRISMTM v3.0, Graphpad, San Diego, CA). Differences between treatment groups 
were considered statistically significant at p<0.05. Time course data for locomotor activity 
tests were analysed using 3-Way ANOVAs (time X pretreatment X drug dose) with time as 
the repeated measure. Univariate analyses followed by Tukey post hoc tests determined 
whether there were significant differences as a result of pretreatment in the event of main 
effects or interactions. 
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Results 
Part 1 – Preliminary Work 
MDMA-Produced Hyperactivity 
Dose Effects of MDMA on Locomotor Activity in Old Equipment 
Figure 1 shows the time course and dose-dependency for the hyperactivity 
produced by MDMA (0.0, 5.0, 10.0, 15.0 and 20.0mg/kg, IP).  A 2-Way interaction (time 
X MDMA dose) with time as a repeated measure revealed a significant interaction between 
these factors (F(13,110)=13.19, p<.001) and a main effect of MDMA dose (F(4,35)=18.80, 
p<.001). Post hoc analyses showed that the 10.0, 15.0 and 20.0mg/kg doses of MDMA 
significantly potentiated locomotor activity above baseline. 
 
 
Figure 1 Activity counts produced after MDMA (0.0, 5.0, 10.0, 15.0 or 20.0mg/kg, IP 
at time=0) administration in drug-naïve rats. The time course of the mean activity 
counts produced following the MDMA injection is shown (+SEM). The inset shows 
total activity counts at each MDMA dose for the 60-minute period post MDMA 
injection (+SEM). Significant difference relative to vehicle group * p<.001. 
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Dose Effects of MDMA on Locomotor Activity in Med-PC Equipment 
Figure 2 also shows the time course and dose-dependency for the hyperactivity 
produced by MDMA (0.0, 2.5, 5.0, 10.0 and 20.0mg/kg, IP), but in the Med-PC apparatus.  
A 2-Way interaction (time X MDMA dose) with time as a repeated measure revealed a 
significant interaction between these factors (F(21,192)=12.08, p<.001) and a main effect 
of MDMA dose (F(4,37)=37.44, p<.001). Post hoc analyses showed that the 5.0, 10.0 and 
20.0mg/kg doses of MDMA significantly potentiated locomotor activity above baseline. 
 
 
Figure 2 Activity counts produced after MDMA (0.0, 2.5, 5.0, 10.0 or 20.0mg/kg, IP at 
time=0) administration in drug-naïve rats. The time course of the mean ambulatory 
counts produced following the MDMA injection is shown (+SEM). The inset shows 
total ambulatory counts at each MDMA dose for the 60-minute period post MDMA 
injection (+SEM). Significant difference relative to vehicle group * p<.001. 
The Serotonin Transporter 
Dose Effects of Clomipramine on Baseline Locomotor Activity 
Figure 3 shows the time course for the hypolocomotor effects of clomipramine (0.0, 
1.25 and 5.0mg/kg, IP).  Clomipramine did not affect baseline locomotor activity as a 2-
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Way interaction (time X clomipramine dose) with time as a repeated measure failed to 
reach significance (F(7,90)=.374, p>.05).  
 
 
Figure 3 Ambulatory counts produced following clomipramine (0.0, 1.25 or 5.0mg/kg, 
IP) pretreatment. The time course for mean ambulatory counts are shown, where 
clomipramine was administered 30 min prior to behavioural tests (+SEM). The inset 
shows total locomotor activity during the 30 min recording period (+SEM).  
Dose Effects of Clomipramine on MDMA-Produced Hyperactivity 
Figure 4 shows the ability of clomipramine (0.0, 0.3, 1.25, 5.0, 10.0 or 20.0mg/kg, 
IP) to dose-dependently attenuate MDMA-produced hyperactivity (5.0mg/kg, IP). A 2-
Way ANOVA (time X clomipramine dose) with time as the repeated measure showed a 
significant interaction between these factors (F(18,142)=2.62, p<.01) and there was also a 
main effect of clomipramine dose (F(5,39)=5.09, p<.01). Post hoc tests showed that the 
5.0, 10.0 and 20.0mg/kg doses significantly attenuated hyperactivity compared to baseline, 
whereas the 1.25mg/kg dose narrowly missed significance.  
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Figure 4 Ambulatory counts produced following clomipramine (0.0, 0.3, 1.25, 5.0, 10.0 
or 20.0mg/kg, IP) and MDMA (0.0 or 5.0mg/kg, IP) administration. The time course 
for mean ambulatory counts are shown, where clomipramine was administered 30 
min prior to MDMA (time= 0 min) (+SEM). The inset shows total MDMA-produced 
hyperactivity during the 60-minute post-MDMA injection period at each 
clomipramine dose (+SEM). Significant difference relative to vehicle group * p<.05, 
** p<.01.  
Figure 5 shows the ability of clomipramine (0.0, 1.25 or 5.0mg/kg, IP) to dose-
dependently attenuate hyperactivity produced by a higher dose of MDMA (10.0mg/kg, IP). 
A 2-Way ANOVA (time X clomipramine dose) with time as the repeated measure failed to 
show significance (F(9,115)=.814, p>.05) and there was no main effect of clomipramine 
on hyperactivity produced by this MDMA dose (F(2,27)=1.14, p>.05).  
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Figure 5 Ambulatory counts produced following clomipramine (0.0, 1.25 or 5.0mg/kg, 
IP) and MDMA (10.0mg/kg, IP) administration. The time course for mean 
ambulatory counts are shown, where clomipramine was administered 30 min prior to 
MDMA (+SEM). The inset shows total MDMA-produced hyperactivity during the 60 
min post-MDMA injection period at each clomipramine dose (+SEM).  
The 5-HT2c Receptor 
Dose Effects of m-CPP on Baseline Locomotor Activity 
Figure 6 shows the hypolocomotive effects of m-CPP on baseline locomotor 
activity. A 2-Way ANOVA (time X m-CPP dose) where time was the repeated measure 
showed a significant interaction between these factors (F(38,381)=2.46, p<.001) and a 
main effect of m-CPP dose (F(5,50)=3.54, p<.001). Post hoc analyses revealed that the 
5.0mg/kg m-CPP dose significantly attenuated baseline locomotor activity. 
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Figure 6 Activity counts produced following m-CPP (0.0, 0.60, 0.60, 1.25, 2.5, 
5.0mg/kg, IP) pretreatment. The time course for mean ambulatory counts are shown, 
where m-CPP was administered at time=0 and activity recorded for 60 minutes 
(+SEM). The inset shows total locomotor activity during the 60 min recording period 
(+SEM). Significant difference relative to vehicle group * p<.05. 
Dose Effects of m-CPP on Emergence Latency 
Figure 7 shows increased emergence latency time induced by m-CPP. There was a 
main effect of m-CPP dose on emergence latency time (2,34)=3.81, p<.05). Post hoc tests 
showed that the 1.25mg/kg dose significantly increased emergence latency.   
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Figure 7 Emergence latency times following m-CPP (0.0, 0.60 or 1.25mg/kg, IP) 
pretreatment for the 40-minute recording period (+SEM). Significant difference 
relative to vehicle group * p<.05. 
Dose Effects of MDMA Following RS102221 Pretreatment 
Figures 8A, 8B, 8C and 8D show the time course and dose-dependency of MDMA-
produced hyperactivity in rats pretreated with RS102221 (0.0 or 0.5mg/kg). A 3-Way 
ANOVA (time X RS102221 dose X MDMA dose) with time as a repeated measure 
showed no significant interaction between these factors (F(10,170)=1.80, p>.05). There 
was a main effect of MDMA (F(3,50)=44.5, p<.001) but not RS102221 dose 
(F(1,50)=2.08, p>.05). ANOVAs for each dosage group revealed no significant differences 
as a result of RS102221 pretreatment for rats that received the 0.0 (Figure 8A) 
(F(1,13)=.024, p>.05), 5.0 (Figure 8B) (F(1,11)=.004, p>.05) or 20.0mg/kg (Figure 8D) 
(F(1,13)=.001, p>.05) doses, however, 10mg/kg MDMA-produced hyperactivity was 
potentiated by RS102221 (Figure 8C) (F(1,13)=9.21, p<.05).  
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Figure 8 The time course of the mean activity counts produced after 0.0 (Figure 8A), 
5.0 (Figure 8B), 10.0 (Figure 8C) or 20.0mg/kg (Figure 8D) MDMA administration is 
shown (+SEM). Insets show total activity counts during the 60-minute period post 
MDMA injection for the 0.0 or 0.5mg/kg RS102221 groups (+SEM). Figure 8E shows 
total activity produced at all MDMA doses for the 60-minute period post MDMA 
injection for the 0.0 or 0.5mg/kg RS102221 groups (+SEM). Significant difference 
relative to the 0.0mg/kg RS 102221 group * p<.05. 
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Dose Effects of RS102221 on MDMA-Produced Hyperactivity 
The ability of RS102221 to potentiate MDMA-produced hyperactivity was 
observed at the 10.0mg/kg MDMA dose, as demonstrated in 8C. This MDMA dose was 
selected to assess the dose effects of RS102221. Figure 9 shows the time course and dose-
dependency for the ability of RS102221 (0.0, 0.06, 0.50, 1.25, 1.0 and 2.0mg/kg, IP) to 
potentiate MDMA (10.0mg/kg, IP)-produced hyperactivity. A 2-Way interaction (time X 
RS102221 dose) with time as a repeated measure failed to reach significance 
(F(19,131)=1.25, p>.05), but there was a significant main effect of RS102221 dose on 
MDMA-produced hyperactivity (F(5,34)=3.15, p<.05).  
 
 
Figure 9 Activity counts produced after RS102221 (0.0, 0.06, 0.5, 1.25, 1.0 or 
2.0mg/kg, IP at time=-30) and MDMA (0.0 or 10.0mg/kg, IP at time =0)) 
administration in drug-naïve rats. The time course of the mean activity counts 
produced after RS102221 and MDMA pretreatment are shown (+SEM). The inset 
shows total ambulatory counts at each RS102221 dose for the 60-minute period post 
MDMA injection (+SEM).  
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The 5-HT2a Receptor 
Dose Effects of DOI on Wetdog Shakes 
Table 1 shows the number of wetdog shakes (WDS) produced in a 10-minute 
recording period 15-minutes following a DOI injection (0.0, 1.0 or 2.0mg/kg, IP). 
Univariate analyses revealed that there was a significant main effect of DOI treatment 
(F(2,14)=3.94, p<.05). Post hoc tests showed that both the 1.0 and 2.0mg/kg DOI doses 
significantly increased WDS behaviour, but there were no differences between doses. The 
animals that received DOI exhibited different behavioural characteristics to control rats. 
For example, DOI-treated rats did not curl up and sleep, were constantly moving with a 
wobbling gait around the chamber periphery and there was also evidence of 5-HT 
syndrome with a flattened posture. Additionally, some rats, but not all that received DOI, 
exhibited back muscle contractions, which was purported to be a 5-HT2a receptor 
mediated effect (Bull, 2004). Back muscle contractions were not recorded, as they 
originate from 5-HT2a receptors located near the brain stem and were separate from 5-
HT2a receptor-mediated WDS. Also, WDS were consistently produced by DOI 
administration, whereas back muscle contractions were not always observed.   
 
DOI Dose (mg/kg) Number WDS 
0.0 (n=4) 1 ± 0.4 
1.0 (n=7) 5.3 ± 0.8 * 
2.0 (n=6) 5.3 ± 1.5 * 
 
Table 1 Mean total number of DOI-induced WDS during a 10-minute recording 
period + SEM.  Significant difference relative to vehicle group * p<.05 
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Dose Effects of DOI on Baseline Locomotor Activity 
Figure 10 shows the effects of DOI pretreatment on baseline locomotor activity 
(0.0, 1.0 and 2.0mg/kg, IP).  The time course for the mean ambulatory counts over the 30-
minute recording period is shown (+SEM). DOI pretreatment did not affect locomotor 
activity measures as revealed by a 2-Way ANOVA (time X DOI dose) with time as a 
repeated measure (F(5,35)=.822, p>.05). 
 
 
Figure 10 Ambulatory counts produced following DOI (0.0, 1.0 or 2.0mg/kg, IP) 
pretreatment. The time course for mean ambulatory counts are shown, where DOI 
was administered at time=0 (+SEM). The inset shows total ambulatory counts during 
the 30-minute recording period (+SEM).  
Dose Effects of Ritanserin on MDMA-Produced Hyperactivity 
Figure 11 shows the time course and dose-dependency for the ability of ritanserin 
(0.0, 2.5, 5.0 and 10.0mg/kg, IP) to attenuate MDMA (10.0mg/kg, IP)-produced 
hyperactivity.  A 2-Way ANOVA (time X ritanserin dose) with time as a repeated measure 
showed a significant interaction between these factors (F(12,194)=2.00, p<.05). There was 
a main effect of ritanserin dose on MDMA-produced hyperactivity (F(3,49)=4.38, p<.01) 
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and post hoc analyses revealed that the 5.0mg/kg dose significantly attenuated ambulatory 
counts compared to baseline (P<0.05). 
 
 
Figure 11 Ambulatory counts produced after ritanserin (0.0, 2.5, 5.0 or 10.0mg/kg, IP 
at time=-30) and MDMA (0.0 or 10.0mg/kg, IP at time =0)) administration in drug-
naïve rats. The time course of the mean ambulatory counts produced after ritanserin 
and MDMA pretreatment are shown (+SEM). The inset shows total ambulatory 
counts at each ritanserin dose for the 60-minute period post MDMA injection 
(+SEM). Significant difference relative to vehicle and 10mg/kg MDMA group  *p<.05. 
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Part 2 – Effects of MDMA Pretreatment 
MDMA-Produced Hyperactivity 
MDMA-Produced Hyperactivity 2-5 Weeks Post Exposure 
Figure 12 shows MDMA-produced hyperactivity  (0.0 or 10.0mg/kg) 2-5 weeks 
following MDMA pretreatment. Tolerance to the locomotor-activating effect of MDMA 
was observed two weeks later, and with repeated weekly administrations, the effect of the 
10.0 mg/kg dose decreased in control rats such that the response was comparable to rats 
that had initially received 40.0mg/kg MDMA pretreatment by 5 weeks. A 3-Way ANOVA 
(week X pretreatment X MDMA dose) where week was the repeated measure, did not 
reveal a significant interaction between these factors (F(2,56)=.74, p>.05) but there were 
main effects of pretreatment (F(1,25)=10.15, p<.01) and MDMA dose (F(1,25)=55.92, 
p<.001). Within subjects contrasts revealed that there were significant differences between 
weeks 2 and 5 on the effects of pretreatment (F(1,25)=.04, p<.05) and MDMA dose 
(F(1,25)=14.45, p<.01). 
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Figure 12 Total activity counts produced for the 60-minute period following an acute 
MDMA (0.0 or 10.0mg/kg, IP) injection in MDMA (40mg/kg) or vehicle pretreated 
groups at the 2, 3, 4 and 5 week time points post pretreatment (+SEM).  
Dose Effects of MDMA-Produced Hyperactivity 2- and 12-Weeks Post Exposure 
Figures 13A, 13B, 13C and 13D show the time course and dose-dependency of 
MDMA-produced hyperactivity for saline and MDMA-pretreated rats following a 2-week 
withdrawal period. A 3-Way ANOVA (time X pretreatment X MDMA dose) with time as 
a repeated measure showed a significant interaction between these factors (F(13, 
227)=1.96, p<.05) and main effects of MDMA dose (F(3,51)=84.33, p<.001) and 
pretreatment (F(1,51)=21.64, p<.001). ANOVAs on total ambulatory counts for each 
dosage group revealed no significant differences as a result of pretreatment for rats that 
received either the 0.0 (Figure 13A) or 2.5 (F(1,15)=.380, p>.05), 2.5 (Figure 13B) 
(F(1,10)=.007, p>.05) mg/kg doses. MDMA-produced hyperactivity was greater for the 
saline pretreated rats that received 5.0 (Figure 13C) (F(1,14)=8.07, p<.05) and 10.0 mg/kg 
(Figure 13D) (F(1,12)=16.42, p<.01) doses.  
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Figure 13 Ambulatory counts produced after acute MDMA (0.0, 2.5, 5.0 or 10mg/kg) 
administration 2 weeks following saline or MDMA pretreatment. The time course of 
the mean ambulatory counts produced after 0.0 (Figure 13A), 2.5 (Figure 13B), 5.0 
(Figure 13C), or 10.0mg/kg (Figure 13D) MDMA are shown (+SEM). Insets show 
total ambulatory counts during the 60-minute period post MDMA injection for the 
two pretreatment groups (+SEM). Figure 13E shows total ambulatory counts 
produced by all MDMA doses for the 60-minute period post MDMA injection for the 
two pretreatment groups (+SEM). Significant difference relative to saline pretreated 
group  * p<.05  ** p<.01. 
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Figures 14A, 14B, 14C and 14D show the time course and dose-dependency of 
MDMA-produced hyperactivity for saline and MDMA-pretreated rats after a 12-week 
withdrawal period. A 3-Way ANOVA (time X pretreatment X MDMA dose) with time as 
a repeated measure failed to reveal a significant interaction between these factors 
(F(11,214)=1.04, p>.05) and ANOVAs did not reveal differences as a result of 
pretreatment for any of the doses tested (0.0 mg/kg; (F(1,14)=3.11, p>.05); 2.5 mg/kg; 
(F(1,14)=.071, p>.05); 5.0 mg/kg; (F(1,18)=2.00, p>.05) and 10.0 mg/kg(F(1,14)=.162, 
p>.05). There was still a main effect of MDMA on locomotor activity levels 
(F(3,60)=47.89, p<.001), but pretreatment did not affect overall responses (F(1,60)=1.16, 
p>.05). 
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Figure 14 Ambulatory counts produced after acute MDMA (0.0, 2.5, 5.0 or 
10.0mg/kg) administration in rats 12 weeks following saline or MDMA pretreatment. 
The time course of the mean ambulatory counts produced after 0.0 (Figure 14A), 2.5 
(Figure 14B), 5.0 (Figure 14C) or 10.0mg/kg (Figure 14D) MDMA (+SEM) are shown. 
Insets show total ambulatory counts at each MDMA dose for the 60-minute period 
post MDMA injection for the two pretreatment groups (+SEM). Figure 14E shows 
total ambulatory counts produced during the 60-minute period post MDMA injection 
for the two pretreatment groups (+SEM).  
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The Serotonin Transporter  
Paroxetine Binding Densities 
Specific [3H] paroxetine binding was measured in regional assays of brain tissue 
homogenates from frontal cortex, hippocampus and striatum.  Bmax values were determined 
by assaying at two concentrations of radioligand (0.06 and 0.2 nM) and correcting for 
occupancy (KD=0.25 nM, (Sanchez et al., 2001)). MDMA pretreated rats had significantly 
lower levels of SERT binding compared to the control animals in all regions assayed 
(p<0.05).   
 CONTROL MDMA 
Frontal Cortex 29.25 ± 3.29 15.44 ± 2.17 * (53% of control) 
Caudate Putamen 47.35 ± 2.15 23.85 ± 5.92 *** (50% of control)
Hippocampus 29.96 ± 3.22 15.32 ± 2.65 *(51% of control) 
Brain Stem 47.52 ± 4.28  17.64 ± 4.22 ***(37% of control)
 
Table 2 Regional measurements of SERT densities following MDMA pretreatment. 
Bmax values are expressed as the mean + SEM.  * p<.05, **p<.01 and ***p<.001 
Clomipramine-Induced Attenuation of MDMA-Produced Hyperactivity 
Figures 15A and 15B show the time course for the dose effects of clomipramine 
(0.0, 0.3, 1.25 or 5.0mg/kg) on MDMA (5.0mg/kg, IP)-produced locomotor activity in 
saline and MDMA-pretreated rats. A 3-Way ANOVA with time as the repeated measure 
(time X clomipramine dose X pretreatment) failed to reveal a significant interaction 
between these factors (F(11,247)=1.41, p>.05). There were main effects of pretreatment 
(F(1,67)=5.10, p<.05) and clomipramine dose (F(3,67)=8.74, p<.001). Post hoc tests 
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showed that clomipramine significantly attenuated MDMA-produced hyperactivity in the 
saline pretreated rats at the 1.25 and 5.0mg/kg doses, whereas clomipramine did not affect 
MDMA pretreated rats. 
 
 
 
Figure 15 Ambulatory counts produced after acute MDMA (5.0mg/kg) and 
clomipramine (0.0, 0.3, 1.25 or 5.0mg/kg) administration in rats that had received 
saline or MDMA pretreatment. The top panels show the time course of hyperactivity 
in saline (Figure 3A) and MDMA (Figure 3B) pretreated rats (+SEM). Insets show 
total ambulatory counts following each clomipramine dose for the 60-minute period 
post MDMA injection for each of the pretreatment groups (+SEM). Figure 3C shows 
total ambulatory counts produced at all clomipramine doses for the 60-minute period 
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post MDMA injection for the two pretreatment groups (+SEM). Significant 
difference relative to vehicle group within pretreatment condition * p<.01. 
The 5-HT2c Receptor  
m-CPP-Induced Hypolocomotion 
Figures 16A and 16B show the time course for the dose effects of m-CPP (0.0, 
0.60, 1.25 and 2.5mg/kg) on baseline locomotion in saline and MDMA-pretreated rats. m-
CPP did not produce differential effects on the two pretreatment groups as revealed by a 3-
Way ANOVA with time as the repeated measure (time X m-CPP dose X pretreatment) that 
did not show a significant interaction (F(12,199)=1.12, p>.05). m-CPP did significantly 
alter behaviour, as there was a main effect of m-CPP dose (F(3,49)=14.45 p<.001) but not 
pretreatment (F(1,49)=3.96, p>0.05). Post hoc tests showed that the 2.5mg/kg dose 
significantly lowered ambulatory counts in saline-, whilst both the 1.25 and 2.5mg/kg 
doses were effective in MDMA-pretreated rats. 
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Figure 16 Ambulatory counts produced after acute m-CPP administration (0.0, 0.6, 
1.25 or 2.5mg/kg). Top panels show the time course of the mean ambulatory counts in 
saline (Figure 16A) and MDMA (Figure 16B) pretreated rats (+SEM). Insets show 
total ambulatory counts following each m-CPP dose for the 30-minute recording 
period for each of the pretreatment groups (+SEM). Figure 16C shows total 
ambulatory counts produced at all m-CPP doses for the 30-minute recording period 
for the two pretreatment groups (+SEM). Significant difference relative to vehicle 
within preteatment group  * p<.05 ** p<.001.  
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m-CPP-Induced Increased Emergence Latency 
Figure 17 shows mean emergence latency times (minutes) following m-CPP (0.0, 
0.6 or 1.25mg/kg) administration in saline and MDMA-pretreated rats. There were no 
differences as a result of pretreatment in the ability of m-CPP to increase emergence 
latencies as shown by a 2-Way ANOVA (m-CPP dose X pretreatment) that failed to reveal 
a significant interaction between these factors (F(2,47)=.03, p>.05). There was a main 
effect of m-CPP dose (F(2,47)=27.32, p<.001) but not of pretreatment (F(1,47)=.023, 
p>.05). Post hoc analyses showed that the 1.25mg/kg dose produced significantly higher 
emergence latencies than baseline in both pretreatment conditions.  
 
Figure 17 Mean emergence latencies for MDMA and saline pretreated rats following 
administration of m-CPP (0.0, 0.6 or 1.25mg/kg) (+SEM). Significant difference 
relative to vehicle group within pretreatment condition* p<.001. 
RS102221-Induced Potentiation of MDMA-Produced Hyperactivity 
Figures 18A and 18B show the time course for the dose effects of RS102221 (0.0, 
0.5 and 1.0mg/kg) on MDMA (5.0mg/kg, IP)-produced locomotor activity in saline and 
MDMA-pretreated rats. A 3-Way ANOVA (time X pretreatment X RS102221 dose) 
revealed a significant interaction (F(11,281)=2.45, p<.01) where there was a main effect of 
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pretreatment (F(1,52)=9.17, p<.01) but not RS102221 dose (F(2,52)=.911, p>.05). Post 
hoc analyses showed that only the 0.5mg/kg RS102221 dose significantly increased 
activity counts above the vehicle group in saline pretreated rats. The response of the 
MDMA pretreated group to 1.0mg/kg RS102221 was significantly greater than the 
response to the 0.5mg/kg dose, indicating a rightward dose-effect shift  (p<.05).  
  
  
110 
  
 
 
Figure 18 Ambulatory counts produced following MDMA (5.0mg/kg) and RS 102221 
(0.0, 0.5 or 1.0mg/kg) administration, where top panels show the time course of the 
mean ambulatory counts in saline (Figure 18A) and MDMA (Figure 18B) pretreated 
rats (+SEM). Insets show total ambulatory counts at each RS 102221 dose for the 60-
minute period post MDMA injection for each of the pretreatment groups (+SEM). 
Figure 18C shows total ambulatory counts produced following all RS 102221 doses 
for the 60-minute period post MDMA injection for the two pretreatment groups 
(+SEM). Significant difference relative to vehicle group within pretreatment 
condition* p<.05.  
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The 5-HT2a Receptor  
DOI-Induced Wetdog Shakes 
Table 3 shows that DOI produced significantly more WDS in saline than MDMA 
pretreated rats. Univariate analyses (pretreatment X DOI dose) revealed a significant 
interaction between these factors (F(1,18)=16.38, p<.01) as well as main effects of DOI 
dose (F(1,18)=18.50, p<.001) and pretreatment (F(1,18)=14.40, p<.01).  
 
DOI (mg/kg) SALINE MDMA 
0.0 (n=6 per group) 1.0 ± 0.4 1.2 ± 0.3
1.0 (n=6 per group) 6.5 ± 1.1 * 1.3 ± 0.2
 
Table 3 Mean total number of DOI-induced WDS during a 10-minute recording 
period in MDMA and saline pretreatment groups + SEM.  Significant difference 
relative to vehicle group * p<.001 
Ritanserin-Induced Attenuation of MDMA-Produced Hyperactivity 
Figures 19A and 19B show the time course for the dose effects of ritanserin (0.0, 
2.5, 5.0 and 10.0mg/kg) on MDMA (10.0mg/kg, IP)-produced locomotor activity in saline 
and MDMA-pretreated rats. A 3-Way ANOVA with time as the repeated measure (time X 
ritanserin dose X pretreatment) revealed a significant interaction between these factors 
(F(16,387)=1.92, p>.05) and a main effect of ritanserin dose (F(3,74)=10.16, p<.001). Post 
hoc analyses showed that all doses of ritanserin dose-dependently and significantly 
attenuated MDMA-produced hyperactivity in the saline pretreated rats, where the 10mg/kg 
dose appeared to lose some selectivity. The MDMA pretreated group was unresponsive to 
ritanserin, although there was a tendency towards attenuation. 
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Figure 19 Ambulatory counts produced following MDMA (10.0mg/kg) and ritanserin 
(0.0, 2.5, 5.0 or 10.0mg/kg) administration, where top panels show the time course of 
the mean ambulatory counts in saline (Figure 19A) and MDMA (Figure 19B) 
pretreated rats (+SEM). Insets show total ambulatory counts at each ritanserin dose 
for the 60-minute period post MDMA injection for each of the pretreatment groups 
(+SEM). Figure 19C shows total ambulatory counts produced following all ritanserin 
doses for the 60-minute period post MDMA injection for the two pretreatment groups 
(+SEM). Significant difference relative to vehicle group within pretreatment 
condition* p<.01, ** p<.001.  
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Discussion 
Overview 
The present study investigated the contribution of decreased SERT densities and/or 
reduced responsiveness of 5-HT2c and 5-HT2a receptors to MDMA-induced tolerance. 
The MDMA pretreatment regimen used in the present study previously produced tolerance 
to several behavioural effects of MDMA which were attributable to serotonergic deficits 
(Shankaran and Gudelsky, 1999). Paroxetine binding verified that the pretreatment 
regimen produced comparable decreases in SERT binding densities to those previously 
reported (Scanzello et al., 1993; Fischer et al., 1995). Neurochemical studies have 
documented the time course for recovery of these deficits, so the present study investigated 
whether recovery of function was also evident. Since it was presumed that functional and 
neurochemical recoveries were related, the effect on tolerant locomotor behaviour of 
repeatedly challenging 5-HT systems with MDMA was investigated. Further, the 
functional implications of decreased SERT densities were assessed by examining the 
ability of the SERT selective ligand, clomipramine, to block MDMA-produced 
hyperactivity in tolerant animals. 
Previous investigations revealed that 5-HT2c receptor-mediated m-CPP-produced 
behaviours remained unchanged (Bull, 2003), whilst 5-HT2a receptor-mediated DOI-
produced behaviours were diminished following MDMA exposure (Bull, 2004). The 
present study aimed to determine whether these findings were replicable, using improved 
methodologies. However, the functions whereby 5-HT2a and 5-HT2c receptors modulate 
MDMA-produced hyperactivity might be distinct from behaviour produced by agonists 
such as m-CPP and DOI. To these ends, two novel assays were developed that combined 
MDMA with 5-HT2c or 5-HT2a receptor antagonists to directly assess receptor ability to 
modulate MDMA-produced hyperactivity following MDMA exposure.  
 
  
  
114 
MDMA-Produced Hyperactivity 
Acute MDMA Response 
MDMA produced dose-dependent increases in locomotor activity in both 
measuring apparatus (Figure 1 and 2), which concurs with similar studies (Kehne et al., 
1996; Herin et al., 2005). Dose-dependent MDMA-induced hyperactivity has also been 
reliably paired with dose-dependent elevations in 5-HT and DA levels in the nucleus 
accumbens (Baumann et al., 2005). Release of DA contributes to hyperactivity, as 
increased DA outflow and concomitant hyperactivity after MDMA administration 
(Yamamoto and Spanos, 1988; Bubar, 2003) was attenuated by DA receptor antagonists 
(Kehne et al., 1996; Bubar et al., 2004; Daniela et al., 2004) or 6-hydroxydopamine lesions 
(Gold et al., 1989b). However, the effects of MDMA on 5-HT release are predominant 
compared to other psychostimulants (Crespi et al., 1997; Baumann et al., 2005), which has 
been attributed to the high affinity for the SERT (Battaglia et al., 1988).  
MDMA-induced 5-HT levels were elevated more rapidly than DA immediately 
following administration. MDMA has some affinity for the DAT, but it is likely that 
increased 5-HT levels indirectly release DA via facilitatory 5-HT receptors, such as the 5-
HT1b and 5-HT2a subtypes (Benloucif and Galloway, 1991; Parsons and Justice, 1993; 
Yamamoto et al., 1995). The differential time course for the elevation of 5-HT and DA 
levels after MDMA support this idea. For example, following MDMA administration, 
microdialysis revealed an increase in DA that was delayed in relation to 5-HT increases 
(White et al., 1994). It was suggested that MDMA might produce an initial but relatively 
small increase in DA, probably via DAT-mediated mechanisms, whereas the later increase 
might be 5-HT2 receptor-mediated (White et al., 1994). This idea was further supported in 
that local 5-HT application to the nucleus accumbens induced DA release (Jacocks and 
Cox, 1992) and TTX largely attenuated DA elevations, suggesting impulse-mediated 
mechanisms (Yamamoto et al., 1995).  
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Evidence suggests that 5-HT is the main contributor to MDMA-produced 
hyperactivity, as 5-HT depletion following 5,7-DHT lesions or pCPA administration 
attenuated the expression of MDMA-produced hyperactivity (Callaway et al., 1990; Kehne 
et al., 1996a). The MDMA 5-HT-releasing mechanism was purported to be SERT-
mediated (Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 1992; 
Gudelsky and Nash, 1996; Pifl et al., 2005), supported by the observation that pretreatment 
with SSRIs such as clomipramine, fluoxetine, sertraline and zimelidine completely or 
partially attenuated MDMA-produced hyperactivity (Callaway et al., 1990; Callaway and 
Geyer, 1992b) and SERT knockout mice did not exhibit  hyperactivity following MDMA 
administration (Bengel et al., 1998). Additionally, pretreatment with 5-HT1b, 5-HT2a and 
5-HT2c receptor ligands modulate the expression of MDMA-produced hyperactivity 
(Bankson, 2002; Herin et al., 2005; Fletcher et al., 2006). 
The different measuring apparatus used in the present study yielded different 
MDMA dose effect curves. The MDMA used for each experiment, however, was prepared 
in a similar manner and equivalent doses administered. These discrepancies can be 
explained in terms of the differential mechanisms by which these apparatus measured 
locomotor activity. The MDMA dose effect data produced by the older equipment shows 
an ascending curve, where the 20.0mg/kg MDMA dose appears to produce maximal 
activity levels (Figure 1). Any beam break was counted by the computer as an ‘activity 
count’, thus all forward locomotion, head weaving, tail movements would all be counted as 
‘activity’. Behaviours such as head weaving are components of the 5-HT syndrome, which 
tend to be exhibited predominantly at the higher MDMA doses (Spanos and Yamamoto, 
1989). This equipment, therefore, did not allow the differentiation of the aforementioned 
behaviours.  
The newer Med-PC equipment was considerably more sensitive in that it could 
differentiate between forward locomotion (where distance was travelled in order for the 
movement to be registered as an ‘ambulatory count’) and head weaving (termed 
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‘stereotypy counts’, which are small movements made when the animal remains 
stationary). The MDMA dose effect curve produced by the newer equipment revealed that 
10.0mg/kg MDMA produced maximal levels of forward locomotion, whilst 20.0mg/kg did 
not produce greater forward locomotion than the 5.0mg/kg dose (Figure 2). The combined 
data from the old and new equipment indicate that the 20.0mg/kg MDMA dose produced 
non-selective behavioural activation. There were high levels of beam-breaks after 
20.0mg/kg MDMA as shown by the older apparatus (Figure 1), but the Med-PC data 
revealed that forward locomotion was reduced at this dose (Figure 2). In order to examine 
the effects of MDMA pretreatment on the ability of MDMA to increase forward 
locomotion as measured using the Med-PC equipment, the 2.5, 5.0 and 10.0mg/kg MDMA 
doses were selected because the 20.0mg/kg dose produced non-selective effects. 
Effects of MDMA Pretreatment  
Acute Response to MDMA 
Despite large decreases in SERT binding densities (Table 2), baseline locomotor 
behaviour following vehicle challenge was unaffected by MDMA pretreatment (Figure 
12). These findings contrast with the hyperactivity that has been observed following 
neurotoxic 5,7-DHT lesions (Kostowski, 1968; Fibiger HC, 1971; Borbely, 1973; Jacobs, 
1975; Marsden and Curzon, 1976; Steigrad et al., 1978; Dringenberg, 1995). Thus, 
MDMA-pretreatment must produce deficits that are not as extensive or widespread as these 
other more radical and neurotoxic treatments. It is not likely that higher MDMA doses than 
those used in this study would have altered baseline activity, as pretreatment with a 
160.0mg/kg MDMA did not alter baseline activity (McNamara et al., 1995). These 
findings are consistent with the idea that MDMA exposure produces serotonergic 
alterations rather than neurotoxicity (Baumann et al., 2006). The present results also 
indicate that MDMA-produced serotonergic deficits are not functionally evident under 
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baseline conditions. This concurs with other studies that have also reported no change in 
locomotor (McNamara et al., 1995; Bull, 2003) or EPM (Bull, 2004; Sumnall et al., 2004) 
behaviours following MDMA pretreatment.  
Behavioural alteration following MDMA pretreatment might depend upon which 
behaviour is examined. For example, although locomotor (McNamara et al., 1995; Bull, 
2003) and EPM (Bull, 2004; Sumnall et al., 2004) behaviours were consistently unaffected 
following MDMA pretreatment, altered anxiety states were detected in the social 
interaction and emergence tests (Gurtman et al., 2002; McGregor et al., 2003; Thompson et 
al., 2004). Although 5-HT has been shown to have a role in numerous baseline behaviours 
(locomotor activity, emergence behaviour, social interaction, EPM tests and the FST), 
there are also varying contributions from other neurotransmitter systems, brain regions and 
5-HT receptor subtypes. Since MDMA-produced serotonergic deficits were dose and brain 
region-dependent (McGregor et al., 2003), it follows that some behaviours might be more 
susceptible to MDMA pretreatment than others. For instance, social interaction has been 
associated with postsynaptic 5-HT1a receptor activation (Morley et al., 2005), and MDMA 
substantially alters functional properties, mRNA expression and binding densities of this 
receptor (Aguirre et al., 1995; Aguirre et al., 1997; Aguirre, 1998). This might explain why 
decreased social interaction has been frequently reported following MDMA exposure. 
Other behaviours that might be less reliant on single contributors and involve input from 
numerous 5-HT receptors and neurotransmitter systems, such as exploratory EPM 
behaviour (Rodgers et al., 1997), might be less affected. 
Extracellular 5-HT dialysate levels in MDMA pretreated rats were comparable to 
controls (Matuszewich et al., 2002), which might also explain unchanged baseline 
locomotion. Indeed, it was observed that 5-HT release was consistently impaired in 
response to pharmacological, physiological or stressful stimuli in MDMA pretreated 
animals (Gartside et al., 1996; Shankaran and Gudelsky, 1999; Matuszewich et al., 2002). 
These findings might explain why rats tolerant to the behavioural effects produced by an 
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acute MDMA challenge showed little change in baseline behaviour (Callaway and Geyer, 
1992a; Shankaran and Gudelsky, 1999) and suggest that pharmacological challenge might 
be required for functional impairments to be evident. 
Indeed, MDMA pretreatment in the present study produced locomotor tolerance to 
the MDMA (5.0 and 10.0mg/kg) doses that produced significant hyperactivity (Figure 12 
and 13E). The 2.5mg/kg MDMA dose did not significantly elevate baseline ambulatory 
counts (Figure 13B), and there were no differences as a function of pretreatment. This is 
consistent with the idea that the serotonergic system must be pharmacologically challenged 
to observe deficits, but challenged to an extent where significant behavioural effects are 
evident. 
 Tolerance to the activating effects of MDMA has been associated with 
serotonergic deficits. Sprague Dawley rats that received an identical pretreatment regimen 
to the present study exhibited diminished dialysate striatal 5-HT release and tolerance to 
the behavioural effects of acute MDMA (Shankaran and Gudelsky, 1999). It was unclear 
whether these observations were attributable to MDMA-induced attenuation of 5-HT 
releasing abilities or vesicular 5-HT depletions, however, MDMA-induced increases in 
dialysate DA levels were comparable between pretreatment groups, suggesting that the 
diminished serotonergic response was associated with the tolerant behavioural profile. 
Further, pharmacologically induced 5-HT depletion attenuated the ability for MDMA to 
produce hyperactivity (Callaway et al., 1990; Kehne et al., 1996a), which presumably 
mirrors the tolerance to MDMA observed by Shankaran et al. (1999) and the present 
results. Since the present study utilised a regimen that produced extensive 5-HT depletions 
and reduced SERT densities (Scanzello et al., 1993; Fischer et al., 1995), tolerance was 
likely due predominantly to serotonergic deficits. 
Pharmacokinetics could affect behavioural response to acute MDMA challenge. 
MDMA is demethylenated by the CYP2D1 hepatic cytochrome P450 enzymes in the rat 
(Kumagai et al., 1994). This enzyme is polymorphically expressed, therefore different rat 
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strains have been purported to have differential metabolism of MDMA (Malpass et al., 
1999). For example, the Dark Agouti rat exhibits enzymic deficiencies whereas the 
Sprague Dawley strain has more effective CYP2D1 enzyme capacity. Behavioural 
differences in response to MDMA were observed, which were purported to relate to 
differential drug metabolism. Dark Agouti rats did not exhibit increased locomotor activity 
following 2.0, 5.0 or 10.0mg/kg MDMA, whilst Sprague Dawley rats showed dose-
dependent increases. The relationship between the acute locomotor response to MDMA 
and enzyme function was unclear, but these findings suggest that tolerance to MDMA 
could be related to impaired enzyme function. The effects of MDMA exposure on these 
hepatic enzymes has not been characterised, but it has been reported that 
methamphetamine pretreatment decreased cytochrome P450 enzyme activity (Yamamoto 
et al., 1988). It is possible that enzymic deficiencies and altered MDMA metabolism were 
contributors to behavioural tolerance.  
Although kinetics might have a role, behavioural tolerance to MDMA was 
relatively selective. For example, MDMA pretreated rats that were tolerant to the effects of 
MDMA exhibited a sensitised response to amphetamine challenge (Callaway and Geyer, 
1992a). Amphetamine and MDMA are metabolised via similar pathways (Yamamoto et 
al., 1984; Kumagai et al., 1994), therefore the pharmacokinetics explanation could not 
account for these differences. Since diminished 5-HT levels have potentiated the locomotor 
response to amphetamine (Segal, 1976), it is most likely that these differential responses 
were attributable to MDMA-induced 5-HT depletions. These differential responses also 
indicate that behavioural tolerance to MDMA is not a general suppression of locomotor 
behaviour, as in this instance, tolerance to both drugs would have been expected.  
The specificity of tolerance for certain serotonergic compounds has reported. For 
example, m-CPP-produced hypolocomotion and anxiogenesis in the EPM were not altered 
by MDMA pretreatment (Bull, 2003), whereas behavioural responses to DOI (Bull, 2004) 
or the 5-HT1 agonist, RU24969 (Callaway and Geyer, 1992a) were diminished. These 
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findings suggest that the receptors and associated mechanisms that contribute to MDMA-
produced hyperactivity undergo desensitisation or downregulation, producing tolerance to 
compounds that selectively target affected systems.  
Repeated MDMA Exposure 
In the present study, MDMA and vehicle pretreatment groups were challenged on a 
weekly basis with MDMA for 1 month. Tolerance to MDMA was persistent in the MDMA 
pretreated group, whereas the saline pretreated group appeared to become increasingly 
tolerant to the 10.0mg/kg MDMA challenge over the 4-week period (Figure 12). Within 
subject comparisons revealed that there were significant differences of MDMA and 
pretreatment between weeks 2 and 5. These effects were attributed to the decreasing 
locomotor response of the saline pretreated group to MDMA, since responses of other 
groups were relatively stable. Interestingly, these now tolerant rats had been administered a 
total of 40.0mg/kg MDMA after the last test day, which was equivalent to the total dose 
administered initially to the MDMA pretreated rats. The level of hyperactivity in this group 
was comparable to the MDMA pretreated group at week 2, suggesting that these 
procedures, although spread over a 4-week period, might have produced equivalent 
serotonergic deficits.  
Contrary to the present findings, repeated administration of MDMA followed by a 
withdrawal period, has produced an augmented response to subsequent challenge (Spanos 
and Yamamoto, 1989; Dafters, 1995; Kalivas et al., 1998; McCreary et al., 1999; Ramos et 
al., 2004, 2005). The pretreatment regimen and consequent duration of drug exposure 
might determine whether tolerance or sensitisation to MDMA is expressed. Indeed, chronic 
cocaine administration via osmotic minipumps produced tolerance to the locomotor effects 
of cocaine (Reith et al., 1987; Izenwasser and French, 2002; Hope et al., 2005), whereas 
repeated daily injections produced sensitisation (Reith et al., 1987; Martin-Iverson and 
Burger, 1995; Izenwasser and French, 2002; Hope et al., 2005). Intermittent exposure to 
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methamphetamine also resulted in behavioural sensitisation (Hirabayashi et al., 1991; 
Kuribara, 1996; Davidson et al., 2005) whereas chronic exposure via minipump 
administration resulted in tolerance to the behavioural effects of the drug (Kuribara, 1996; 
Davidson et al., 2005). Similarly, either sensitised or tolerant responses have been 
observed following either intermittent or chronic exposure to methylphenidate (McNamara 
et al., 1993; Gaytan et al., 1997; McDougall et al., 1999) or morphine (Kuribara, 1996). 
Regimens typically used to produce locomotor sensitisation to MDMA might 
involve a specific set of changes to the receptors that produce potentiated hyperactivity. 
Sensitisation-producing regimens usually involve consecutive daily MDMA injections in a 
test chamber followed by a withdrawal period before MDMA challenge (Spanos and 
Yamamoto, 1989; Dafters, 1995; Kalivas et al., 1998; McCreary et al., 1999; Ramos et al., 
2004, 2005). The present study indicates that pretreatment protocols necessary to produce 
sensitisation might be more specific than those required to produce tolerance, as 40.0mg/kg 
MDMA administered either in 1 day, or over 1 month both produced locomotor tolerance.  
Different MDMA pretreatment regimens might differentially affect receptor 
populations that produce hyperactivity. For example, decreased sensitivity of receptors that 
facilitate MDMA-produced hyperactivity, such as the 5-HT1b or 5-HT2a subtypes, might 
contribute to tolerance. Conversely, receptor supersensitisation might lead to a sensitised 
behavioural response. Recently, repeated treatment with a 5-HT2a receptor agonist 
produced a sensitised response to MDMA challenge (Ross et al., 2006), suggesting  that 
MDMA-produced sensitisation might be partly mediated via the 5-HT2a receptor. 
Additionally activation of the inhibitory 5-HT2c receptors in the prefrontal cortex 
prevented the expression of locomotor sensitisation in MDMA-pretreated animals (Ramos 
et al., 2005). Conversely, chronic MDMA exposure produced tolerance to MDMA and 5-
HT1 (Callaway and Geyer, 1992a) and 5-HT2 (Bull, 2004) receptor agonists, suggesting 
decreased receptor responsivities.  
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It is possible that environmental conditioning might affect the expression of 
sensitisation or tolerance. Only one previous investigation has reported locomotor 
tolerance to MDMA challenge following pretreatment (Callaway and Geyer, 1992a). The 
animals were pretreated with MDMA in the home cage and exhibited tolerance to MDMA-
produced hyperactivity when placed in the test chamber and injected with MDMA 3 days 
later. It has been well established that environmental conditioning significantly enhances 
the sensitised locomotor response (Badiani et al., 1997; Bonate et al., 1997; Uslaner et al., 
2001). These principles also apply to MDMA, as MDMA pretreated rats exhibited 
potentiated locomotion in response to environmental cues previously paired with the drug 
(Gold and Koob, 1989a). It was suggested that because there were no drug-test chamber 
pairings in Callaway and Geyer’s study (1992), a sensitised response was not observed 
(Kalivas et al., 1998). The present study refutes this claim, as the saline pretreated group 
that received weekly MDMA injections in the test chamber were exposed to 4 drug-test 
chamber pairings, but did not exhibit sensitisation. Additionally, activity of the rats that 
received saline did not change with each week, reducing the possibility that progressive 
tolerance might have been due to increasing familiarity with the test chamber. These 
observations indicate that tolerance was predominantly attributable to MDMA-produced 
pharmacological alterations rather than conditioning effects.  
The MDMA dosing regimen used in the present study was not selected to replicate 
human use patterns, as species differences, such as pharmacokinetic and 
neurophysiological considerations (de la Torre and Farre, 2004) render the task of 
determining equivalent doses difficult. However, the tolerance to the behavioural effects of 
MDMA reported in this study might be highly relevant to the effects reported by humans 
who consume MDMA. Indeed, the most frequently reported consequence of MDMA use in 
humans was tolerance to the subjective effects of the drug (Verheyden et al., 2003; Scholey 
et al., 2004; Parrott, 2005). It is of interest to note that recreational MDMA users typically 
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ingest the drug on weekends (de Almeida and Silva, 2003), which might be comparable to 
the rat model in the present study that also produces tolerance (Figure 12).  
Comparison Between 2- and 12-Week Recovery Periods 
The data from both the present (Table 2) and past studies indicate that MDMA 
exposure altered serotonergic neurotransmission. Despite these extensive changes, SERT 
binding reductions and 5-HT depletions produced by the pretreatment regimen used in this 
thesis exhibited significant recovery to control levels over time (Scanzello et al., 1993; 
Fischer et al., 1995). Other studies have also shown recovery after a similar time period 
following MDMA pretreatment for other markers of serotonergic integrity. For example, 
TPH levels increased as did TPH mRNA expression in cortical regions (Garcia-Osta et al., 
2004) and 5-HT2a receptor binding densities (Reneman et al., 2002) recovered to control 
levels. These neurochemical findings are consistent with the notion that MDMA produces 
neuroadaptations that recover over time.  
In order to elucidate whether tolerance to MDMA-produced hyperactivity (Figure 
13) also exhibited recovery over time, a 12-week period after MDMA exposure before 
behavioural testing was imposed for additional groups of rats. Following this more 
extensive period, differences in responsiveness to MDMA between pretreatment groups 
were no longer apparent (Figure 14). These findings concur with Callaway and Geyer’s 
(1992a) study, where a higher MDMA dose treatment regimen was used (10mg/kg X 8, 
total 80mg/kg MDMA) and tolerance to MDMA occurred after 3 days and recovery 3 
weeks later.  
Comparisons between the 2 and 12-week experiments reveal that the dose effects of 
MDMA differ between the saline pretreated groups. For instance, the response to 5.0mg/kg 
MDMA was equivalent between groups, whereas the 12-week rats showed a much lower 
response to the 10.0mg/kg MDMA dose (Figure 13E and 14E). Although the differences 
between pretreatment groups were not significant in the 12-week rats, there appears to be a 
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tendency for lower responsiveness to MDMA in the MDMA pretreated group. It was a 
possibility that there were no pretreatment differences because control values were too 
low. However, this was a between subjects design, where the only difference between the 2 
and 12 week groups was recovery time and rat age at the time of the behavioural tests. 
Aging has been associated with decreased 5-HT-containing fibres, 5-HT levels, 5-HT 
receptor densities (Keck and Lakoski, 1997), SERT binding sites (Kakiuchi et al., 2001) 
and DA receptor densities (Hyttel, 1987) in the rat brain. Consistent with these 
neurochemical changes, locomotor response to amphetamine was reduced in older rats 
(Huang et al., 1995). Reduced response and a different MDMA dose-effect profile 
exhibited by the 12-week group were consistent with the idea that the aging process 
involves substantial changes the serotonergic system. Further, the comparable response to 
MDMA between pretreatment groups demonstrates considerable neuroadaptation 
following MDMA exposure, as aging was also continually diminishing serotonergic 
function.  
Data from the present thesis (Figure 12) suggests that repeated exposure to MDMA 
might prevent or slow the recovery of function in the MDMA pretreated group. Tolerance 
diminished 3 weeks after MDMA preexposure in rats that received much higher doses of 
MDMA than those used in the present study (Callaway and Geyer, 1992a). Thus it was 
expected that the MDMA pretreated rats in the present study would have started showing 
behavioural recovery by 3 weeks. However, tolerance persisted over the 7-week period 
when MDMA was administered weekly. It is possible that persistent tolerance might be 
related to the inability for MDMA-produced serotonergic deficits, such as reduced SERT 
binding densities or 5-HT depletions, to recover when MDMA is constantly being 
administered. In support for this suggestion, our laboratory conducted paroxetine binding 
on rats that had received the MDMA pretreatment regimen used in the present study and 
compared this group to MDMA self-administering rats that were receiving MDMA daily. 
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The results showed that both groups exhibited comparable decreases in SERT binding 
densities (unpublished results). 
The Serotonin Transporter 
Preliminary Clomipramine Experiments 
Clomipramine pretreatment did not significantly affect baseline locomotor activity, 
although there was a tendency towards hypolocomotion (Figure 3). Doses beyond 
5.0mg/kg were not assessed in this experiment, because clomipramine non-selectively 
binds 5-HT receptors and has cholinergic effects at these doses (McTavish and Benfield, 
1990) and the aim was to develop a SERT-selective behavioural assay. These results were 
not surprising, as the ability for SSRIs to produce hypolocomotion was reported as a 
modest effect (Rodriguez Echandia et al., 1983; To et al., 1999; McMahon and 
Cunningham, 2001a). These findings concur with existing literature showing that acute 
SSRI administration produce few consistent and easily measurable behavioural effects.  
The behavioural effects of SSRIs, however, are consistently evident when they are 
combined with MDMA. In the present study, clomipramine dose-dependently attenuated 
5.0mg/kg MDMA-produced hyperactivity (Figure 4). These findings concur with a similar 
study, where SSRI pretreatment inhibited MDMA-produced hyperactivity (Callaway et al., 
1990). MDMA-produced increases in extracellular 5-HT occur via the SERT 
(Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 1992; Gudelsky 
and Nash, 1996; Iravani et al., 2000; Pifl et al., 2005), as shown when SSRIs administered 
in conjunction with MDMA antagonised the MDMA-induced synaptic 5-HT increase 
(Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 1992; Gudelsky 
and Nash, 1996). In vitro experiments showed that clomipramine alone did not affect 
SERT-mediated 5-HT release, but completely abolished MDMA-induced release (Pifl et 
al., 2005). The clomipramine-induced attenuation of MDMA-produced hyperactivity is 
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attributable to decreased 5-HT release, as this leads to reduced activation of postsynaptic 5-
HT receptors that facilitate MDMA-produced hyperactivity (Bankson, 2002). 
It is possible that the effects of SSRIs on locomotion were due to general 
behavioural suppression, but the evidence suggests that these effects were SERT-selective. 
Firstly, although SSRIs have been purported to produce hypolocomotion, doses that did not 
significantly affect baseline activity levels (Figure 3) significantly attenuated MDMA-
produced hyperactivity (Figure 4). Additionally, Callaway et al. (1990) reported that only 
MDMA-produced forward locomotion, but not increases in holepokes and rearings, were 
attenuated by SSRI pretreatment.  
When clomipramine was combined with 10.0mg/kg MDMA, there was a tendency 
towards attenuation, but these effects were not significant (Figure 5). The inability of 
clomipramine to affect behaviour produced by high-dose MDMA might reflect saturated 
SERT-binding and concomitant binding to lower affinity sites. For example, at the 
10.0mg/kg MDMA dose, all SERT sites might be occupied, thus sites such as the NET and 
DAT with lower affinity for MDMA could be bound (Battaglia et al., 1988). Hyperactivity 
at the highest dose, therefore, might have a larger NE and DA component than that 
produced by the lower MDMA dose. This might explain why SERT blockade did not 
greatly impact hyperactivity produced by the 10.0mg/kg MDMA dose. 
Effects of MDMA Pretreatment  
Paroxetine Binding 
The paroxetine binding data showed significant and region-dependent reduction of 
SERT sites (Table 2), which concurs with other studies that used this pretreatment regimen 
(Scanzello et al., 1993; Fischer et al., 1995). The present results extended these findings to 
include the brain stem region, which showed 37% reductions of control levels. It is 
surprising that no studies that have assessed the impact of MDMA exposure on behaviour 
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have assessed brain stem SERT densities, as 5-HT neurons originating in the brain stem 
raphe nuclei project to numerous other structures (Molliver, 1987). Altered 
neurotransmission in this region would have the potential to affect a large number of brain 
functions. Since it was reported that the raphe nucleus contained the highest densities of 
SERT (Lin et al., 2004), decreases in this population following MDMA pretreatment 
would likely affect ascending structures. For example, MDMA might not significantly 
elevate brain stem 5-HT levels in MDMA pretreated rats, as this is a predominantly SERT-
mediated effect (Hekmatpanah and Peroutka, 1990; Berger et al., 1992; Rudnick and Wall, 
1992; Gudelsky and Nash, 1996; Iravani et al., 2000; Pifl et al., 2005). Decreased 5-HT 
release in this region might reduce the activation of serotonergic neurons that project to 
other structures in the brain that are involved in the behavioural responses to MDMA. 
Indeed, the brainstem projects to the hippocampus, frontal cortex and caudate putamen 
(Molliver, 1987) and these regions exhibited MDMA-induced SERT binding decreases 
(Table 2), which might be independent from those observed in the brain stem.  
The frontal cortex and hippocampus have both been associated with 5-HT-mediated 
hyperactivity. Local infusions of 5-HT receptor agonists/antagonists into the frontal cortex 
modulated stimulant-produced hyperactivity (Filip and Cunningham, 2003) and it was also 
demonstrated that 5-HT2c receptors in this region mediated locomotor sensitisation to 
MDMA following a chronic exposure regimen (Ramos et al., 2005). The hippocampus 
contributes to hyperactivity, as systemic administration of a monoamine oxidase inhibitor 
that elevated hippocampal 5-HT levels produced hyperactivity (Takahashi et al., 2000). A 
role for the hippocampus in these 5-HT-mediated effects was verified when hyperactivity 
was induced by direct 5-HT or monoamine oxidase infusion. It is possible that 
hippocampal 5-HT2c receptor activation contributed to this hyperactivity, as hyperactivity 
was elevated by the direct infusion of m-CPP into this area (Takahashi et al., 2001). 5-
HT2c receptor activation in most regions produces hypomotility (Klodzinska et al., 1989; 
Kennett et al., 1994a; Martin et al., 1998; McCreary et al., 1999; Gleason et al., 2001), but 
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evidence suggests that a population exists in the hippocampus with a facilitatory role, as a 
selective 5-HT2c antagonist attenuated m-CPP-produced hyperactivity.  
Behaviour is the product of complex interactions between different brain structures 
and neurotransmitter systems. Indeed, it appears that the frontal cortex and hippocampus 
interact and contribute to 5-HT-mediated hyperactivity, but the striatum might have less of 
a role. Systemic administration of a monoamine oxidase inhibitor increased 5-HT levels in 
all three regions, which was paired with hyperactivity (Takahashi et al., 2000). Subsequent 
experiments showed that hyperactivity was only exhibited following local infusions into 
the hippocampus or prefrontal cortex and not the striatum. Further, these regions were 
interconnected, as local infusion of tetrodotoxin (TTX) into the hippocampus prevented 
hyperactivity produced by 5-HT infusion into either area. However, TTX infusion into the 
prefrontal cortex failed to affect hippocampal-mediated hyperactivity, suggesting that the 
hippocampus was directly involved in locomotor activity and that the prefrontal cortex 
might facilitate hippocampal control of locomotion.  
 MDMA pretreatment reduced SERT binding densities to the greatest extent in the 
brain stem, thereby producing widespread alterations in serotonergic neurotransmission. 
The brain stem projects to the hippocampus, striatum and frontal cortex, which would 
receive altered signals. Additionally, these regions also exhibited decreased SERT binding 
densities, although to a lesser degree. It was not clear whether these decreases were 
independent from those observed in the brain stem, but since the hippocampus and frontal 
cortex are involved in 5-HT mediated hyperactivity, these local SERT changes would also 
be expected to affect MDMA-produced locomotor behaviour.  
Clomipramine-Induced Attenuation of MDMA-Produced Hyperactivity 
The behavioural effects of MDMA pretreatment were assessed using 5.0mg/kg 
MDMA, as this was the only dose where significant clomipramine-induced attenuation of 
MDMA-produced hyperactivity was evident (Figure 4). The results showed that 
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clomipramine significantly attenuated MDMA-produced hyperactivity in the saline 
pretreated rats (Figure 15A), which closely resembled the results obtained in the 
preliminary studies (Figure 4). The 1.25mg/kg clomipramine dose significantly attenuated 
hyperactivity in the saline pretreated group, whereas it just missed significance in the 
preliminary work (Figure 4). The response to 5.0mg/kg MDMA was equivalent between 
control groups from both experiments, indicating that the 1.25mg/kg clomipramine was the 
‘threshold dose’ for attenuation. 
It is of interest to note that clomipramine failed to completely block MDMA-
produced hyperactivity (Figures 4 and 15), even when doses as high as 20.0mg/kg were 
administered (Figure 4). These findings suggest that effects at the SERT cannot fully 
account for hyperactivity produced by MDMA and indicate that other mechanisms might 
also play a role. Indeed, hyperactivity following administration of psychostimulant drugs 
has frequently been attributed to effects on central dopaminergic systems (Roberts et al., 
1975; Koob et al., 1981; Di Chiara and Imperato, 1988; Gold et al., 1989b; Kehne et al., 
1996; Le et al., 1997; Louis and Clarke, 1998; O'Neill and Shaw, 1999; Schindler and 
Carmona, 2002; Bubar et al., 2004; Daniela et al., 2004). MDMA, like other drugs, 
increases synaptic DA in addition to its effects on the 5-HT system (Yamamoto and 
Spanos, 1988; Gough et al., 1991; Rudnick and Wall, 1992; Yamamoto et al., 1995; 
Shankaran and Gudelsky, 1999) and DA release contributes to MDMA-produced 
hyperactivity (Gold et al., 1989b; Kehne et al., 1996; Bubar et al., 2004; Daniela et al., 
2004). These findings suggest that residual MDMA-induced hyperactivity exhibited by 
clomipramine-pretreated animals was possibly attributable to elevated DA or NE levels.  
Ascending doses of clomipramine failed to affect MDMA-produced hyperactivity 
in the MDMA pretreated rats (Figure 15B). The preliminary data suggest that residual 
hyperactivity evident at the highest clomipramine doses, as previously discussed, was due 
mostly to DA and NE release. Decreased SERT densities in MDMA pretreated rats might, 
therefore, produce a comparable situation to high dose clomipramine pretreatment in drug-
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naïve rats. In this instance, administering clomipramine would not be expected to produce 
any notable behavioural effect. The present data suggest that the MDMA-produced 
hyperactivity in the pretreated rats was not mediated by remaining SERT sites, as even the 
highest clomipramine dose was ineffectual.  
Alternatively, the hyperactivity exhibited by the MDMA pretreated rats was too 
low to be attenuated further. It might have resolved this question to examine the effects of 
clomipramine pretreatment in conjunction with 10.0mg/kg MDMA, as this would have 
presumably raised the activity levels higher in the MDMA pretreated rats and perhaps 
allowed for clomipramine-induced attenuation to become evident. The results from the 
preliminary studies showed, however, that this dose of MDMA appeared to produce 
hyperactivity that was highly resistant to SERT-manipulation (Figure 5).  
There have been no previous attempts to assess the functional status of the SERT 
following MDMA pretreatment, thus these novel results are the first demonstration that 
MDMA-reduced SERT binding densities have functional consequences. These 
experiments were fraught with difficulties, as SERT manipulations are not usually apparent 
in behavioural models, particularly the acute effects. Although the results must be 
interpreted cautiously, it can be tentatively concluded when combined with the paroxetine 
binding data that MDMA pretreated rats were unresponsive to clomipramine due to 
extensive SERT binding reductions. Additionally, MDMA-produced hyperactivity in 
MDMA pretreated rats might be mediated predominantly by non-serotonergic 
mechanisms.  
The 5-HT2c Receptor  
Preliminary m-CPP Experiments 
m-CPP pretreatment produced relatively dose-dependent hypolocomotion in 
preliminary studies (Figure 6). These findings concur with previous work showing that m-
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CPP (Sills et al., 1985; Aulakh et al., 1987; Kennett and Curzon, 1988; Aulakh et al., 1989; 
Bagdy et al., 1989; Klodzinska et al., 1989; Lucki et al., 1989; Freo et al., 1990; Kennett et 
al., 1994a; Bonhaus, 1997; Kennett et al., 1997a; Gleason and Shannon, 1998; Gleason et 
al., 2001) or other more selective 5-HT2c agonists (Martin et al., 1998) produced 
hypolocomotive effects. Hypolocomotion following 5-HT2c receptor activation has been 
reliably attenuated by 5-HT2c antagonists (Klodzinska et al., 1989; Kennett et al., 1994a; 
Martin et al., 1998; McCreary et al., 1999; Gleason et al., 2001) but not 5-HT2a or 5-HT2b 
antagonists (Gleason et al., 2001). In addition, there were no changes to basal locomotion 
in 5-HT2c receptor knockout mice after m-CPP administration (Heisler and Tecott, 2000; 
Dalton et al., 2004). These findings indicate that the suppressive effects of m-CPP were 5-
HT2c receptor-mediated and not due to general sedation, although the mechanisms for m-
CPP-induced hypolocomotive effects are yet to be determined. 
The results indicate that only the 5.0mg/kg m-CPP dose significantly attenuated 
baseline locomotor activity (Figure 6). Generally, when rats were placed in the test 
chambers there were initially high activity levels during the habituation phase, which 
became almost non-existent over time. For these reasons, it was difficult to significantly 
decrease these activity levels any lower and explains why differences were relatively small 
between vehicle- and m-CPP-pretreated rats. 
The doses selected for emergence were based on the experiment examining the 
hypolocomotive effects of m-CPP on saline and MDMA pretreated rats (Figure 16). Doses 
were selected that did not significantly affect baseline locomotion. These doses were not 
based on the preliminary study examining the hypolocomotive effects of m-CPP (Figure 
6), because this was conducted in the old recording equipment. The 5.0mg/kg m-CPP dose 
significantly decreased baseline locomotion in the preliminary studies, but it was evident 
that the 2.5mg/kg dose significantly attenuated activity in the saline pretreated rats 
measured by the new equipment (Figure 16A). These differential effects suggest a lack of 
consistency between experiments, however, the old apparatus was much less sensitive. 
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Since the differences in activity between groups were relatively small due to the nature of 
this assay, it is not surprising that the old recording program failed to detect a significant 
difference between vehicle and the 2.5mg/kg m-CPP dose. The preliminary studies did, 
however, indicate which doses to use in the MDMA pretreated rats and provided 
verification that the results obtained by other researchers regarding the hypolocomotive 
effects of m-CPP (Sills et al., 1985; Aulakh et al., 1987; Kennett and Curzon, 1988; 
Aulakh et al., 1989; Bagdy et al., 1989; Klodzinska et al., 1989; Lucki et al., 1989; Freo et 
al., 1990; Kennett et al., 1994a; Bonhaus, 1997; Kennett et al., 1997a; Gleason and 
Shannon, 1998; Gleason et al., 2001) were replicable.  
In the present study, m-CPP decreased emergence latency (Figure 7), which was 
consistent with previous findings (Bilkei-Gorzo et al., 1998). Although the effects 
appeared to be dose-dependent, extensive variability between subjects meant that only the 
1.25mg/kg m-CPP dose produced significant increases in emergence latency. This 
variability might be due to the ‘all or nothing’ nature of this test, as each rat only received 
one time score for full body emergence. Conversely, activity counts provide numerous 
scores within 5-minute blocks, so gradual changes in behaviour and dose-dependent effects 
are easily observable. Despite this apparent weakness of the m-CPP emergence assay, the 
lack of confounding locomotor effects were indicative that the test was measuring an 
alternate function of the 5-HT2c receptor. Indeed, a role for the 5-HT2c receptor was 
established in that m-CPP-increased emergence latency was attenuated by 5-HT2a/2c 
antagonists (Bilkei-Gorzo et al., 1998). Additionally, it has been demonstrated that the 
selective 5-HT2c receptor antagonist, RS102221, dose-dependently attenuated the effects 
of m-CPP on emergence latencies (Jones 2006, VUW PhD thesis).  
Preliminary RS102221 Experiments 
MDMA-produced hyperactivity was potentiated by RS102221 pretreatment 
(Figures 8, 9 and 18A), which concurs with previous studies. 5-HT2c receptor antagonists 
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have potentiated cocaine (McCreary et al., 1999; Fletcher PJ, 2002a; Filip et al., 2004), 
amphetamine, methylphenidate, nicotine, morphine, phencyclidine and MDMA-produced 
hyperactivity (Gold, 1988b; Hutson et al., 2000; Herin, 2001; Bankson, 2002; Fletcher PJ, 
2002b; Fletcher et al., 2006). These behavioural effects were attributed to the ability of the 
5-HT2c receptor to modulate mesolimbic DA (Millan et al., 1998; Gobert et al., 2000; 
Lucas et al., 2000; Lucas and Spampinato, 2000; Yan, 2000), for example, pretreatment 
with SB242084 potentiated the increase in extracellular levels of DA in the nucleus 
accumbens and striatum elicited by 15mg/kg of cocaine (Navailles et al., 2004).  
Since there were no reports where RS102221 had been combined with MDMA, the 
first experiment aimed to determine which MDMA doses (if any) were most potentiated by 
the 0.5mg/kg RS102221 (Figure 8). The results showed that RS102221 significantly 
potentiated 10.0mg/kg MDMA-produced hyperactivity (Figure 8C), which was in 
agreement with previous findings using selective 5-HT2c antagonists (Fletcher et al., 
2006). This MDMA dose was subsequently utilised to assess the effects of a range of 
RS102221 doses. The results showed that there was a significant main effect of RS102221 
dose on MDMA-produced hyperactivity, but the differences between doses were not 
significant (Figure 9). The 0.5mg/kg dose produced maximal potentiation, whereas the 1.0 
and 2.0mg/kg RS102221 doses produced non-selective effects. Similarly in saline 
pretreated rats, there was potentiation of MDMA-produced hyperactivity following the 
lower dose of 0.5mg/kg but not following 1.0mg/kg RS102221 (Figure 18A). Non-
selective binding might account for these observations, as RS102221 might also block 5-
HT2a receptors at this higher dose. Activation of 5-HT2a receptors facilitated MDMA-
induced DA outflow (Schmidt et al., 1992b; Schmidt et al., 1994) and selective 5-HT2a 
receptor antagonists attenuated MDMA-produced hyperactivity (Gold, 1988b; Kehne et al., 
1996; Herin, 2001; Bankson, 2002; Fletcher PJ, 2002b; Herin et al., 2005). The additional 
effect on the 5-HT2a receptors following higher dose administration might be expected to 
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counteract the effect of selective 5-HT2c receptor antagonism produced by lower 
RS102221 dose administration.  
Of interest, it has been suggested that there are 5-HT2c receptor populations with 
differential effects on DA (Millan et al., 1998; De Deurwaerdere, 1999; Di Giovanni, 
1999; Di Matteo, 2000; Gobert et al., 2000; Lucas et al., 2000; Lucas and Spampinato, 
2000; Yan, 2000) and locomotor activity (Takahashi et al., 2001; Filip, 2002; Filip and 
Cunningham, 2003; Dalton et al., 2004) It is equally possible that the lower RS102221 
dose produced potentiated locomotor activity via inhibitory receptors located in an area 
such as the prefrontal cortex, as locally applied 5-HT2c receptor antagonists potentiated, 
whilst 5-HT2c receptor agonists attenuated stimulant-produced hyperactivity in this area 
(Filip and Cunningham, 2003). Following administration of higher RS102221 doses and 
more widespread 5-HT2c receptor blockade, facilitatory 5-HT2c receptors in the nucleus 
accumbens or hippocampus might also be affected. 5-HT2c agonists applied directly into 
this area potentiated stimulant-produced hyperactivity, whereas 5-HT2c antagonists 
produced attenuation (Takahashi et al., 2001; Filip, 2002), thus, blockade of these 
receptors might be expected to counteract the potentiated behavioural effects produced by 
prefrontal 5-HT2c receptor blockade. 
The non-significant effects between doses were of little concern, because all of 
these preliminary studies were conducted in the old measuring apparatus. These results 
provided an indication as to which doses to use in later studies, and also verified that 
RS102221 potentiated MDMA-produced hyperactivity. 
 The ability of the 5-HT2c receptor to modulate MDMA-produced behaviour is likely due 
to effects on DA systems. Microdialysis studies have shown that 5-HT2c receptor blockade 
increased, whilst 5-HT2c agonist decreased DA levels in striatum, nucleus accumbens and 
frontal cortex (Millan et al., 1998; De Deurwaerdere, 1999; Di Giovanni, 1999; Gobert et 
al., 2000). Potentiated cocaine-produced DA increases in the striatum and nucleus 
accumbens were also found after 5-HT2c antagonist pretreatment (Navailles et al., 2004). 
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Additional support for an inhibitory role on DA outflow for the 5-HT2c receptors was 
demonstrated in that 5-HT2c receptor knockout mice had higher DA levels in the nucleus 
accumbens than wildtypes following cocaine administration (Rocha et al., 2002). As these 
findings suggest that 5-HT2c receptor activation inhibits DA release, antagonists allow 
dopaminergic disinhibition, thereby potentiating MDMA-produced hyperactivity. 
It is possible that NE might contribute to the potentiation of hyperactivity. In 
addition to releasing 5-HT and DA, MDMA, amphetamine, methylphenidate and cocaine 
increase NE neurotransmission (Florin et al., 1994; Kuczenski and Segal, 1997; Rothman 
et al., 2001). SB242084 also elevated NE levels (Millan et al., 1998), thus it was possible 
that this might have been contributing or producing the potentiated behavioural response. 
A role for NE is not clear, however, as selective NE reuptake inhibitors do not stimulate 
activity (Brocco et al., 2002; Davids et al., 2002) although amphetamine-produced 
locomotor activation was blocked by prazosin and clonidine, and enhanced by propranolol 
(Vanderschuren et al., 2003). The majority of the evidence from other compounds that 
have been assessed indicates that dopaminergic effects are predominant 
The possibility that the potentiation of stimulant-produced hyperactivity was 
related to altered pharmacokinetics was investigated.  The selective 5-HT2c antagonist, 
SB242084, has reliably potentiated amphetamine, methylphenidate, morphine and 
MDMA-produced hyperactivity (Fletcher et al., 2006), It was established that SB242084 
had negligible affinity for several major cytochrome enzymes responsible for metabolism 
of cocaine, amphetamine, nicotine, morphine and fenfluramine (Bromidge et al., 1997). It 
was also reported that SB242084 did not alter brain levels of MDMA, amphetamine or 
cocaine (Fletcher PJ, 2002). These findings suggest that the ability of SB242084 to 
potentiate MDMA-produced hyperactivity was not related to altered pharmacokinetics. 
Although RS102221 is a different pharmacological compound, these findings also suggest 
that the potentiated response were not attributable to pharmacokinetics. 
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Effects of MDMA Pretreatment on m-CPP-Produced Behaviour 
MDMA pretreatment did not affect the ability of m-CPP to produce 
hypolocomotion (Figure 16). These findings replicate a similar study that reported that m-
CPP-induced hypolocomotion and decreased EPM and open field exploration were 
unaltered by MDMA preexposure (Bull, 2003). The present findings extend this work, as 
the MDMA pretreatment regimen used has been extensively characterised and shown to 
produce serotonergic (Scanzello et al., 1993; Fischer et al., 1995; Shankaran and Gudelsky, 
1999; Sumnall et al., 2004; Nair and Gudelsky, 2006) and behavioural (Shankaran and 
Gudelsky, 1999) deficits. The pretreatment regimen used by Bull and colleagues (2003) 
had not previously been characterised and only mild 5-HT depletions in hippocampus and 
frontal cortex were reported.  
The young Listar Hooded rats received higher MDMA doses (15.0mg/kg twice 
daily for 3 days, total 90.0mg/kg) (Bull, 2003) than the rats in the present study. Although 
the present results suggest that tolerance can be produced despite variation in pretreatment 
regimen (Figure 12), there was concern that the Listar rats in Bull’s study were somewhat 
more resilient to the effects of MDMA because they were young and small relative to those 
used in similar studies. These explanations likely account for more extensive MDMA-
produced serotonergic deficits evident in older Sprague Dawley rats used in the present 
study when compared to the young Listar Hooded rats (Colado et al., 1997).  
Given these different effects on serotonergic parameters, it was a possibility that 
that the lack of change in m-CPP-induced behavioural responses following MDMA 
pretreatment might have been attributable to more resilient rats rather than no change to 5-
HT2c receptors. Additionally, an m-CPP dose was used in the hypolocomotion tests that 
did not significantly attenuate baseline activity in the saline pretreated rats. This was 
problematic, as the MDMA pretreated rats were expected to exhibit tolerance as opposed 
to sensitisation to m-CPP, thus a dose that did not significantly affect baseline behaviour 
  
  
137 
would not be expected to show pretreatment differences. The results from the present study 
show that there were no pretreatment differences in response to an m-CPP dose that 
induced significant locomotor decreases. Additionally, the present study utilised rats that 
were tolerant to the activating effects of MDMA (Figures 12 and 13) and displayed 
extensive serotonergic deficits. These results suggest that the tolerance to MDMA was 
pharmacologically specific and indicates that the hypolocomotive function of the 5-HT2c 
receptors was not altered by MDMA pretreatment. 
 MDMA pretreated rats exhibited greater responsiveness to m-CPP at the highest 
doses (Figure 16B), however, these differences were not substantial enough to produce a 
significant main effect of pretreatment. These findings do, however, reflect the complexity 
of behaviour and suggest the contribution of other neurotransmitters. In addition to 
predominant effects on the 5-HT2c receptor (Fiorella et al., 1995), m-CPP also binds other 
5-HT receptor subtypes (Harel-Dupas et al., 1991; Kahn and Wetzler, 1991), the SERT 
(Eriksson et al., 1999) and alters cortical acetylcholine release (Zhelyazkova-Savova et al., 
1999). 5-HT and acetylcholine contribute to hypolocomotive effects, as a role for 
acetylcholine in these effects has been established (Salas et al., 2004; Howell et al., 2005). 
Since MDMA pretreated rats exhibited significant SERT binding reductions (Table 2), and 
likely 5-HT receptor density changes (Scheffel et al., 1992; Aguirre, 1998; Shankaran et 
al., 1999; Reneman et al., 2002; McGregor et al., 2003), m-CPP would likely be displaced 
from binding targets. Despite changes in 5-HT systems, the acetylcholine response to drug 
challenge was unaltered in MDMA pretreated rats that received an identical pretreatment 
to the one used in the present study (Nair and Gudelsky, 2006). The differential dose-
response profile exhibited by different pretreatment groups in the present study might, 
therefore, reflect a greater cholinergic contribution to m-CPP-induced hypolocomotion. 
MDMA pretreatment did not affect latency to emerge for the groups that received a 
saline injection (Figure 17). These findings correspond to other reports documenting no 
change in baseline open field (McNamara et al., 1995; Bull, 2003) or EPM (Bull, 2004; 
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Sumnall et al., 2004) exploratory behaviours following MDMA pretreatment and indicate 
that MDMA exposure does not detrimentally affect associated mechanisms. Conversely, 
decreased social interaction is a widely reported consequence of MDMA exposure (Morley 
et al., 2001; Fone et al., 2002; Bull, 2003; McGregor et al., 2003; Thompson et al., 2004), 
suggesting that the mechanisms involved are dissociable from the aforementioned tests and 
more susceptible to MDMA-induced change.  
The present results were in direct contrast with the only other study that has 
conducted similar experiments (McGregor et al., 2003). In these experiments, MDMA 
pretreated rats exhibited delayed emergence in comparison to controls following a 12-week 
recovery period. However, in our laboratory, rats that received the same pretreatment 
regimen as the present study did not show any pretreatment differences in emergence 
following a 12-week recovery period either (data not shown). These differential findings 
are possibly related to rat strain, as McGregor and colleagues (2003) used the Wistar rat. 
Indeed, Wistar rats have displayed differential baseline and drug-induced behaviour in the 
emergence test when compared to the Sprague Dawley strain (Pare et al., 2001). These 
findings suggest that the emergence test is a relatively sensitive measure, and only 
comparisons between studies that utilised similar methodologies should be made. 
In a similar manner to the hyplocomotion experiment, MDMA pretreatment did not 
affect m-CPP-induced increased emergence latency (Figure 17). These findings also 
concur with Bull (2003), who assessed open field and EPM behaviour and did not find any 
pretreatment differences, despite the use of different m-CPP assays, rat strains and ages 
and MDMA pretreatment regimens. These findings suggest that the 5-HT2c receptor 
mechanisms underlying these m-CPP-produced behaviours were unaffected by MDMA 
exposure. 
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Effects of MDMA Pretreatment on RS102221-Potentiated MDMA-Produced 
Hyperactivity 
MDMA-pretreated rats were less responsive to RS102221-produced potentiation of 
MDMA-produced hyperactivity (Figure 5B), suggesting receptor desensitisation as a 
function of MDMA exposure. Preliminary investigations revealed that MDMA pretreated 
rats also exhibited tolerance to the effect of SB200646, a 5-HT2b/2c antagonist 
(Australasian Winter Conference on Brain Research Abstracts, 2003). The present study 
utilised RS102221 due to higher 5-HT2c receptor selectivity, but both compounds are 5-
HT2c receptor antagonists. These findings suggest that tolerance to the effects of these 
antagonists was related to 5-HT2c receptor desensitisation. Dose-effect studies with 
RS102221 show that potentiation of MDMA-produced hyperactivity was shifted to the 
right in the MDMA pretreated group (Figure 5B), as the response to 1.0mg/kg RS102221 
was significantly greater than the response to the 0.5mg/kg dose. These findings concur 
with other studies that have suggested reduced 5-HT2 receptor binding densities (Scheffel 
et al., 1992; Reneman et al., 2002; McGregor et al., 2003) following MDMA exposure.  
Reduced 5-HT2c receptor functional response might be attributable to mRNA 
editing. mRNA editing of 5-HT2c receptors has been reported to produce receptor 
isoforms with altered functional properties (Herrick-Davis et al., 1999; Niswender et al., 
1999; Wang et al., 2000; Berg et al., 2001; Visiers et al., 2001) and editing has occurred in 
response to fluctuating 5-HT levels (Gurevich, 2002). For example, 5-HT2c receptor 
agonist administration produced an isoform with decreased sensitivity to 5-HT, as 
evidenced by decreased ability to activate G-proteins (Gurevich, 2002). The implications 
are that less sensitive 5-HT2c receptor isoforms might also have reduced ability to 
modulate DA outflow under these circumstances. Conversely, 5-HT depletion produced 5-
HT2c receptor isoforms with increased sensitivity to 5-HT (Gurevich, 2002). Since 
MDMA induces massive 5-HT release (Gough et al., 1991; White et al., 1996; Lyles and 
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Cadet, 2003; Colado et al., 2004; Green et al., 2004) followed by central serotonergic 
depletions (Battaglia et al., 1987; Commins et al., 1987; Ricaurte et al., 1988a; Ricaurte et 
al., 1988b; Insel et al., 1989; Molliver, 1990; Scanzello et al., 1993; Aguirre et al., 1995; 
Colado and Green, 1995; Fischer et al., 1995; McNamara et al., 1995; Sabol et al., 1996; 
Sexton et al., 1999; Mayerhofer et al., 2001; Boot, 2002; McGregor et al., 2003; Clemens 
et al., 2004; Sumnall et al., 2004; Wang et al., 2004), mRNA editing of the 5-HT2c 
receptor might occur. The RS102221 data from the present study suggest that the initial 
MDMA-produced 5-HT efflux might have produced desensitised 5-HT2c receptor 
isoforms that were only responsive to the highest RS102221 dose. 
5-HT2c Receptor Conclusions 
Despite large decreases in SERT binding (Table 2) and a tendency towards a 
rightward shift in the dose-effect curve for RS102221-produced potentiation of MDMA-
produced hyperactivity, the behavioural effects of m-CPP were not altered by prior 
exposure to MDMA (Figures 16C and 17). This dissociation might reflect the existence of 
separate 5-HT2c receptor populations with differential vulnerability to MDMA exposure. 
Indeed, evidence suggests that there are 5-HT2c receptor populations that not only have 
different functional roles (Filip and Cunningham, 2003), but also anatomical locations. For 
instance, the ability to modulate DA release and inhibit stimulant-induced hyperactivity 
has been attributed to receptors located in the prefrontal cortex, whereas faciliatory 5-HT2c 
receptors have been identified in the nucleus accumbens (Filip, 2002).  
In contrast, there is no evidence to suggest that the receptors that mediate m-CPP-
produced behaviours alter DA release. Additionally, m-CPP-responsive 5-HT2c receptors 
might have differential locations, as local m-CPP injection into the ventral hippocampus 
and basolateral amygdala reduced exploratory behaviour in the EPM (Alves et al., 2004) 
and altered open field behaviours, ultrasonic vocalisation and latency to approach a novel 
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object (Kennett et al., 1994a; Campbell and Merchant, 2003), however, administration to 
other regions such as the dorsal hippocampus did not alter behaviour.  
It was purported that MDMA exposure produced region-dependent alterations in 5-
HT2a/2c receptor binding, where the most significant downregulations were evident in the 
caudate putamen, insular cortex, cingulate cortex, lateral septum, frontal cortex and 
entorhinal cortex (McGregor et al., 2003). The potentiating effects of systemically 
administered 5-HT2c receptor antagonists have been attributed to 5-HT2c receptors in the 
prefrontal cortex (Filip and Cunningham, 2003), thus the observation that 5-HT2 binding 
was most severely affected in this area might explain desensitised responses to RS102221 
manipulation in MDMA pretreated rats. Conversely, 5-HT2 receptor binding in the 
amygdala and hippocampus were not significantly affected, which were the sites where 5-
HT2c receptors that mediated m-CPP-produced behaviours were localised (Kennett et al., 
1994a; Campbell and Merchant, 2003; Alves et al., 2004). It could be tentatively 
concluded that the 5-HT2c receptor sites involved in the m-CPP-induced responses were 
more resistant to MDMA exposure than those receptors that modulate hyperactivity.  
Reduced 5-HT2c receptor responsivity, as evident in the RS102221 experiments, 
cannot explain tolerance to the behavioural effects of MDMA (Figure 12 and 13E). The 
effect of 5-HT2c receptor activation was to attenuate stimulant-produced hyperactivity 
(Grottick et al., 2000), therefore desensitised 5-HT2c receptors would be expected to 
potentiate MDMA-produced hyperactivity. Even though there was a small decrease in the 
potency of RS102221 as a function of MDMA exposure, this effect is not likely relevant to 
the behavioural deficits observed. These findings indicate that the 5-HT2c receptor does 
not contribute significantly to the expression of MDMA-produced hyperactivity and that 
MDMA-produced desensitisation is not sufficient to counteract the tolerance attributable to 
other serotonergic deficits. 
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The 5-HT2a Receptor 
Preliminary DOI Experiments 
DOI administration significantly increased the frequency of wetdog shakes (WDS) 
over the 10-minute recording period (Table 1) in concurrence with previous reports 
(Schreiber et al., 1995; Granoff and Ashby, 1998; Bull, 2004). Indeed, both WDS and back 
muscle contractions (BMC) have been used as an index of 5-HT2a receptor activation in 
the rat, as these behaviours were attenuated by ritanserin and the more selective 5-HT2a 
receptor antagonist, MDL100907 (Fone et al., 1989). It was also established that these 5-
HT2a receptor-mediated behaviours had different anatomical origins, as BMC were 
localised to the spinal cord, whereas WDS were related to receptor activation in the cortex 
and brainstem (Fone et al., 1989; Fone et al., 1991).  
It was observed that some rats exhibited BMC, but the occurrence was inconsistent 
(results not presented). The occurrence of both behaviours confirmed that DOI was 
activating 5-HT2a receptors, but the unreliability of the BMC response provided reason for 
exclusion from the present results. The inconsistent BMC response might reflect the 
inability of systemically administered DOI to reach spinal cord areas, as studies reporting 
DOI-induced BMC injected DOI locally into the spinal regions (Fone et al., 1989; Fone et 
al., 1991).  
 DOI-induced WDS were not dose-dependent, as the 1.0 and 2.0mg/kg doses 
produced equivalent behaviour. There was, however, a previous report where DOI 
produced dose-dependent increases in the head twitch response (Granoff and Ashby, 
1998). Head twitch behaviour was observed for 1 hour rather than the 10-minute 
assessment period used in the present study. Differences between doses might have been 
apparent in this study because the time-course for the behavioural effects was not assessed. 
It is possible that the highest dose might have had a longer duration of action, thus 
producing more behaviour. The WDS in the present study were counted in 2-minute blocks 
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in order to verify that there were no dose-induced differences in time course for these 
effects, and since none were evident, the data was presented as totals. 
Measuring WDS rather than head twitches might also explain the lack of DOI dose 
effects. Different definitions of what constitutes a ‘WDS’ as opposed to a ‘head twitch’ 
might explain these observations. A WDS was defined as a ‘paroxysmic shudder of the 
head and trunk’ (Darmani and Ahmad, 1999) whereas a head twitch was a ‘rapid rhythmic 
shaking of the head in a radial motion’ (Granoff and Ashby, 1998). Rats in the present 
study had to exhibit a shudder that included the head and the trunk in order to be counted 
as a WDS. The counts would probably have been much higher if all head twitches had 
been included. However, the present methodology was based on a study where MDMA 
pretreated rats exhibited tolerance to the ability of DOI to produce WDS (Bull, 2004). Bull 
only used the 1.0mg/kg DOI dose, thus the significant effect of the 1.0mg/kg dose in the 
present study and the knowledge that an MDMA pretreatment difference had been 
observed previously at this dose provided justification to examine the effects of MDMA 
pretreatment using this model. 
DOI did not affect baseline locomotor activity in the present study (Figure 10), 
however, an increase (Darmani et al., 1996; Hillegaart et al., 1996; Kaur and Ahlenius, 
1997; Bull, 2004; Ross et al., 2005), no change (Darmani et al., 1994; Hawkins et al., 
2002) or a decrease in locomotion following DOI administration (Granoff and Ashby, 
1998) have all been reported. It is possible that these mixed results were due to the use of 
different measuring methods and apparatus. For example, line crosses were manually 
recorded as indices of locomotor activity (Hawkins et al., 2002), whereas other studies 
utilised total number of beam breaks as counted by a computer (Granoff and Ashby, 1998). 
There was one notable study where DOI-produced locomotor activity was assessed as 
separate components (Hillegaart et al., 1996). DOI (1.0mg/kg) administration decreased 
total locomotor counts and rearing, but increased forward locomotion and peripheral 
activity. The DOI-produced changes were however, mild in comparison to another more 
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effective 5-HT agonist. These differential effects of DOI on several components of 
locomotor behaviours suggest that ‘total beam breaks’ or ‘line crosses’ were not sensitive 
enough to observe DOI-produced behavioural effects. 
Although the present study assessed forward locomotion, no DOI effects were 
visible, whereas Hillegardt and colleagues (1996) observed an increase. Again, these 
differences were attributable to measuring methodology. Forward locomotion was defined 
as ‘successive interruptions of photocell beams when the animal was moving in the same 
direction’ (Hillegaart et al., 1996), whereas the Activity Monitor program in the present 
study divided the chamber into zones, or ‘boxes ‘and when the rat travelled distance and 
crossed the box perimeters into an adjacent box, this was registered as an ambulatory 
count. The Activity Monitor program simultaneously recorded forward locomotion as well 
as ‘stereotypy counts’, which were all beam breaks made whilst the rat was within a ‘box’. 
As the program can differentiate between behaviours, the DOI data were subsequently re-
analysed to determine whether stereotypy counts were influenced by drug treatment 
(results not shown). It was evident that the doses of DOI administered in the present study 
did not significantly alter ambulatory or stereotypy counts. Interestingly, the same DOI 
dose and rat strain/age were utilised as subjects for both the present study and Hillegardt’s 
work (1996), but the present results suggest that DOI does not produce robust effects on 
these behavioural paradigms. 
It has been suggested that the ability for DOI to increase locomotor activity might 
be due to effects on DA release (Herin et al., 2005). It is well established that 5-HT2a 
receptor activation facilitates stimulant-induced hyperactivity due to the ability to increase 
dopaminergic neurotransmission, however, DOI administration did not alter DA release in 
the mPFC, striatum and NAc (Ichikawa and Meltzer, 1995; Kuroki et al., 2003). 
Amphetamine administration produced a marked increase in extracellular DA levels in 
these areas, and when DOI was administered in conjunction with amphetamine, DA 
increases were significantly potentiated in all areas. Additionally, pretreatment with the 
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selective antagonist, MDL100907, reversed the DOI-produced potentiation of DA, thereby 
implicating 5-HT2a receptor activation (Kuroki et al., 2003). Although these studies did 
not report concomitant locomotor responses, the effects on DA release largely determine 
the expression of hyperactivity. Thus, when DOI-induced increases in activity were 
previously reported, it was unlikely that the underlying mechanisms were DA-related. The 
behavioural results from the present study are consistent with the idea that 5-HT2a receptor 
manipulations might only exert consistent effects on locomotor activity under conditions of 
increased monoamine neurotransmission.  
Preliminary Ritanserin Experiments 
Ritanserin pretreatment dose-dependently attenuated 10.0mg/kg MDMA-produced 
hyperactivity (Figure 11). The 10.0mg/kg ritanserin dose produced some non-selective 
effects, as evidenced by the inability to significantly attenuate MDMA-produced 
hyperactivity. It would be expected that increasing ritanserin dose would eventually 
antagonise 5-HT2c receptors, thus negating the inhibitory effects from 5-HT2a receptor 
blockade. Despite the non-selective nature of ritanserin, evidence suggests that the ability 
to attenuate MDMA-produced hyperactivity is a 5-HT2a receptor-mediated effect. The 
selective 5-HT2a antagonist, MDL100907, attenuated MDMA-produced forward 
locomotion in a comparable manner to ritanserin (Kehne et al., 1996), whilst MDMA-
induced rearing behaviours were unaffected. These results indicate that these 5-HT2a 
receptor manipulations selectively altered forward locomotion.  
The 5-HT2a receptor-mediated attenuation of MDMA-produced hyperactivity was 
attributable to the ability for these receptors to facilitate DA release. An electrophysiology 
study revealed that MDMA-induced 5-HT2a receptor activation increased neuronal firing 
in the striatum, as a 5-HT2a receptor antagonist blocked nearly all MDMA-induced striatal 
excitations.(Ball and Rebec, 2005). Additionally, MDMA significantly elevated striatal 
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extracellular DA levels, which were dose-dependently attenuated by MDL100907 
(Schmidt et al., 1994). 
Effects of MDMA Pretreatment on DOI-Induced Behaviour 
MDMA pretreated rats did not exhibit WDS following 1.0mg/kg DOI 
administration (Table 3). These results support previous findings where Wistar rats that 
had received MDMA pretreatment (5mg/kg every hour for 4 hours on 2 consecutive days, 
40.0mg/kg total) and an 8 week withdrawal period subsequently showed no DOI-induced 
WDS in comparison to controls (Bull, 2004). The present findings suggest that MDMA-
induced desensitisation of 5-HT2a receptors involved in this response was a relatively 
robust effect, since rat strain and differential pretreatment/withdrawal times did not 
significantly change the outcome.  
Bull (2004) used the same rat strain, pretreatment regimen and similar withdrawal 
time to a study that conducted extensive DOI-binding assays (McGregor et al., 2003). It 
was reported that the caudate putamen, lateral septum, insular cortex, cingulate cortex, 
piriform cortex, perirhinal cortical area, medial hypothalamic area and the medial and 
lateral thalamic nuclei exhibited significant [125I] DOI binding decreases. WDS were 
localised generally to the cortex and brainstem (Fone et al., 1989; Fone et al., 1991), 
therefore it was possible that there were downregulations in 5-HT2a receptor populations 
that mediate DOI-induced WDS following MDMA pretreatment. 
There was another study that reported no change in the ability for DOI to produce 
head twitches in the rat following MDMA pretreatment (Granoff and Ashby, 1998). Male 
Sprague Dawley rats of the same age and size to the present study were used, but rats 
received 20.0mg/kg MDMA twice daily for 4 consecutive days, totalling 160.0mg/kg. 
Comparable (and lower) doses than 160.0mg/kg MDMA have produced non-specific 
neurotoxicity (Commins et al., 1987; Jensen et al., 1993; Schmued, 2003). These effects 
were purported to relate to drug-induced hyperthermia and not pharmacological effects of 
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MDMA (Baumann et al., 2006). Indeed, during the MDMA dose-effect experiments in the 
present investigation, it was occasionally observed that a single 20.0mg/kg MDMA 
administration resulted in lethality, presumably due to hyperthermia. The MDMA exposure 
regimen used by Granoff and Ashby (1998) did deplete brain 5-HT levels below 80% as 
intended, but this regimen would not likely have selectively affected serotonergic systems, 
making it difficult to compare these results to the present study.  
Effects of MDMA Pretreatment on Ritanserin-Attenuated MDMA-Produced Hyperactivity 
Ritanserin pretreatment had no effect on MDMA-produced hyperactivity in 
MDMA pretreated rats (Figure 19B). These results indicate that the 5-HT2a receptors 
involved in this response were completely desensitised. Firstly, three ritanserin doses were 
tested that encompassed the range of effective doses, as the highest 10.0mg/kg dose started 
to produce non-selective effects. Tolerance to ritanserin would have been expected to shift 
the dose effect curve to the right in a similar manner to the RS102221 response (Figure 
18B), but instead, there was no indication of attenuation at any dose. Secondly, although 
MDMA pretreated rats were tolerant to 10.0mg/kg MDMA, there were still sufficient 
levels of activity present for significant attenuation to occur. For example, the 
hyperactivity exhibited by the saline pretreated rats that received 2.5mg/kg ritanserin was 
comparable to the levels exhibited by the MDMA pretreated rats that received no 
ritanserin. MDMA-produced hyperactivity exhibited by the saline pretreated group was 
attenuated further following 5.0mg/kg ritanserin administration, whereas the MDMA rats 
remained completely unresponsive. 
There was some variability evident between the preliminary study (Figure 11) and 
the response of the saline pretreated group (Figure 19A). This variability was due to higher 
response to 10.0mg/kg MDMA by the saline pretreated rats. The reasons for these 
differences were unclear, but the response to ritanserin was equivalent between studies. It 
appears that the saline pretreated rats were more responsive to ritanserin because the higher 
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baseline made the differences between doses more significant. The 10.0mg/kg ritanserin 
dose also significantly attenuated activity, whereas it had not in the preliminary study. 
However, it was evident that 10.0mg/kg ritanserin did not attenuate activity to the same 
extent as the 5.0mg.kg dose. Despite these differences, both experiments had internal 
control groups and the same pattern/profile of ritanserin effects were observed each time. 
Failure of ritanserin pretreatment to affect MDMA-produced hyperactivity might 
reflect the extensive 5-HT2a receptor binding decreases that have been reported following 
MDMA exposure (Reneman et al., 2002; McGregor et al., 2003). Approximately 40% of 
5-HT2a receptor-labelled dendrites contained tyrosine hydroxylase in the ventral tegmental 
area, suggesting that these receptors were localised on dopaminergic neurons (Doherty and 
Pickel, 2000). 5-HT2a receptors were expressed on DA neurons in several A10 subnuclei 
in the ventral tegmental area that project to mesolimbic forebrain regions, which could 
potentially produce widespread changes to frontal dopaminergic neurotransmission (Nocjar 
et al., 2002). The behavioural results from the present study indicate that the 5-HT2a 
receptors found on/around DA neurons were desensitised and/or downregulated following 
MDMA pretreatment. 
5-HT2a Receptor Conclusions 
The inability of DOI or ritanserin to produce any behavioural response indicates 
that MDMA exposure produced widespread 5-HT2a receptor desensitisation. Evidence 
strongly suggests that DOI-induced behaviours and the ability for ritanserin to modulate 
MDMA-produced hyperactivity might be related to different 5-HT2a receptor functions 
and/or different populations. The present results, therefore suggest desensitisation of the 
receptors involved in both functions. These are novel findings, as there have been no 
previous attempts to distinguish between 5-HT2a receptor-related responses. 
The ritanserin results indicate that tolerance to the activating effects of MDMA 
could largely be attributed to complete desensitisation of the 5-HT2a receptors involved in 
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modulating DA. Desensitised 5-HT2a receptors that produced DOI-induced WDS do not, 
however, explain decreased locomotor response to MDMA, as the role for these receptors 
in locomotion (and DA release) was negligible. However, tolerance in other MDMA-
produced behaviours might be attributable to these receptors. Indeed, DOI administration 
has produced hyperthermia (Pranzatelli and Pluchino, 1991; Mazzola-Pomietto et al., 
1995) and further studies have attributed hyperthermia to the 5-HT2a receptor (Mazzola-
Pomietto et al., 1995; Nisijima et al., 2001; Fantegrossi et al., 2003; Herin et al., 2005). 
The selective 5-HT2a receptor antagonist, MDL100907, attenuated hyperactivity and 
hyperthermia produced by 8 and 12mg/kg MDMA in Sprague Dawley rats (Herin et al., 
2005). Although the 5-HT2a receptor was implicated in both MDMA-produced 
behaviours, the time course for the attenuation of these effects were not consistent with a 
common mechanism (Herin et al., 2005). These studies suggest that 5-HT2a receptor-
mediated hyperthermia might be related to the receptors that mediate DOI-produced 
behaviours. Tolerance to DOI and MDMA-induced hyperthermia might be due to 
downregulation/desensitisation of similar 5-HT2a receptor populations.  
Conclusions 
MDMA pretreatment reduced SERT binding densities in brain regions that have 
been implicated in 5-HT mediated hyperactivity (Table 2). MDMA pretreated rats were 
tolerant to MDMA-produced hyperactivity (Figures 12 and 13) and unresponsive to the 
attenuating effects of the SSRI, clomipramine (Figure 15B). Since 5-HT release via the 
SERT contributes to the majority of MDMA-produced hyperactivity (Callaway et al., 
1990; Callaway and Geyer, 1992b), reduced SERT densities probably decreased 5-HT 
release in response to acute MDMA challenge, producing a tolerant behavioural response. 
Tolerance might also potentially reflect desensitised 5-HT2 receptors that contribute to the 
expression of MDMA-produced hyperactivity. 
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Indeed, both the 5-HT2c and 5-HT2a receptor subtypes modulated MDMA-
produced hyperactivity, but the present results indicated that 5-HT2a receptors had a 
greater role. For example, the 5-HT2c receptor antagonist, RS102221, is a highly selective 
ligand for its target (Bonhaus, 1997) in comparison to the 5-HT2a/2b/2c antagonist, 
ritanserin, yet there was only one dose that produced significant potentiation of MDMA-
produced hyperactivity in control rats (Figure 18A). In contrast, ritanserin produced 
significant attenuation of hyperactivity at several doses (Figure 19A). Additionally, if 5-
HT2c receptors were significant contributors to MDMA-produced hyperactivity, 
desensitisation would have produced a sensitised, and not a tolerant, locomotor response to 
MDMA challenge. Cell recordings following MDMA administration support the idea for a 
greater role for the 5-HT2a receptor in MDMA-produced hyperactivity (Ball and Rebec, 
2005). 5-HT2a receptor antagonist pretreatment prevented MDMA-induced striatal 
excitations, which paralleled attenuation of MDMA-induced hyperactivity, whilst a 5-
HT2c receptor antagonist had comparatively little effect on neuron excitability or 
hyperactivity.  
Interestingly, 5-HT2a receptors that facilitate MDMA-produced hyperactivity 
might be more susceptible to MDMA-induced desensitisation than 5-HT2c receptors. The 
present study showed that MDMA pretreated rats exhibited tolerance to the potentiating 
effects of RS102221 (Figure 18B), as revealed by a rightward shift in the dose effect curve. 
In contrast, MDMA pretreated rats showed no response to any ritanserin dose (Figure 
19B). The results suggest that the 5-HT2a receptors not only have a greater role in 
MDMA-produced hyperactivity, but also were also more susceptible to MDMA-induced 
desensitisation. Given these findings, tolerance to MDMA-produced hyperactivity was 
attributable to 5-HT2a receptor desensitisation.  
There is evidence to suggest that the 5-HT2a and 5-HT2c receptors that modulate 
MDMA-produced hyperactivity are functionally distinct from the receptors that mediate 
m-CPP- and DOI-induced behavioural responses. The dissociation in the present results 
  
  
151 
supports this idea, whereby m-CPP-produced behaviours were resilient (Figures 16B and 
17), yet RS102221-induced effects were reduced (Figure 18B), by MDMA pretreatment. 
The 5-HT2a receptors that mediate DOI-produced effects might also be separate to those 
involved in the modulation of MDMA-produced hyperactivity. In order for the 5-HT2a 
receptors that modulate stimulant release to exert behavioural affect, monoamine 
neurotransmission must be increased, and antagonists/agonists then modulate DA release 
(Ichikawa and Meltzer, 1995; Kuroki et al., 2003) and subsequent locomotor behaviour 
(Schmidt et al., 1994). However, behavioural effects produced by DOI occur 
independently to effects on monoamine neurotransmission, as DOI did not alter DA 
neurotransmission on its own (Ichikawa and Meltzer, 1995; Kuroki et al., 2003). These 
represent either differential functions of the same 5-HT2a receptors, or functions of 
separate 5-HT2a receptors. MDMA pretreatment produced tolerance to DOI-induced WDS 
(Table 3), but it was unclear whether this would directly impact tolerance to MDMA-
produced hyperactivity. It was evident that MDMA pretreatment did not affect 5-HT2c 
receptors involved in m-CPP produced behaviours, but receptors associated with DOI-
produced effects might have a role in tolerance to other 5-HT2a receptor-mediated MDMA 
behaviours, such as hyperthermia.  
Tolerance to the subjective effects of MDMA might be related to the presence of 
decreased SERT densities in users (McCann et al., 1998; Semple et al., 1999; Buchert et 
al., 2003; Thomasius et al., 2003), as SERT blockade with citalopram reduced the positive 
drug effects (Liechti et al., 2000b; Liechti et al., 2001; Liechti and Vollenweider, 2001). In 
addition to SERT binding, activation of 5-HT receptor subtypes might also contribute to 
MDMA-produced effects in humans. Activation of the 5-HT2a receptor has been 
associated with hallucinogenic-related drug effects (Jakab and Goldman-Rakic, 1998; 
Aghajanian and Marek, 1999; Nelson et al., 1999) and pretreatment with ketanserin, a 5-
HT2a/2c antagonist, decreased MDMA-produced perceptual changes and emotional 
excitation (Liechti et al., 2000a; Liechti et al., 2001; Liechti and Vollenweider, 2001). 
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Since MDMA exposure in humans has also been reported to decrease 5-HT2a binding 
densities (Reneman et al., 2002), changes to this particular receptor subtype might explain 
tolerance in MDMA-related perceptual changes.  
Return to control values of MDMA-produced 5-HT depletions and SERT binding 
reductions was reported by 12 weeks (Scanzello et al., 1993; Fischer et al., 1995). These 
neurochemical findings following the pretreatment regimen used in the present study were 
in correspondence with the behavioural data, showing a recovery of function (Figure 14). 
These findings further implicate serotonergic deficits as the major contributors to 
behavioural tolerance to MDMA and also show that these effects are reversible. The 
present study showed that repeated weekly exposure to MDMA resulted in persistent 
tolerance in MDMA pretreated rats, suggesting that drug abstinence is necessary for 
recovery to occur. 
Indeed, abstinence from MDMA led to recovery of SERT binding in ex-users 
(Semple et al., 1999; Buchert et al., 2003; Thomasius et al., 2003) but behavioural effects 
of MDMA following abstinence have not been measured in humans. Because effects in 
humans are comparable to the effects reported in laboratory animals in these experiments, 
the present data suggest that tolerance to the effects of MDMA might also diminish in 
humans who abstain from drug use for significant period of time. However, chronic use of 
MDMA without an abstinence period to allow for serotonergic recovery might result in 
persistent tolerance to MDMA. 
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